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1. Introduction 
As of 2008, cancer was the second most frequent cause of death in both sexes worldwide 
(WHO), with hepatocellular carcinoma (HCC) accounting for 9.2% of deaths caused by 
cancer (GLOBOCAN 2008 project, http://globocan.iarc.fr, status of November 2012). The 
term cancer describes not one but many diseases defined by very diverse genotypes and 
phenotypes, which, however, have one thing in common: they are triggered by a complex 
combination of genetic lesions and epigenetic effects. Tumor promoters, such as 
phenobarbital in the mouse liver, drive the selective proliferation of cells harboring specific 
genetic defects via indirect, non-genotoxic mechanisms. The modes of action of tumor 
promoters are understood to only a small extent, and their effects are extremely difficult to 
predict as, in contrast to mutagenicity, no reliable short-term assays exist to assess non-
genotoxic carcinogenicity. In the age of high-throughput microarray technology, the 
integrative bioinformatic and biological analysis of large “omics” datasets to identify early 
molecular biomarkers is a new approach in understanding the global molecular changes 
during carcinogenesis and has already been applied to a number of human cancers (Kristensen 
et al.; Shen et al., 2007; Martín-Subero et al., 2009). As the liver is the main target organ for 
non-genotoxic carcinogens (NGCs), the assessment and integration of global molecular 
changes in liver tissue is specifically important for predicting non-genotoxic carcinogenesis 
(http://www.imi-marcar.eu). 
1.1 Physiology of the liver 
The liver is the largest gland in vertebrates and plays a crucial role in many vitally important 
processes in the organism, including uptake of nutrients from the intestine, biosynthesis, 
degradation and distribution of various biomolecules, as well as biotransformation of 
xenobiotics and drugs. It is composed of four lobes of unequal sizes and shapes and, in 
humans, constitutes 2-4% of the entire body weight. The liver is supplied with blood by two 
main vessels that enter at its transverse fissure, or porta: the hepatic artery which branches off 
the abdominal aorta and delivers oxygen-rich blood, and the portal vein delivering blood 
which is low in oxygen but nutrient-rich from the stomach, intestine, spleen and pancreas. 
Blood is transported out of the liver via the hepatic vein and flows further to the heart and 
lung via the caudal vena cava. Hepatocytes, also called parenchymal liver cells, are the 
functional hepatic cells and account for approximately 60% of all cells in the liver and 80% of 
the total organ volume. In addition to metabolizing both endogenous molecules and 
xenobiotics, an important function of hepatocytes is bile production. Secreted bile is collected 
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by canaliculi and eventually transported into the gall bladder via the common hepatic duct. In 
the gall bladder, bile is stored and, upon food uptake, discharged into the duodenum, where it 
acts as an emulsifier and facilitates lipid digestion. The distribution of the branches of the 
hepatic blood vessels and bile canaliculi in a liver section defines the smallest anatomical and 
functional units of the liver at the histological scale, the liver lobule and acinus, respectively 
(figure 1.1). The liver lobule has an idealized hexagonic shape, with the central vein in the 
middle. The corners of the hexagon are formed by the terminal branches of the portal vein, the 
hepatic artery and a bile canaliculus, a structure called portal triad. The hepatocytes are 
arranged in plates which radiate from the central vein to the portal triads. From the portal vein 
and hepatic artery in the portal triad, a mix of oxygen- and nutrient-rich blood flows through 
the lobule in fenestrated sinusoidal capillaries to the central vein. As bile is secreted by 
hepatocytes and transported to the canaliculi in the portal triad, bile flow is opposite to that of 
blood. 
 
 
 
 
 
 
 
 
 
 
 
 
The liver parenchyma shows heterogeneity in function which is based on the location of the 
hepatocytes within the lobule, and according to this, it can be divided into three arbitrary 
zones: the pericentral zone (surrounding the central vein, poorest in oxygen), the periportal 
Figure 1.1. Schematic description of liver architecture according to the lobule and the 
acinus model, respectively. “CV” indicates the central vein. 
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zone (closest to the portal triad, forming the rim of the virtual hexagon), and the midzonal 
area (between pericentral and periportal zone) (see figure 1.1). Periportal and pericentral 
hepatocytes vary in their phenotypes and gene expression patterns concerning a number of 
processes, such as intermediary and xenobiotic metabolism (see figure 1.2). For example, 
periportal hepatocytes show increased rates of gluconeogenesis and amino acid catabolism, 
whereas their pericentral counterparts display higher levels of glycolysis and cytochrome 
P450 enzymes (Jungermann et al., 1989; Gebhardt, 1992; Jungermann et al., 1996; Oinonen et 
al., 1998; Braeuning et al., 2006). The gene expression patterns in the periportal and 
pericentral hepatocytes are similar to those found in mouse liver tumors mutated in the Ha-ras 
(Harvey rat sarcoma)- and Ctnnb1 (β-Catenin)-genes, respectively (Braeuning et al., 2007a). 
Indeed, recent data indicate that activation of the MAPK (mitogen-activated protein kinase) 
signaling pathway, which is up-regulated in Ha-ras-mutated tumors, maintains the periportal 
and inhibits the pericentral phenotype (Braeuning et al., 2007b), whereas Wnt/β-Catenin 
signaling, which is constitutively active in Ctnnb1-mutated tumors, keeps up the pericentral 
phenotype (Benhamouche et al., 2006a; Benhamouche et al., 2006b; Hailfinger et al., 2006; 
Torre et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Overview of zonated gene expression in the liver. 
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1.2 Chemical carcinogenesis 
According to the classic view, the formation of malignant tumors, or carcinogenesis, is 
described as a stepwise sequence of tumor initiation, promotion and progression (for reviews 
see Armitage, 1985; Nowell, 1976). During the first step of initiation, a single normal cell is 
irreversibly converted into a so-called pre-neoplastic cell by induction of mutations in either 
proto-oncogenes or tumor suppressor genes. Proto-oncogenes are genes which, upon 
initiation, are excessively transcribed or result in constitutively activated gene products, so-
called oncoproteins, whereas tumor suppressor genes undergo loss or decrease of function 
when mutated in the course of initiation. In their normal form, these two types of genes ensure 
the homeostasis of central regulatory processes in the cell. For instance, the gene products of 
Ha-ras (Harvey rat sarcoma) and B-raf (rat fibrosarcoma) (section 1.2.2) regulate the 
transmission of growth-factor-mediated signaling and induce cell proliferation, whereas the 
proteins encoded by p53 (Vogelstein et al., 2000) or INK4a/ARF (p19(Arf)) (Sherr et al., 
2000) are responsible for the physiological induction of apoptosis. Once a cell has been 
initiated, it is susceptible to the effects of tumor promoters, non-genotoxic agents that provide 
the cell with a selective proliferation advantage. This leads to clonal expansion of the pre-
cancerous cell and, eventually, the formation of a well-defined, benign tumor. Finally, as the 
tumor progresses into a malignant state, more mutations are introduced and the tumor cells 
increasingly dedifferentiate and proliferate, pushing aside healthy tissue and gaining the 
potential to form metastases. Hanahan and Weinberg have extended the classical view of the 
multistep process in 2000 and 2011, respectively, hypothesizing that a cell has to acquire six 
characteristic capabilities before it gains independence from internal and external regulatory 
mechanisms and eventually becomes a cancer cell (Hanahan et al., 2000; Hanahan et al., 
2011).  
In the mouse model, the genotype and phenotype of chemically generated tumors can be 
influenced by the initiation-promotion treatment regimen (Stahl et al., 2005a). Mouse liver 
tumors initiated with the genotoxin N-nitrosodiethylamine (DEN) mainly harbor mutations in 
Ha-ras (~50%) or B-raf (~20%) (Aydinlik et al., 2001; Jaworski et al., 2005a), which lead to 
constitutive activation of the MAPK signaling pathway (see section 1.2.2). If DEN-initiated 
mice are additionally treated with the anticonvulsant phenobarbital (PB) as a tumor promoter, 
the resulting tumors harbor activating mutations in the proto-oncogene Ctnnb1 (see section 
1.2.1), which encodes β-Catenin, a key mediator in the canonical Wnt signaling pathway 
(Aydinlik et al., 2001; Strathmann et al., 2006). PB activates target gene transcription by 
inducing the nuclear translocation of the constitutive androstane receptor (CAR) (Honkakoski 
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et al., 1998) and has recently been shown to induce DNA-methylation changes in the 
promoter region of the CAR target gene Cyp2b10 (cytochrome P450, family 2, subfamily b, 
polypeptide 10) (Lempiainen et al., 2011). However, how PB stimulates the selective 
outgrowth of Ctnnb1-mutated cells remains unknown.  
1.2.1 Canonical Wnt signaling pathway 
The Wnt gene (a portmanteau of Wg, Wingless, and Int1, Integration 1) was identified in 1982 
by Nusse and Varmus, who found that Int1 was activated in mice by insertion of the mouse 
mammary tumor virus (MMTV) (Nusse et al., 1982). Later, the homology between Int1 and 
the wingless gene in drosophila melanogaster was discovered, hence the term Wnt (Rijsewijk 
et al., 1987). The protein encoded by Wnt is an extracellular ligand which binds to Frizzled 
receptors and thus activates the Wnt/β-Catenin signaling pathway, a highly conserved 
signaling cascade controlling development, mitogenic stimulation and differentiation of cells 
by regulating transcription factors of the TCF/LEF family (TCF = T-cell factor, LEF = 
lymphoid enhancer factor). In the absence of Wnt, an intracellular protein complex is formed, 
which consists of Axin, APC (adenomatous polyposis coli), GSK3β (glycogen synthase 
kinase 3β), CK1 (casein kinase 1) and β-Catenin (figure 1.3) (Luo et al., 2007). β-Catenin is 
then phosphorylated in two steps: first, CK1 acts as a “priming kinase” and phosphorylates β-
Catenin at serine 45 (Amit et al., 2002). This is followed by phosphorylation of serine 33, 
serine 37 and threonine 41 by GSK3β (Liu et al., 2002). β-Catenin is then targeted for 
proteasomal degradation. Upon binding of Wnt to Frizzled, the cytoplasmic protein 
Dishevelled (Dvl) inhibits the formation of the protein complex, which leads to the 
stabilization of β-Catenin. The latter can thus translocate into the nucleus and, as a complex 
with TCF/LEF, activate target gene transcription (figure 1.3). 
Mutations affecting the phosphorylation sites of β-Catenin, e.g. in codons 33, 37, 41, 45 or 
neighboring sites of the murine Ctnnb1-gene, can lead to the protein’s stabilization and thus 
to a constitutive activation of β-Catenin-mediated signaling. Such activating point mutations 
in Ctnnb1 are frequent in both mouse and human hepatocellular carcinoma and a number of 
other cancers (de La Coste et al., 1998). 
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1.2.2 Mitogen-activated protein kinase (MAPK) signaling pathway 
The mitogen-activated protein kinase (MAPK) pathway is a signaling cascade which mediates 
signals from cell surface receptors to the nucleus via a number of effector kinases. Small 
monomeric G-proteins of the Ras-family (rat sarcoma) are transformed into their active GTP-
binding forms upon receptor-mediated extracellular mitogenic stimuli (figure 1.4) (Kolch, 
2000). Ras acts as a molecular switch which can bind and activate its downstream kinase Raf 
(rat fibrosarcoma). Activated Raf launches a phosphorylation cascade in the cytosol: first, Raf 
phosphorylates MEK (mitogen-activated protein kinase kinase, also known as MAP2K), 
which then phosphorylates MAPK (mitogen-activated protein kinase, also known as ERK). 
MAPK can phosphorylate a number of substrates, including transcription factors such as 
ELK1 (E twenty-six (ETS)-like transcription factor 1) and thus regulates cell growth, 
proliferation and differentiation. It is therefore not surprising that some genes encoding 
components of the MAPK pathway are proto-oncogenes, the mutation of which can lead to 
constitutive activation of the pathway and thus to cancer. Codons 12, 13 and 61 of the Ha-ras-
gene (Harvey rat sarcoma) are hotspot point mutation sites in mice. Mutations at these 
codons inhibit the interaction of the Ras-protein with its inactivator GAP (GTPase-activating 
protein) and thus lead to constitutive activity of Ras. Similarly, point mutations in codon 637 
(formerly referred to as codon 624) in the murine B-raf-gene activate the B-raf kinase. The 
Figure 1.3: Wnt/β-Catenin signaling pathway in absence (left panel) and presence (right panel) of 
Wnt (modified from Eisenmann, 2005). Abbreviations: LRP, LDL-receptor-relacted protein; Dsh, 
dishevelled; Ck1, casein kinase 1; GSK3β, glycogen synthase kinase 3β; APC, adenomatous 
polyposis coli; TCF, T-cell factor; CBP, CREB-binding protein. 
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MAPK pathway is constitutively activated in a large number of tumor cell lines and primary 
human tumors (Hoshino et al., 1999), and both Ras- and Raf-mutations have been detected in 
many human cancers (Bos, 1989; Davies et al., 2002; Garnett et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
1.3 Epigenetic mechanisms in carcinogenesis 
Epigenetics, which involves DNA methylation, modification of histones and non-coding 
RNAs, is crucial for normal development and maintenance of cellular homeostasis. Correct 
DNA methylation patterns established during embryogenesis in mammals are a precondition 
for the maturation of healthy adult organisms (for review see Hall, 1990; Bartolomei et al., 
2011), and posttranslational modification of histones is a key determinant of chromatin 
regulation and thus gene expression in the cell (Wolffe et al., 1999). Small non-coding RNAs, 
so-called microRNAs or miRNAs, negatively regulate the expression of genes containing 
complementary target sequences (for review see Bartel, 2004; He et al., 2004). Thus, 
functional impairment of any of these mechanisms can lead to severe diseases, including 
cancer. 
A number of miRNAs have been associated with cancer, in this case termed “oncomirs” 
(Esquela-Kerscher et al., 2006; Braconi et al., 2011; Wang et al., 2012c). Their longer 
relatives, the long non-coding RNAs, or lncRNAs, also play a role in tumorigenesis, but their 
Figure 1.4: MAPK pathway (modified from Kolch, 2000). 
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function is less understood than that of miRNAs (Chen et al., 2010; Prensner et al., 2011). An 
observation frequently made in tumors is a global change in the methylation at the 5’-position 
of cytosine in the context of CG-rich sequences (Ehrlich, 2002; Esteller, 2005). 5’-
methylcytosine (5’-mC) is a well characterized DNA modification and can be enzymatically 
transformed into a number of derivatives, including 5’-hydroxymethylcytosine (5’-hmC) 
(Tahiliani et al., 2009; Ito et al., 2011; Wu et al., 2011). Originally considered a mere 
intermediate of DNA demethylation, 5’-hmC has recently been shown to be altered in tumors 
(Yang et al., 2012) and is meanwhile assumed to be an independent regulatory DNA 
modification. 
The epigenetic effects of many tumor promoters have been characterized and published. For 
instance, PB causes specific DNA methylation changes in the rodent liver which may underlie 
its capacity to promote the outgrowth of cancer cells (Watson et al., 2002; Bachman et al., 
2006; Phillips et al., 2007). The chronology of epigenetic mechanisms in carcinogenesis is not 
entirely clear. According to the classic 3-step-model of carcinogenesis, tumor promoters can 
stimulate the growth of already initiated cells via non-genotoxic mechanisms, but there are 
also indications that epigenetic mechanisms are among the earliest events in carcinogenesis 
and occur long before the genotoxic events of intiation (Feinberg et al., 2006). This 
complexity and lack of a consistent detectable endpoint make it difficult to predict the effects 
of NGCs, which underlines the relevance of current endeavors to identify early and predictive 
biomarkers for these substances (Lempiainen et al., 2013) (www.imi-marcar.eu). 
1.3.1 The Dlk1-Dio3 imprinted gene cluster 
Genomic imprinting is an epigenetic mechanism unique to mammals which causes the parent-
of-origin-specific transcription of some genes by methylation and silencing of either the 
paternal or the maternal allele. The methylation marks leading to transcriptional inactivation 
of one allele are established during gametogenesis and maintained in the somatic cells of the 
adult organism (figure 1.5). Less than 1% of mammalian genes are imprinted (Wilkinson et 
al., 2007), including those encoding insulin-like growth factor 2 (Igf2) (DeChiara et al., 
1991), insulin-like growth factor 2-receptor (Igf2r) (Stoger et al., 1993) and H19 (Bartolomei 
et al., 1991) in mice, and loss of imprinting is associated with a number of diseases, such as 
Prader-Willi syndrome, Angelman syndrome and cancer (Egger et al., 2004; Sharma et al., 
2010). 
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The imprinted Dlk1-Dio3 gene cluster (figure 1.6) is located on mouse distal chromosome 12 
(Schuster-Gossler et al., 1998) and human chromosome 14q32, respectively (Schuster-Gossler 
et al., 1998; Miyoshi et al., 2000). It consists of the three paternally expressed protein-coding 
genes Dlk1 (delta-like 1), Dio3 (deiodinase, iodothyronine, type III) and Rtl1 
(retrotransposon-like 1), as well as a number of maternally expressed long non-coding RNAs 
(lncRNAs), microRNAs (miRNAs) and small nucleolar RNAs (snoRNAs), including Meg3 
(maternally expressed gene 3, also known as Gtl2, gene trap locus 2), anti-Rtl1, Mirg 
(microRNA-containing gene), Rian (RNA imprinted and accumulated in nucleus, also known 
as Meg8) and Irm (imprinted RNA near Meg3/Gtl2). The cluster also contains three 
differentially methylated regions (DMRs) which control gene expression on the locus: the 
Dlk1-DMR upstream of Dlk1, the IG-DMR (intergenic DMR) 15 kb upstream of Meg3/Gtl2 
and the Gtl2-DMR overlapping with the Meg3/Gtl2-promoter (Takada et al., 2000; Hagan et 
al., 2009; Takahashi et al., 2009). 
Correct imprinting of the Dlk1-Dio3 cluster is essential for embryonic development in mice. It 
was recently shown that maternal deletion of large parts of Meg3/Gtl2 leads to perinatal 
lethality, whereas the paternal knockout seemed to have either no effect or resulted in 
postnatal growth retardation and perinatal death (Takahashi et al., 2009; Zhou et al., 2010). 
Figure 1.5: Mechanism of genomic imprinting (modified from Wilkinson et al., 2007). 
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These results indicate a crucial role of Meg3/Gtl2 and its downstream maternally expressed 
genes in the regulation of Dlk1-Dio3 cluster imprinting. Furthermore, transcriptional up-
regulation of Meg3/Gtl2 is associated with the hypertrophic phenotype in cells of PB-treated 
normal mouse liver (Lempiainen et al., 2013). 
 
 
 
 
 
 
 
 
1.4 Aims and objectives 
The mode of action of NGCs such as PB is still widely unknown. The aim of this project was 
to elucidate the molecular mechanisms of NGCs by examining the differences between liver 
tumors that developed with or without promoter treatment. To this end, mRNA and miRNA 
expression, protein expression and phosphorylation, as well as DNA methylation datasets 
were generated for Ha-ras-mutated and Ctnnb1-mutated mouse liver tumors. The experiments 
were complemented by immunohistochemical staining. Furthermore, the novel bioinformatic 
tool InCroMAP was used to integrate the different datasets. The analyses should allow for 
creation of global and comprehensive molecular profiles of the two tumor types and thus for 
identifying characteristic differences between them. To additionally characterize epigenetic 
alterations in the differently mutated tumors, E-cadherin- and GS-positive tumors in fixed and 
embedded livers were immunohistochemically stained for 5’-methyl- (5’-mC) and 5’-
hydroxymethylcytosine (5’-hmC). Another goal was to examine whether perturbations of the 
Dlk1-Dio3 imprinted gene cluster play a role in PB-promoted tumorigenesis in the liver and 
could thus provide biomarkers which are specific for and predictive of epigenetic, non-
genotoxic carcinogens. All in all, these analyses aimed at creating a global picture of the two 
types of tumors, thereby assessing the different molecular and biochemical programs 
triggered by constitutive activation of the β-Catenin and Ha-ras proteins. 
Figure 1.6: Structure of the Dlk1-Dio3 imprinted gene cluster (modified from da Rocha et 
al., 2008). 
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2. Material 
2.1 Chemicals and biochemicals 
Reagent Manufacturer 
(3-Aminopropyl)triethoxysilane Sigma, Taufkirchen, Germany 
10x Taq Buffer with KCl +15 mM MgCl2 Fermentas GmbH, St. Leon-Rot, 
Germany 
3-Amino-9-ethylcarbazole ICN Biochemicals, Aurora, OH, USA 
Acetone Sigma, Taufkirchen, Germany 
Acrylamide (30%) Roth, Karlsruhe, Germany 
Agarose Lonza, Rockland, ME, USA 
Agilent RNA Pico Kit Agilent Technologies, Santa Clara, 
CA, USA 
Ammonium persulfate Serva, Heidelberg, Germany 
Ampuwa Fresenius Kabi Deutschland GmbH, 
Bad Homburg, Germany 
AMV Reverse Transcriptase 10u/µl Promega, Madison, WI, USA 
Boric acid Merck KGaA, Darmstadt, Germany 
Bovine serum albumin Fermentas GmbH, St. Leon-Rot, 
Germany 
Bromophenol blue Serva, Heidelberg, Germany 
BspHI (restriction endonuclease) Fermentas GmbH, St. Leon-Rot, 
Germany 
Chloroform Merck KGaA, Darmstadt, Germany 
dNTPs Fermentas GmbH, St. Leon-Rot, 
Germany 
dNTPs 2mM Thermo Fisher Scientific, Waltham, 
MA, USA 
dT20 primer Genaxxon BioScience, Ulm, 
Germany 
EDTA Sigma, Taufkirchen, Germany 
Entellan Merck KGaA, Darmstadt, Germany 
Ethanol Merck KGaA, Darmstadt, Germany 
Ethidium bromide Serva, Heidelberg, Germany 
Fast Red substrate Kem-En-Tec, Copenhagen, 
Denmark 
FastStart DNA MasterPLUS SYBR Green I kit Roche Applied Science, Penzberg, 
Germany 
FastStart SYBR Green Master kit Roche Applied Science, Penzberg, 
Germany 
Ficoll type 400 Sigma, Taufkirchen, Germany 
GeneRuler 100 bp plus DNA ladder (for agarose gel 
electrophoresis) 
Thermo Fisher Scientific, Waltham, 
MA, USA 
H2O2 (30%) Sigma, Taufkirchen, Germany 
HCl Merck KGaA, Darmstadt, Germany 
HpyIII (restriction endonuclease) Fermentas GmbH, St. Leon-Rot, 
Germany 
Kaiser’s glycerol gelatin Merck KGaA, Darmstadt, Germany 
MgCl2 Roche Diagnostics, Mannheim, 
Germany 
N,N-Dimethylformamide Merck KGaA, Darmstadt, Germany 
NaCl Merck KGaA, Darmstadt, Germany 
NaOH Merck KGaA, Darmstadt, Germany 
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Reagent Manufacturer 
Orange G Peqlab, Erlange, Germany 
pBR322 DNA-MspI digest (molecular weight standard 
for acrylamide gel electrophoresis) 
New England Biolabs, Ipswich, MA, 
USA 
Periodic acid Merck KGaA, Darmstadt, Germany 
Phenobarbital-containing diet (0.05% w/v) Ssniff, Soest, Germany 
Phenol Roth, Karlsruhe, Germany 
Qiagen RNAse-free H2O Qiagen, Hilden, Germany 
QuantiTect Primer Assays Qiagen, Hilden, Germany 
QuantiTect SYBR Green Mix Qiagen, Hilden, Germany 
Random hexamer primers Genaxxon BioScience, Ulm, 
Germany 
Restriction buffer Fermentas GmbH, St. Leon-Rot, 
Germany 
Restriction endonuclease buffer 4 New England Biolabs, Ipswich, MA, 
USA 
Schiff solution Merck KGaA, Darmstadt, Germany 
SDS Serva, Heidelberg, Germany 
Sodium acetate Merck KGaA, Darmstadt, Germany 
Sucrose Merck KGaA, Darmstadt, Germany 
Swine serum (normal) Dako, Glostrup, Denmark 
Taq polymerase (1u/µl) Fermentas GmbH, St. Leon-Rot, 
Germany 
TaqI (restriction endonuclease) Fermentas GmbH, St. Leon-Rot, 
Germany 
Tetramethylethylenediamine (TEMED) Serva, Heidelberg, Germany 
TrisHCl Sigma, Taufkirchen, Germany 
TspRI (restriction endonuclease) Fermentas GmbH, St. Leon-Rot, 
Germany 
Tween 20 Sigma, Taufkirchen, Germany 
Xylene Merck KGaA, Darmstadt, Germany 
Xylene cyanol Sigma, Taufkirchen, Germany 
 
2.2  Antibodies 
2.2.1  Immunohistochemistry 
Antigen 5’-hydroxymethylcytosine (5’-mC) 
Manufacturer Active Motif, Carlsbad, CA, USA 
Catalog number 39769 
Source Rabbit, polyclonal 
Application IHC, 1:500 dilution 
Antigen 5’-methylcytosine (5’-mC) 
Manufacturer Eurogentec, Seraing, Belgium 
Catalog number BI-MECY-0100 
Source Mouse, monoclonal 
Application IHC, 1:500 dilution 
Antigen E-Cadherin 
Manufacturer Cell Signaling, Danvers, MA, USA 
Catalog number 3194 
Source Rabbit, monoclonal 
Application IHC, 1:25 dilution 
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2.2.2 Reverse phase protein microarray 
Antibody Supplier 
4E-BP1   Epitomics (Burlingame, CA, USA) 
Akt Cell Signaling Technology 
Akt - phospho S473 Cell Signaling Technology 
AMPK alpha Cell Signaling Technology 
AMPK alpha - phospho T172 Cell Signaling Technology 
APC Cell Signaling Technology 
ATM/ATR Substrate - phospho, S/T Cell Signaling Technology 
Aurora A - phospho T288 Cell Signaling Technology 
Aurora A (AIK) Cell Signaling Technology 
Aurora A/B/C - phospho 
T288/T232/T198 Cell Signaling Technology 
Aurora B (AIM1) Cell Signaling Technology 
Aven   Cell Signaling Technology 
Bad   Cell Signaling Technology 
Bax   Cell Signaling Technology 
Bcl-xL   Cell Signaling Technology 
β-Actin   Sigma Aldrich (St. Louis, MO, USA) 
Antigen Egr1 (15F7) 
Manufacturer Cell Signaling, Danvers, MA, USA 
Catalog number 4153 
Source Rabbit, monoclonal 
Application IHC, 1:100 dilution 
Antigen Glutamine synthetase (GS) 
Manufacturer Sigma, Taufkirchen, Germany 
Catalog number G2781 
Source Rabbit, polyclonal 
Application IHC, 1:1000 dilution 
Antigen Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) 
Manufacturer Cell Signaling, Danvers, MA, USA 
Catalog number 4376 
Source Rabbit, monoclonal 
Application IHC, 1:100 dilution 
Antigen Rabbit IgG 
Manufacturer Dako, Glostrup, Denmark 
Catalog number P0217 
Source Swine, polyclonal 
Application Secondary antibody for IHC, HRP-conjugated, 
1:20 dilution 
Antigen Rabbit IgG 
Manufacturer MolMed S.p.A, Milan, Italy 
Catalog number FR14-61 
Source Goat, polyclonal 
Application Secondary antibody for IHC, biotin-conjugated, 
1:200 dilution 
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Antibody Supplier 
β -Catenin - phospho S675 Cell Signaling Technology 
β -Catenin - phospho T41/S45 Cell Signaling Technology 
β -Catenin Upstate Biotechnology  (Lake Placid, NY, USA) 
Bik   Abcam (Cambridge, UK) 
b-Raf - phospho S445 Cell Signaling Technology 
Canceroembryogenic Antigen (CEA) Dianova (Hamburg, Germany) 
Caseinkinase 1 alpha  Cell Signaling Technology 
CASK   
BD Transduction Laboratories (San Jose, CA, 
USA) 
CD51 (VNR alpha)   BD Transduction Laboratories 
cdc25A (M-phase inducer phosphatase 
1) 
Applied Biological Materials (Richmond, BC, 
Canada) 
cdc25C Epitomics 
c-Jun   Cell Signaling Technology 
c-Jun - phospho S63  Cell Signaling Technology 
c-Met (HGF/SF Receptor) R&D Systems (Minneapolis, MN, USA) 
c-Met (HGF/SF Receptor) - phospho 
Y1349 Cell Signaling Technology 
c-myc  Cell Signaling Technology 
c-myc - phospho T58/S62  Epitomics 
c-Raf  Cell Signaling Technology 
c-Raf - phospho S259 Cell Signaling Technology 
CREB   Cell Signaling Technology 
Cyclin A  Abcam 
Cyclin D1 Cell Signaling Technology 
Cyclin E2 Cell Signaling Technology 
Cyp 1A1 U. Zanger, IKP, Stuttgart  
Cyp 1A2 PanVera (Madison,  WI, USA) 
Cyp 2B1 R. Wolf, MRI, Dundee 
Cyp 2B6 BD Biosciences (San Jose, CA, USA) 
Cyp 2C6 R. Wolf, MRI, Dundee 
Cyp 2C8 Puracyp (Carlsbad, CA, USA) 
Cyp 2D6 U. Zanger, IKP, Stuttgart 
Cyp 2E1 Acris (Herford, Germany) 
Cyp 3A4 BD Biosciences 
Cyp 3A4, 3A1, 3A11 Millipore (Billerica, MA, USA) 
Cyp 3A5 BD Biosciences 
Cyp 4F2 Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
Cytochrome b5  
Oxford Biomedical Research (Rochester Hills, MI, 
USA) 
DUSP4  Abcam 
Dvl2  Cell Signaling Technology 
EGFR Epitomics 
EGFR - phospho Y1068 Cell Signaling Technology 
EGFR - phospho Y845 Cell Signaling Technology 
EGFR - phospho, Y1045 Cell Signaling Technology 
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Antibody Supplier 
EGFR - phospho, Y1173 Cell Signaling Technology 
eIF2 alpha  Cell Signaling Technology 
eIF2 alpha - phospho S51 Cell Signaling Technology 
Elk-1 Cell Signaling Technology 
Erk1/2 Cell Signaling Technology 
Erk1/2  Cell Signaling Technology 
Erk1/2 - phospho T202/Y204 Cell Signaling Technology 
Erk2 (p42 MAPK)   Cell Signaling Technology 
FAK 1 Epitomics 
FAK 1 - phospho, Y576, Y577 Epitomics 
GAPDH Abcam 
Glutamine synthetase   Sigma Aldrich 
GSK3 beta  Cell Signaling Technology 
GSK3 beta - phospho S9 Cell Signaling Technology 
Ha-ras Upstate Biotechnology   
Her2  Dako (Glostrup, Denmark) 
Her2 - phospho Y1248 Cell Signaling Technology 
Her2 - phospho Y877 Cell Signaling Technology 
Histone Deacetylase 2   Epitomics 
Histone Deacetylase 3   Epitomics 
Histone Deacetylase 6 Millipore 
Histone H2B   Epitomics 
Histone H3  Cell Signaling Technology 
Histone H3   Cell Signaling Technology 
Histone H3 - acetyl K18  Epitomics 
Histone H3 - dimethyl K4  Epitomics 
Histone H3 - phospho S10 Cell Signaling Technology 
Histone H3 - phospho S28 Cell Signaling Technology 
Histone H3 - trimethyl K27 Cell Signaling Technology 
Histone H4 - acetyl K8  Epitomics 
HNF-4α  Santa Cruz Biotechnology 
IGF1 Receptor  Ventana Medical Systems (Tucson, AZ, USA) 
IGFBP-1  Santa Cruz Biotechnology 
IkappaB alpha  Cell Signaling Technology 
IkappaB alpha - phospho S32 Cell Signaling Technology 
ILK1 Cell Signaling Technology 
ILK1  Cell Signaling Technology 
Jak 1 Cell Signaling Technology 
Jak 1 - phospho Y1022/Y1023 Cell Signaling Technology 
Jak 2 Cell Signaling Technology 
Jak 2 - phospho Y1007/Y1008 Cell Signaling Technology 
JNK/SAPK  Cell Signaling Technology 
JNK/SAPK - phospho T183/Y185 Cell Signaling Technology 
Ki-67 United States Biological (Swampscott, MA, USA) 
Mcl-1   Cell Signaling Technology 
MEK1  Cell Signaling Technology 
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Antibody Supplier 
MEK1/2 - phospho S217/S221 Cell Signaling Technology 
MEK2 Cell Signaling Technology 
MKK4 Epitomics 
MKK4 - phospho, S257, T261 Cell Signaling Technology 
mTOR  Cell Signaling Technology 
mTOR - phospho S2448 Cell Signaling Technology 
mTOR - phospho S2481 Cell Signaling Technology 
N-Cadherin BD Biosciences 
Neo-P-Transferase 2  Abcam 
p27 Kip1 - phospho T187 Signalway Antibody (College Park, MD, USA) 
p27(Kip1) - phospho S10 - (CDKN1B) Epitomics 
p27(Kip1) (CDKN1B) Cell Signaling Technology 
p38/MAPK Cell Signaling Technology 
p38/MAPK - phospho T180,Y182 Cell Signaling Technology 
p53  R&D Systems 
p53 - phospho, S15 Cell Signaling Technology 
p53 - phospho, S392 Cell Signaling Technology 
p53 - phospho, S9 Cell Signaling Technology 
p70 S6 kinase   Cell Signaling Technology 
p70 S6 kinase - phospho T389 Cell Signaling Technology 
PAK 1/2/3 Cell Signaling Technology 
PAK1/2/3 - phospho S141 Life Technologies (Carlsbad, CA, USA) 
PDK1 Cell Signaling Technology 
PDK1 - phospho, S241 Cell Signaling Technology 
PERK Cell Signaling Technology 
PI3-kinase p85 subunit alpha Epitomics 
PKA C alpha/beta/gamma - phospho 
T197 Cell Signaling Technology 
PON1  Santa Cruz Biotechnology 
PON3  Abcam 
PP2A C - phospho Y307 R&D Systems 
PPAR alpha Abcam 
PPAR alpha Santa Cruz Biotechnology 
PPAR alpha, S12 Abcam 
PPAR alpha, S21 Abcam 
PTEN Cell Signaling Technology 
PTEN - phospho S380 Cell Signaling Technology 
Pyk2 Millipore 
Rad51 Epitomics 
Reduktase POR U. Zanger, IKP, Stuttgart 
RSK 1 Upstate Biotechnology   
RSK 1 - phospho, T573 Epitomics 
RSK 1 (p90RSK) - phospho, S380 Cell Signaling Technology 
RSK 3 - phospho, T353/T356 Epitomics 
RSK 4 Epitomics 
RSK 4 - phospho, S235 Epitomics 
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Antibody Supplier 
RXR alpha  R&D Systems 
S6 Ribosomal Protein  Cell Signaling Technology 
S6 Ribosomal Protein - phospho 
S235/S236 Cell Signaling Technology 
SHP-2   Epitomics 
Smad2 - phospho S245/S250/S255 Cell Signaling Technology 
Smad2/3  Cell Signaling Technology 
SOCS-3 Cell Signaling Technology 
ß-Actin  Sigma Aldrich 
ß-Gal  MoBiTec (Goettingen, Germany) 
STAT 1   Cell Signaling Technology 
STAT 3 Cell Signaling Technology 
STAT 3 - phospho S727  Cell Signaling Technology 
STAT 3 - phospho Y705 Cell Signaling Technology 
STAT 5  Cell Signaling Technology 
STAT 5 - phospho Y694 Cell Signaling Technology 
TAK1  Cell Signaling Technology 
TAK1 - phospho S412 Cell Signaling Technology 
UGT1A1  BD Biosciences 
 
 
2.2.3  Western Blot 
 
 
Antigen Actin 
Manufacturer Santa Cruz Biotechnology,Santa Cruz, CA, USA 
Catalog number sc-1616 
Source Donkey, polyclonal 
Application Loading control for Western Blot, 1:1000 dilution 
Antigen Phospho-MEK1/2 (Ser217/Ser221) 
Manufacturer Cell Signaling, Danvers, MA, USA 
Catalog number 9121 
Source Rabbit, polyclonal 
Application Western Blot, 1:1000 dilution 
Antigen Rabbit IgG 
Manufacturer Jackson ImmunoResearch, West Grove, PA, USA 
Catalog number 711-035-152 
Source Donkey, polyclonal 
Application Secondary antibody for Western Blot, conjugated with 
horseradish peroxidase, 1:2000 dilution 
Antigen Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
Manufacturer Cell Signaling, Danvers, MA, USA 
Catalog number 4376 
Source Rabbit, monoclonal 
Application Western Blot, 1:1000 dilution 
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2.3 Buffers and solutions: 
2.3.1 Electrophoresis 
50x TAE buffer (pH 8.5) for agarose gel electrophoresis 
Tris base 242 g 
EDTA (0.5 M, pH 8) 100 ml 
Glacial acetic acid 57.1 ml 
H2Odest ad 1000 ml 
 
GeneRuler 100 bp plus DNA ladder for agarose gels 
1 kb DNA ladder 1 µl (1 µg/µl) 
6x loading buffer for agarose gel electrophoresis 1 µl 
H2Odest ad 7 µl 
 
Ethidium bromide solution for agarose gels 
Ethidium bromide 10 mg 
H2Odest ad 1 ml 
 
10x loading buffer for acrylamide gel electrophoresis 
Bromophenol blue 25 mg 
Xylene cyanol 25 mg 
Ficoll type 405 1.5 g 
EDTA (0.5 M, pH 8) 1 ml 
H2Odest ad 10 ml 
 
Ammonium persulfate for acrylamide gel electrophoresis 
APS 1.2 g 
H2Odest ad 12 ml 
 
5x TBE buffer (pH 8.3) for acrylamide gel electrophoresis 
Tris base 54 g 
EDTA (0.5 M, pH 8) 20 ml 
Boric acid 27.5 g 
H2Odest ad 1000 ml 
 
 
6x loading buffer for agarose gel electrophoresis 
Sucrose 50 g 
SDS 1 g 
Orange G dye 0.5 g 
H2Odest ad 100 ml 
Ethidium bromide solution for acrylamide gel electrophoresis 
Ethidium bromide 0.5 mg 
H2Odest ad 1000 ml 
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pBR322 DNA-Msp1 Digest for acrylamide gels 
pBR322 DNA-MspI Digest (1 µg/µl) 10 µl 
10x Ladepuffer für Acrylamidgelelektrophorese 10 µl 
H2Odest ad 50 µl 
 
2.3.2 Isolation of genomic DNA 
Sodium acetate mixture for isolation of genomic DNA 
Sodium acetate solution (3 M) 10 ml 
SDS solution (20%) 2.5 ml 
EDTA solution (0.5 M, pH 8) 1 ml 
H2Odest ad 100 ml 
 
2.3.3 Immunohistochemistry 
 
 
TE buffer for isolation of genomic DNA 
TrisHCl (1 M, pH 7.5) 5 ml 
EDTA solution (0.5 M, pH 8) 1 ml 
H2Odest ad 500 ml 
Acetate buffer 
Sodium acetate 6.48 g 
Glacial acetic acid 1.21 ml 
H2Odest ad 1000 ml 
3-Amino-9-ethylcarbazole (AEC) solution 
3-Amino-9-ethylcarbazole 4 mg 
N,N-Dimethylformamide 1 ml 
Dissolve AEC in N,N-Dimethylformamide 
Acetate buffer 14 ml 
H2O2 (30%) 15 µl 
Alcoholic eosin solution 
Eosin Y 0.8 g 
Ethanol (60%) ad 200 ml 
Filter through fluted filter paper 
Carnoy fixative 
Ethanol 60 ml 
Chloroform 30 ml 
Glacial acetic acid 10 ml 
10x citrate buffer (0.1 M, pH 6) 
Citric acid (sodium salt) 29.41 g 
H2Odest ad 1000 ml 
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2.3.4 Western Blot 
 
 
2.4 Primers 
2.4.1 RFLP analysis and sequencing 
Gene Forward primer (5’3’) Reverse primer (5’3’) Amplicon 
Ctnnb1 AGCTCAGCGCAGAGCTGCTG GAGCGCATGATGGCATGTCTG 1473 bp 
Ctnnb1 ACTCTGTTTTTACAGCTGACCT GAGCGCATGATGGCATGTCTG 248 bp 
Ha-ras GAGACATGTCTACTGGACATCCT 
GCTAGCCATAGGTGGCTCACC
TG 166 bp 
B-raf TTCCTTTACTTACTGCACCTCAGA 
AGCAGTCACTAGTTTAGGACT
G 426 bp 
 
2.4.2 LightCycler PCR 
Gene Forward primer (5’3’) Reverse primer (5’3’) Amplicon 
Meg3/Gtl2 Mm_Meg3_1_SG QuantiTect Primer Assay 148 bp 
Rian Mm_Rian_2_SG QuantiTect Primer Assay 149 bp 
Mirg Mm_Mirg_4_SG QuantiTect Primer Assay 168 bp 
Dio3 Mm_Dio3_1_SG QuantiTect Primer Assay 143 bp 
Dlk1 Mm_Dlk1_1_SG QuantiTect Primer Assay 120 bp 
Rtl1 Mm_Rtl1_2_SG QuantiTect Primer Assay 88 bp 
Coating solution for silanization of microscope slides 
(3-Aminopropyl)triethoxysilane 4 ml 
Acetone ad 200 ml 
PBS/S 
NaCl 2.03 g 
BSA 1 g 
PBS ad 100 ml 
PBS/T 
Tween 20 1 ml 
PBS ad 1000 ml 
TBS/T 
Tween 20 1 ml 
NaCl 8.76 g 
Tris base 2.42 g 
H2Odest ad 1000 ml 
10x transfer buffer 
Tris base 30 g 
Glycine 144 g 
H2Odest ad 1000 ml 
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Gene Forward primer (5’3’) Reverse primer (5’3’) Amplicon 
18s rRNA Mm_Rn18s_3_SG QuantiTect Primer Assay 143 bp 
Cyp7a1 Mm_Cyp7a1_1_SG QuantiTect Primer Assay 67 bp 
18s rRNA CGGCTACCACATCCAAGGAA GCTGGAATTACCGCGGCT 187 bp 
Glul 
(glutamine 
synthetase) 
GCGAAGACTTTGGGGTGA
TA 
GTGCCTCTTGCTCAGTTTGT
C 158 bp 
H19 CTGCTGCTCTCTGGATCCTC 
GTGGGTGGGTGCTATGAGT
C 408 bp 
CAR1 AACAACAGTCTCGGCTCCAAA  AGCATTTCATTGCCACTCCC  273 bp 
Hnf6 GAGCCCAACCCTTCGGTGAC 
CTCTGTCCTTCCCGTGTTCT
TG 337 bp 
 
 
2.5 Laboratory equipment 
Device Manufacturer Type designation 
Autoclave Webeco, Selmsdorf, Germany Autoclave C 
Balance Mettler-Toledo, Gießen, Germany P1200 
Balance Sartorius, Göttingen, Germany Analytic 
Bench top portable mini-
cleanroom 
Safetech Limited, 
Hongkong SAR, 
China 
Cleansphere CA 100 
Camera 
Raytest, 
Straubenhardt, 
Germany 
CSC Chemoluminescense 
detection module 
Centrifuge (for falcon tubes) Heraeus Instruments, Hanau, Germany Multifuge 1 L-R 
Centrifuge (for Eppendorf 
cups) 
Eppendorf, Hamburg, 
Germany 5417R 
Electrophoresis chambers 
GibcoBRL, Karlsruhe, 
Germany 
Horizontal Gel Electrophoresis 
System, H6 
Bio-Rad, Munich, 
Germany Mini Protean II 
Magnetic stirrers 
Heidolph Instruments, 
Schwabach, Germany MR 80 
IKA, Staufen im 
Breisgau, Germany Combimac RCT/RET 
IKA, Staufen im 
Breisgau, Germany Mag RH 
Microscope camera Zeiss, Oberkochen, Germany AxioCam MRc 
Microtome Reichert-Jung, Wetzlar, Germany Frigocut 2800 
Microwave 
Bosch, Gerlingen-
Schillerhöhe, 
Germany 
600 W 
PCR machine for reverse 
transcription 
PerkinElmer, 
Waltham, MA, USA GeneAmp PCR System 2400 
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Device Manufacturer Type designation 
PCR machine for standard 
PCR 
Biometra, Göttingen, 
Germany UNO thermoblock 
Bio-Rad, Munich, 
Germany MyCycler
TM
 thermal cycler 
pH meter WTW, Weilheim, Germany pH 522 
Power supply for gel 
electrophoresis 
Pharmacia, Uppsala, 
Sweden LKB EPS 500/400 
Desaga, Wiesloch, 
Germany Desatronic 3x500/100 
GibcoBRL, Karlsruhe, 
Germany ST 305 
GibcoBRL, Karlsruhe, 
Germany ST 606 T 
Tissue homogenizer B. Braun, Melsungen, Germany Mikro-Dismembrator II 
UV illuminator Biometra, Göttingen, Germany TI 1 
Vortex mixer Bender & Hobein AG, Zurich, Switzerland Genie 2
TM
 
Water preparator Merck Millipore, Billerica, MA, USA Milli Q Plus 
 
 
2.6 Expandable items and small devices 
Item Manufacturer Type designation 
15 ml tubes BD, Franklin Lakes, NJ, 
USA 
Falcon 2096 
50 ml tubes BD, Franklin Lakes, NJ, 
USA 
Falcon 2070 
1.5 ml reaction tubes Eppendorf, Hamburg, 
Germany 
- 
Cages Tecniplast, 
Hohenpeißenberg, 
Germany 
Makrolon type 2 
Capillaries (for LightCycler) Roche Applied Science, 
Penzberg, Germany 
LightCycler Capillaries 
(20 µl) 
Centrifuge adapter Roche Applied Science, 
Penzberg, Germany 
LightCycler Centrifuge 
Adapters 
Cover slips Thermo Fisher Scientific, 
Waltham, MA, USA 
30 mm diameter, #1 
Glass Pasteur pipette WU Mainz, Mainz, 
Germany 
- 
Glassware Schott, Mainz, Germany - 
Metal scissors Hauptner, Dietlikon, 
Switzerland 
- 
Metal tweezers 
Eickemeyer, Tuttlingen, 
Germany 
- 
Schnitzer Steel, Portland, 
OR, USA 
- 
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Item Manufacturer Type designation 
Microscope glasses R. Langenbrinck, 
Emmendingen, Germany 
26x76 mm 
Needles (0.9 x 40 mm) BD, Franklin Lakes, NJ, 
USA 
Microlance 3TM 
PCR reaction tubes (0.2 ml) 
Peqlab, Erlangen, 
Germany 
- 
Bio-Rad, Munich, 
Germany 
- 
PCR reaction tubes (0.5 ml) Eppendorf, Hamburg, Germany 
- 
Single channel air displacement 
pipettes and tips 
Biozym Scientific, 
Hessisch Oldendorf, 
Germany 
- 
Eppendorf, Hamburg, 
Germany 
- 
Syringes BD, Franklin Lakes, NJ, 
USA 
1 ml BD slip-tip 
syringe 
 
 
 
2.7 Software 
Adobe Systems, San Jose, CA, USA Photoshop Elements 10 
Microsoft, Redmond, WA, USA Office 2007 
Microsoft, Redmond, WA, USA Windows Vista 
Origin Lab Cooperation, Northampton, MA, 
USA 
OriginPro 8G 
PerkinElmer, Waltham, MA, USA BioDraw Ultra 12.0 
PerkinElmer, Waltham, MA, USA NanoDrop ND-1000 V3.2.1 
Premier Biosoft, Palo Alto, CA, USA Primer Premier 5.00 
Roche Diagnostics, Mannheim, Germany Roche LightCycler Run 5.32 
Zeiss, Oberkochen, Germany AxioVision 4.5 
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3. Methods 
3.1 Animal treatment and housing 
Mice were singly kept in makrolon type 2 cages at a 12 hour light/dark cycle with water and 
food available ad libitum. At the end of an experiment, mice were anesthetized with a mix of 
95% CO2 and 5% O2 and then killed by cervical dislocation. Animals were treated with 
humane care, and all protocols were in compliance with institutional guidelines. 
3.1.1 Tumor tissue from previous initiation-promotion experiments 
Archived frozen Ha-ras-, B-raf- or Ctnnb1-mutated tumor tissue and control tissues were 
available from previous carcinogenesis experiments conducted in our group (Jaworski et al., 
2005b; Strathmann et al., 2006; Marx-Stoelting et al., 2008; Rignall et al., 2010). In brief, 
male C3H/HeJ mice received a single i.p. injection of DEN (10 or 90 µg/g body weight) at 2 
or 6 weeks of age. After a treatment-free interval of 2 weeks, the mice were either kept on a 
diet containing 0.05% PB or on a PB-free control diet for 28 to 36 weeks before they were 
killed (figure 3.1). Tumors were isolated and either flash frozen in liquid nitrogen and stored 
at -80 °C or prepared for immunohistochemistry. 
 
 
 
 
 
 
 
 
3.1.2 PB-treatment of Connexin32-deficient mice 
Connexin32 (Cx32)-deficient mice were generated as previously described (Moennikes et al., 
2000a). Male Cx32Y/+ (wild-type) and C32Y/- mice (knockout) were either kept on a diet 
containing 0.05% PB or on a control diet for 12 weeks (five animals per group), beginning at 
approximately six weeks of age. At approximately 18 weeks of age, mice were killed and 
excised liver tissue was used for RNA isolation. 
Figure 3.1. Treatment scheme for unpromoted tumors (dark gray) and PB-promoted tumors 
(light gray). 
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3.1.3 Obtaining of spontaneous liver tumors 
Male C3H/N mice were purchased from Janvier Europe (Saint-Berthevin Cedex, France) and 
kept at a standard treatment-free diet. Animals were killed in four groups at approximately 52, 
63, 75 and 77 weeks of age and screened for liver tumors. Tumors were isolated and either 
flash frozen in liquid nitrogen and stored at -80 °C or prepared for immunohistochemistry. 
3.1.4 Tumors from DEN-initiated mice after withdrawal of PB-treatment 
Male Ctnnb1loxP/loxP, TTR-Cre-Tam mice generated in our group (Singh et al., 2013, 
manuscript in preparation) were initiated with a single dose of DEN (90 µg/g body weight) at 
the age of 5-6 weeks. After a treatment-free interval of 3 weeks, they received a PB-
containing diet (0.05%) for 25 weeks. After that, the animals were kept on a PB-free control 
diet for another 25 weeks before they were killed and tumors were isolated and flash-frozen. 
3.1.5 APC-knockout mice 
Liver tissue from mice with a liver-specific tamoxifen-inducible APC-knockout was available 
from a previous study of our group (Zeller et al., 2012). 
3.2 Mutation analysis 
3.2.1 Isolation of genomic DNA 
Frozen liver tissue was pulverized under liquid nitrogen using a mortar and pestle. Genomic 
DNA was extracted from the pulverized tissue with phenol/sodium acetate (1.25:1), 
chloroform/isoamyl alcohol (25:1) and finally pure chloroform. For precipitation of genomic 
DNA, ice-cold ethanol was added to the obtained solution. The precipitated DNA was 
washed, dissolved in TE buffer and quantified. 
3.2.2 Standard PCR 
Standard PCR was carried out on an UNO thermoblock (Biometra, Göttingen, Germany) or a 
MyCyclerTM thermal cycler (Bio-Rad, Munich, Germany). 5 µl of a 0.1 mg/ml dilution of 
genomic DNA were used according to the reaction mix in table 3.1. For primer sequences see 
section 2.4.1. 
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Table 3.1. Reaction mix for conventional PCR, used for Ha-ras-, B-raf- and Ctnnb1-specific primer 
pairs. 
 
 
 
 
 
The temperature programs given in table 3.2 were used for the different target genes. 
Table 3.2. PCR conditions for for Ha-ras-, B-raf- and Ctnnb1-specific primer pairs. 
 Target gene 
Activation 
Temperature (°C)  
Duration 
(min) 
Number of 
cycles 
Final 
elongation 
Ha-ras 
95 °C, 10 min  
95 1 
35 
72 °C, 5 min  
65 1 
72 1 
B-raf 95 1 40 60 1 
72 1 
Ctnnb1 95 °C, 5 min  
95 1 
40 72 °C, 10 min  58 1 
72 1 
 
3.2.3 RFLP analysis 
To detect point mutations in codon 61 of Ha-ras (wildtype sequence CAA) and codon 637 of 
B-raf (wildtype sequence CTG), PCR products were fragmented in a restriction digest. Point 
mutations in these codons can lead to the generation of new recognition sites for restriction 
endonucleases or the loss of existing recognition sites and thus to altered restriction fragment 
lengths as compared to wildtype DNA. PCR product was mixed with H2O, the respective 
restriction enzyme and, where required, NEBuffer 4 and BSA, and then incubated according 
to table 3.3.  
 
 
 
 
 
 
  
Volume (µl) 
H2O 29 
10x Taq buffer 5 
dNTPs (2 mM) 5 
Forward primer (10 µM) 2.5 
Reverse primer (10 µM) 2.5 
Taq polymerase (5 U) 1 
Genomic DNA (0.1mg/ml) 5 
Total volume 50 
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Table 3.3. PCR conditions for for Ha-ras-, B-raf- and Ctnnb1-specific primer pairs. 
 
Reaction products were separated on 10% polyacrylamide gels and stained with ethidium 
bromide. 
Mutations in Ctnnb1 were determined by sequencing of a 1473 bp PCR product spanning 
exon 3 of the Ctnnb1 gene which encodes the critical β-Catenin phosphorylation sites. For the 
spontaneous tumors isolated from aged mice, a 248 bp fragment including codons 32-41 of 
Ctnnb1 was sequenced. Primer sequences are indicated in 2.4.1. Sequencing was carried out 
by 4base lab (Reutlingen, Germany).  
3.3 Quantitative Real-time PCR 
3.3.1 Isolation of RNA from frozen liver 
RNA (including miRNA) was isolated from frozen liver tissue using the miRNeasy Mini Kit 
(QIAGEN) according to the manufacturer’s protocol. The concentration of eluted RNA was 
measured on a NanoDrop ND-1000 photometer. 
3.3.2 Reverse transcription 
Reverse transcription of isolated RNA was carried out using the GeneAmp PCR System 2400 
(PerkinElmer, Waltham, MA, USA). The reaction was run for 1 hour at 42 °C followed by an 
inactivation step of 15 minutes at 95 °C. The reaction mix in table 3.4 was used: 
 
 
 Ha-ras B-raf 
 Restriction enzyme TaqI XbaI Hpy188III BspHI TspRI 
Codon mutation CAACGA CAACTA CAAAAA CAACAT CTGGAG 
H2O 11 µl 11 µl 6 µl 9 µl 6 µl 
NEBuffer 4 - - 2 µl 2 µl 2 µl 
BSA 1 mg/ml - - 2 µl - 2 µl 
Enzyme 1 µl 1 µl 2 µl 1 µl 1 µl 
PCR product 8 µl 8 µl 8 µl 8 µl 9 µl 
Reaction conditions 65 °C, 1 h 37 °C, 1 h 37 °C, o/ n 37 °C, 1 h 65 °C, 2 h 
Resulting fragments in wildtype 
(bp) 
125, 41 166 129, 35 166 130, 136, 160 
Resulting fragments in mutated 
amplicon 
89, 41, 36 130, 36 166 130, 36 130, 136, 160, 
266 
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Table 3.4. Reaction mix for reverse transcription of isolated RNA. 
Reagent Volume 
H2O (Ampuwa) 4.85 µl 
MgCl2 (25 mM) 3 µl 
10x PCR buffer 1.5 µl 
dNTPs (10 mM) 1.5 µl 
dT20 (500 ng/µl) 0.38 µl 
dN6 (500 ng/µl) 0.38 µl 
AMV-RT (10 U/µl) 0.39 µl 
RNA (125 ng/µl) 3 µl 
Σ 15 µl 
 
3.3.3 LightCycler PCR 
Quantitative real-time PCR was carried out on a LightCycler 1.5 instrument (Roche Applied 
Science, Penzberg, Germany) using either the FastStart SYBR Green Master kit (Roche), the 
FastStart DNA MasterPLUS SYBR Green I kit (Roche) or the QuantiTect SYBR Green PCR 
kit (QIAGEN, Hilden, Germany). Primers were either synthesized by Eurofins MWG GmbH 
(Ebersberg, Germany) or obtained as predesigned primer assays from Qiagen (Hilden, 
Germany) and used with the QuantiTect SYBR Green PCR kit according to the 
manufacturer’s instructions. The temperature programs for the self-designed primers are listed 
in table 3.5 (for primer sequences see section 2.4.2).  
Table 3.5. Temperature programs used for LightCycler PCR. 
 Gene 
Step 18s rRNA H19 Glul (glutamine 
synthetase) 
Activation 10 minutes, 95 °C 
 
Temperature 
(°C) 
Duration 
(seconds) 
Temperature 
(°C) 
Duration 
(seconds) 
Temperature 
(°C) 
Duration 
(seconds) 
Denaturation 95 5 95 8 95 0 
Annealing 68 5 62 5 60 5 
Elongation 72 8 72 10 72 10 
Cycles 35 35 35 
 Gene 
 
Step Car1 Hnf6 
Activation 10 minutes, 95 °C 
 
Temperature 
(°C) 
Duration 
(seconds) 
Temperature 
(°C) 
Duration 
(seconds) 
Denaturation 95 5 95 5 
Annealing 62 10 65 6 
Elongation 72 12 72 11 
Cycles 45 50 
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3.4 Global gene expression analysis 
Affymetrix gene analysis was carried out as previously described by Lempiäinen et al. 
(Lempiainen et al., 2011) at the department for Discovery and Investigative Safety, Novartis 
Institutes for BioMedical Research, Basel, Switzerland. In brief, biotinylated amplified RNA 
(aRNA) was hybridized to the GeneChip® Mouse430_2 arrays. After washing and staining, 
the arrays were scanned using a solid-state laser scanner (GeneArray® Scanner 3000 
combined with the GeneChip® autoloader, Affymetrix). The Affymetrix GeneChip® 
Operating Software (GCOS) was used to generate the primary and secondary raw data files. 
3.5 miRNA expression analysis 
Analysis of miRNA expression was conducted at CXR Biosciences, Dundee, Scotland. Total 
RNA including miRNA was isolated using the miRNeasy Mini Kit (QIAGEN, Hilden, 
Germany). Prior to the miRNA expression analysis, RNA integrity was checked with an 
Agilent 2100 Bioanalyzer using the Agilent RNA 6000 Pico Kit (Agilent Technologies, Santa 
Clara, CA, USA). 25 ng total RNA was end-labeled using the miRNA complete labeling and 
hybridization kit (Agilent# 5190-0456). Agilent unrestricted Mouse miRNA microarrays 
(8x15K, #G4471A) and Agilent 8x15K gasket slides (#G2534-60015) were used for the 
study. Arrays were hybridized using Agilent hybridization and washing buffers according to 
the Agilent miRNA microarray method entitled ‘miRNA Microarray System with miRNA 
Complete Labeling and Hyb Kit’ (G4170-90011). Following hybridization and washing, the 
arrays were scanned on an Agilent Microarray Scanner (#G2505B) according to the Agilent 
protocol (#G4170-90011). Images from the scanner were processed using Agilent Feature 
Extraction Software v9.5.1. Briefly, miRNA genes that were significantly expressed above 
background on the individual arrays were identified using Agilent Feature Extraction 
software. This process involved deletion control and background subtraction and calculation 
of a p-value reflecting the probability that there was no difference in intensity for a given 
feature to that of a background using a two sided t-test. The p-value calculation was based on 
an error calculated using an Agilent error model (Agilent Feature Extraction Software (v9.5) 
#G2566-90012). 
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3.6 Analysis of proteome and phosphoproteome 
3.6.1 Reverse phase protein microarray analysis 
Reverse phase protein microarray analysis was performed at the Natural and Medical 
Sciences Institute, Reutlingen, Germany, as described in Braeuning et al., 2011, with the 
following modifications: Tissue lysates were generated by adding an 8-fold excess (vol/wt) of 
CeLyA Lysis Buffer CLB1 (Zeptosens, Witterswil, Switzerland) containing 1 M NaCl. A 
microarray layout was chosen that uses two replicates of each sample at a protein 
concentration of 0.3 mg/ml. Antibodies used for detection of proteins and protein 
modifications are listed in section 2.2.2. Fluorescence signal was generated using Alexa647- 
(Invitrogen, Darmstadt, Germany) and Cy5- (Dianova, Hamburg, Germany) labeled anti-
species secondary antibodies. Images of the microarrays were taken using the ZeptoREADER 
microarray imager (Zeptosens), and image analysis was performed using the ZeptoVIEW 3.1 
software package (Zeptosens). 
 
3.7 DNA methylation analysis 
MeDIP analysis was carried out at the department for Discovery and Investigative Safety, 
Novartis Institutes for BioMedical Research, Basel, Switzerland, as previously described 
(Thomson et al., 2012). In brief, genomic DNA isolated from mouse liver was fragmented 
(mean length of around 500 bp), and 6 µg of fragmented DNA were denatured and 
immunoprecipitated for 3 hours at 4 °C with 15 µl mouse monoclonal antibody against 5-
methylcytidine (Eurogentec, Seraing, Belgium; #BI-MECY-1000). The reaction mix was 
incubated with 60 µl of magnetic M-280 protein G Dynabeads (Invitrogen, Grand island, NY, 
USA; #100-03D) for 2 hours and then washed. Washed beads were resuspended in lysis 
buffer and incubated with proteinase K. Immunoprecipitated DNA fragments were then 
purified on DNA purification columns (Qiagen, Venlo, Netherlands) and eluted in TE. For 
microarray analysis, 10 µl of immunoprecipitated DNA was subjected to whole genome 
amplification (WGA) using the WGA2:GenomePlex Complete Whole Genome Kit (Sigma), 
and 6 µg of amplified material were sent to Roche Nimblegen (Iceland) for Cy3 and Cy5 
labeling and hybridization on 2.1M Deluxe mouse promoter tiling arrays. 
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3.8 Histochemistry and in situ hybridization 
Sections of paraffin-embedded tissue (5 µm) were cut with a microtome and transferred to 
silanized object slides. Before they were used for IHC, paraffin sections were incubated in 
xylene twice for 10 minutes for deparaffinization and then rehydratized by sequential 
incubation in aqueous ethanol dilutions (2 minutes each in 100%, 96%, 70%, 50% (v/v) 
ethanol, and finally PBS). If recommended by the antibody manufacturer, antigen demasking 
was carried out by boiling the sections in citrate buffer for approximately 10 minutes. Images 
were acquired under an Axio Imager light microscope (Imager.M1; Zeiss, Göttingen, 
Germany) with Axiovision Rel. 4.5 software (Zeiss). 
 
3.8.1 Staining of E-Cadherin, phospho-MAPK, 5’-hmC, 5’-mC and Egr1 
Sections were washed in PBS for 5 minutes, followed by a 5 minute incubation step in PBS/T. 
After that, sections were incubated in PBS/T containing 3% BSA at room temperature to 
avoid unspecific binding of antibodies. Primary antibody (diluted in PBS/T containing 3% 
BSA) was bound at 4 °C over night. Sections were washed with PBS/T for 5 minutes. 
Biotinylated secondary antibody (diluted 1:200 in TBS/T + 1% BSA) was bound for 1 hour at 
room temperature. After two short washing steps in PBS/T, sections were incubated with 
streptavidin-alkaline phosphatase (AP)-complexes (diluted 1:200 in TBS/T + 1% BSA) for 30 
minutes at room temperature. AP enzyme activity was detected via staining with Fast Red for 
approximately 40 minutes. 
3.8.2 Staining of glutamine synthetase 
Sections were washed in PBS for 5 minutes, followed by a 5 minute incubation step in PBS/S. 
To inactivate endogenous peroxidase activity, sections were incubated with swine normal 
serum (diluted 1:30 in PBS/S) for 5 minutes. Primary antibody was bound at 4 °C over night. 
Sections were washed with PBS for 5 minutes. Horseradish peroxidase (HRP)-conjugated 
secondary antibody (diluted in 1:20 in PBS/S) was bound for 30 minutes at room temperature. 
After a 5 minute incubation step in acetate buffer, HRP activity was detected by incubation 
with AEC solution for 5-10 minutes. Sections were then washed with PBS, followed by 
H2Odest for 5 minutes. Finally, they were embedded in Kaiser’s glycerol gelatin and covered 
with cover slips. 
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3.8.3 Meg3/Gtl2 in situ hybridization 
ISH was performed using the fully automated instrument Ventana Discovery Ultra® (Roche 
Diagnostics) at the department for Discovery and Investigative Safety, Novartis Institutes for 
Biomedical Research, Basel. Template for Meg3/Gtl2 probe synthesis was generated by RT-
PCR on mouse brain RNA using self-priming primers flanked SP6- and T3-promoter 
recognition sequences (forward primer: 5’-SP6-CTCTTCTCCATCGAACGGCT, reverse 
primer 5’T3-AACAATAAAGAACTTGAAGAGGTTTTGAT, amplicon size: 537 bp). The 
PCR product was purified and then transcribed using T3-RNA polymerase (anti-sense) and 
SP6-RNA polymerase (sense) at 37 °C for 2 hours using dNTP containing Digoxigenin-UTP 
according to the manufacturer’s recommendations (Roche Diagnostics, Schweiz AG, 
Rotkreuz, Switzerland). All chemicals were provided by Roche Diagnostics. FFPE sections 
were deparaffinized and rehydrated (EZprep solution). Pretreatment steps were carried out 
with the RiboMap™ kit according to the manufacturer’s instructions. Demasking was 
performed by heat retrieval cycles in RiboCC solution using option mild, followed by a 
complementary enzymatic digestion (Protease 3 for 16 minutes at 37 °C). Hybridization was 
performed by adding 200 µl of RiboHybe solution containing 10 ng of DIG-riboprobe to each 
slide and incubating at 70 °C for 6 hours. Sections were then washed 3 times at 70 °C for 8 
minutes on stringency conditions (2.0 x SSC). DIG-label probe detection was performed 
using an AP-conjugated sheep anti-digoxigenin antibody (Roche Diagnostics) diluted 1:500 in 
antibody diluent. Antibody incubation was carried out for 30 minutes at 37 °C followed by 
chromogenic detection using BlueMap™ Kit with a substrate incubation time of 4hours. 
Counterstaining using ISH nuclear fast red was performed for 2 minutes. Sections were 
mounted in glycerol gelatin mounting medium (Sigma-Aldrich Chemie GmbH, Buchs, 
Switzerland) and post-mounted using Pertex™. 
3.8.4 PAS staining 
Sections were dehydrated using ascending serial aquaeous dilution of ethanol (70% being the 
highest ethanol concentration) and then incubated in a 20% periodic acid solution for 5 
minutes. They were washed under running tap water for 5 minutes and incubated in Schiff 
reagent for 20 minutes. After that, sections were rinsed under running tap water for 30 
minutes. If applicable, a counterstaining with Mayer’s haematoxylin was additionally 
performed (see section 3.8.5).  
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3.8.5 H&E staining 
Sections were washed with H2Odest and then stained with Mayer’s haematoxylin for 5 
minutes. They were rinsed under running tap water for 10 minutes, equilibrated in 50% 
ethanol for 30 seconds and stained with alcoholic eosin solution for 3 minutes. Finally, the 
sections were dehydrated by incubation in 80%, 96% and 100% ethanol for 30 seconds each, 
twice incubated in xylene for 5 minutes and then embedded in Entellan and covered with 
cover slips. 
3.9 Western Blot 
Frozen tissues were pulverized using a micro-dismembrator prior to incubation with an 8-fold 
excess of lysis buffer (CLB1, Zeptosens) for 30 minutes on a tumbler. Afterwards, tissue 
lysates were centrifuged at 16 000 g and room temperature for 10 minutes. Proteins in the 
lyasate were separated via gel electrophoresis and then transferred to nitrocellulose 
membranes in NuPAGE transfer buffer (Invitrogen, Carlsbad, CA, USA) containing 10% 
methanol at 30V for 1 hour. Transfer to polyvinylidene difluoride (PVDF) membranes was 
performed in 1x transfer buffer containing 20% methanol at 100 V for 1 hour. Membranes 
were incubated in TBS/T buffer containing 3% bovine serum albumin (BSA) on a shaker for 
30 minutes at room temperature to avoid unspecific binding. After that, membranes were 
incubated on a tumbler with 4 ml of diluted primary antibodies in TBS/T buffer containing 
1% BSA over night at 4-8 °C. After rinsing and washing 5 times for 5 minutes each with 
TBS/T, the membranes were incubated with 4 ml diluted secondary antibody in TBS/T 
containing 1% BSA for 1 hour at room temperature on a tumbler. Rinsing and washing was 
repeated as described above. Finally, the membranes were incubated with 4 ml SuperSignal 
West Pico Chemiluminescent Substrate, Pierce (Thermo Fisher Scientific, Waltham, MA, 
USA) for 5 minutes. Light emission was detected with the Kodak Image Station 440 CF; 
image analysis was carried out using ImageJ and Adobe Photoshop. 
 
3.10 Statistic data processing 
Statistic processing of all datasets was conducted by Johannes Eichner and Clemens Wrzodek 
(University of Tübingen, Department of Computer Science, Cognitive Systems) and 
Raphaëlle Luisier (Department for Discovery and Investigative Safety, Novartis Institutes for 
BioMedical Research, Basel, Switzerland). 
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3.10.1 mRNA 
Affymetrix CEL files containing the raw probe intensities were normalized using the Robust 
Multichip Average (RMA) method. Quality of the experiments was determined using diverse 
plots and statistics implemented in the package arrayQualityMetrics for R/Bioconductor 
(Kauffmann et al., 2009). On the basis of extensive quality controls, it was concluded that all 
arrays had sufficient quality. A moderated t-statistic was chosen to detect differentially 
expressed genes (implementation from limma package for R/Bioconductor; Smyth, 2004). In 
order to correct for testing multiple genes, the Benjamini-Hochberg method was applied. 
3.10.2 miRNA 
Background correction and pooling of probe signal levels corresponding to the individual 
miRNAs was conducted using the Agilent Feature Extraction (AFE) image analysis algorithm 
from the AgiMicroRna package for R/Bioconductor (Lopez-Romero, 2011). Probe sets 
flagged by the AFE software as not expressed in any samples were excluded from further 
analysis. Subsequently, the mean fold changes were calculated for each replicate group, and 
p-values were computed using a moderated t-test with FDR (false discovery rate) correction 
as described above for mRNA expression data. Experimentally verified mRNA targets of 
miRNAs were extracted and merged from three publicly available databases, namely 
miRecords v3 (Xiao et al., 2009), miRTarBase v2.4 (Hsu et al., 2010) and TarBase v5.0c 
(Hsu et al., 2010). 
3.10.3 DNA methylation 
In order to correct for systematic intensity biases associated with the different fluorescent 
dyes, within-array normalization (Loess-based) was applied to M-values (M being the 
difference in log-ratios between input and IP, and A being the average of the log-ratios). 
Smoothing over individual probe intensities was further applied to the data using the 
computeRunningMedians routine (Ringo package). To this end, intensity of a probe at each 
genomic location was replaced by the median over a region of 500 bp (expected average 
length of DNA fragments after sonication) centered at the given probe. This step was intended 
to correct for systematic biases in individual probe intensities. Smoothed data matrices were 
further normalized by iteratively applying quantile-normalization to groups of probes sharing 
both CpG content (approximated by extending the probe sequence up to 500 bp - as per DNA 
fragment length - and then counting the number of occurrence of “CG” within this sequence) 
and GC content (calculated on the basis of probe-sequence and subsequently rounded up to 
the first decimal to reduce number of bins). This method was designed to reduce inter-array 
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variation which may differ/be specific for groups of probes sharing identical GC/CpG content. 
MeDIP enrichment levels were determined by computing the log-ratios from the red channel 
(enriched methylated DNA) to the green channel (input DNA) probe intensities. As these 
MeDIP enrichment levels were shown to be non-linearly related with absolute DNA 
methylation levels, the MEDME (Model for Experimental Data with MeDIP Enrichment) 
approach proposed by Pelizzola and colleagues was used. In the course of this procedure, a 
sigmoidal model is fitted on a fully methylation dataset needed for calibration (Pelizzola et 
al., 2008). Based on this model, the absolute methylation levels (AML) were inferred from the 
computed log-ratios for each probe. After that, the mean fold-changes for each sample group 
(i.e., tumor type) were computed, and p-values using the same statistical method as for 
mRNA expression data were calculated. To reveal the interactions between differential DNA 
methylation and gene expression, measurements of the probes which interrogate DNA 
methylation in the same proximal promoter were summarized. Proximal promoters were 
defined as the regions spanning from 2 kbp upstream to 0.5 kbp downstream of the TSS 
(transcription start site). As changes in the DNA methylation are typically focused to small 
regulatory regions, the highest peak was used as summary value for the DNA methylation 
status of a promoter. To create volcano plots and Venn diagrams, regions covered by the 
Nimblegen Deluxe Promoter Array (-2 kpb to +0.5 kpb) were analyzed. 
3.10.4 Protein expression and phosphorylation data 
The data obtained from reverse phase protein microarray analysis was subjected to annotation 
with UniProt IDs, log-transformation and median-centering in order to ease the 
interpretability and obtain a symmetrical scale of the protein and protein-modification levels. 
Measurements for which the background noise (i.e., signal of secondary antibody) was higher 
than the combined foreground and background signal (i.e., signal of primary and secondary 
antibody), were treated as missing values (< 1%) and imputed using the k-Nearest-Neighbor 
(kNN) algorithm. For assessment of differential protein expression, the same procedures as 
for mRNA data were applied. 
3.10.5 Data visualization in volcano scatter plots and Venn diagrams 
For volcano scatter plots and Venn diagrams, the log2 of the fold changes of tumor vs. control 
tissue was computed (from now on referred to as log-ratio). Statistic significance was 
determined by performing a moderated t-test with Benjamini-Hochberg correction. As criteria 
of significance for the volcano plots, absolute log-ratios >1.0 and FDR-corrected p-values 
<0.05 were postulated. For the Venn diagrams, no p-values were calculated. 
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3.10.6 Pathway enrichment analysis of mRNA and miRNA data 
Significantly dysregulated mRNAs (log-ratios >1.0, FDR-corrected p-value <0.05) were 
annotated to gene lists of the KEGG pathway database and displayed as lists in InCroMAP. 
For each gene list provided by KEGG, it was investigated if it contained one or more of the 
differentially expressed mRNAs measured in the present study. A “list ratio” was calculated, 
indicating the ratio of significantly dysregulated mRNAs to the total number of genes in a 
KEGG gene list. Furthermore, a “background ratio” was computed, which denotes the 
quotient of the number of genes in one KEGG gene list and the number of all genes in all 
gene lists. From these two values, p-values were calculated using a hypergeometric test with 
Benjamini-Hochberg FDR correction. Identified pathways were then ranked according to 
corrected p-values. 
Enrichment of significantly up- or down-regulated miRNAs was performed on annotated 
mRNA targets of the respective miRNAs. Predicted targets were annotated according to the 3 
databases ElMMo (Gaidatzis et al., 2007), DIANA microT (Maragkakis et al., 2011) and 
TargetScan (Friedman et al., 2009). The resulting mRNA pool was subjected to enrichment 
analysis as described above, with the exception that “list ratio” indicated the ratio of miRNAs 
that contain target mRNAs in a KEGG gene list and the total number of potential regulatory 
miRNAs in this list.  
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4. Results 
4.1. Mutation analysis of PB-promoted and unpromoted tumors 
27 liver tumors from DEN-initiated mice, 7 isolated from PB-promoted and 20 from 
unpromoted animals, were examined with regards to their mutation status. 100% of the PB-
promoted tumors harbored activating point mutations in codons 32, 33, 37 or 41 of the 
Ctnnb1-gene, whereas most of the unpromoted tumors were either mutated in Ha-ras-codon 
61 (35%) or B-raf-codon 637 (45%) (figure 4.1 and table 4.1). In four of the unpromoted 
tumors, no mutations in Ctnnb1, Ha-ras or B-raf could be detected. The outcomes of the 
mutation analysis presented in this thesis are in accordance with previous results (Aydinlik et 
al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment 
Total 
number of 
analyzed 
tumors 
Number of tumors 
Mutation in 
Ha-ras 
(codon 61) 
Mutation in B-
raf (codon 
637) 
Mutations in 
Ctnnb1 (codons 
32, 33, 37 or 41) 
Other 
mutations 
DEN+PB 7 0 0 7 0 
DEN 20 7 9 0 4 
 
Figure 4.1. Percentages of Ha-ras-, B-raf- and Ctnnb1-mutations in DEN-initiated mouse 
liver tumors which were either PB-promoted (“plus“) or unpromoted (“minus“).  
plus plus plus minus minus minus 
Table 4.1. Distribution of Ha-ras-, B-raf- and Ctnnb1-mutations in DEN-initiated mouse liver 
tumors which were either PB-promoted (“DEN+PB“) or unpromoted (“DEN“).  
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Because of the high transcriptional and phenotypic similarities between Ha-ras- and B-raf-
mutated tumors (Jaworski et al., 2007; Rignall et al., 2009), a subset of 10 tumors (3 Ha-ras-
mutated, 7 Ctnnb1-mutated) and 9 samples of surrounding non-tumor tissue (3 from 
unpromoted and 6 from PB-promoted mice) was used for further analyses. Affymetrix 
analysis showed very heterogenous mRNA expression patterns for the 6 samples used as 
control for the Ctnnb1-mutated tumors, 3 of them resembling the pattern in the tumors. To 
exclude contamination of PB-treated control tissue with tumor tissue to the greatest possible 
extent, mRNA levels of the non-mutation-specific liver tumor marker Afp (α-fetoprotein) 
were checked in the control tissue samples. The 3 questionable samples showed increased Afp 
levels and were thus excluded from further data analysis. To ensure that adjacent non-tumor 
tissues are suitable as control, independent tissues from entirely untreated mice and from mice 
treated with PB for 12 weeks were additionally analyzed. As no noteworthy qualitative 
discrepancies between the adjacent and the independent control tissues were detected in 
comparison with tumor tissue, the data from the adjacent tissues were used for further 
analyses described in section 4.2.  
4.2. Global analysis of mRNA and miRNA expression, DNA methylation, and protein 
expression and phosphorylation in Ha-ras- and Ctnnb1-mutated tumors 
The goal of the analyses presented in this section was to create a global molecular profile of 
Ha-ras- and Ctnnb1-mutated mouse liver tumors. The experiments conducted with these 
tissues included the assessment of DNA methylation via methylated DNA 
immunoprecipitation (MeDIP), protein expression and phosphorylation via reverse phase 
protein microarray, mRNA expression via DNA microarray and miRNA expression via 
miRNA microarray (figure 4.2). 
 
 
 
 
 
 
 
Figure 4.2. Schematic workflow of the global molecular characterisation of Ha-ras- and 
Ctnnb1-mutated mouse liver tumors. 
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To obtain a first global overview, volcano scatter plots and Venn diagrams were created for 
mRNA, miRNA, DNA methylation and reverse phase protein microarray data to illustrate 
statistically significant changes in both tumor types (figure 4.3, for detailed gene lists see 
appendix). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
C 
D 
Figure 4.3. Volcano scatter plots and Venn diagrams of A) mRNA expression, B) miRNA 
expression, C) DNA methylation, and D) protein expression (upper panel) and 
phosphorylation (lower panel). 
„Log-ratio“ = log2 of the fold changes of tumor vs. control. As criteria of significance for the 
volcano plots, absolute log-ratios >1.0 and FDR-corrected (Benjamini-Hochberg correction) 
p-values <0.05 were required. Note that in Venn diagrams, p-values were not considered, 
and thus more genes may be indicated in Venn diagrams than in supplementary tables. 
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Comparison between Ha-ras- and Ctnnb1-mutated hepatomas showed that approximately 50 
% of the down-regulated transcripts in Ctnnb1-mutated tumors was also decreased in the Ha-
ras-mutated ones (250 of 534). All in all, the Ha-ras-mutated tumors contained 810 down-
regulated RNAs. 475 transcripts were exclusively up-regulated in Ctnnb1-mutated and 950 
exclusively in Ha-ras-mutated tumors, and another 284 were concomitantly increased in both 
types of lesions. Several general tumor markers were identified among the RNAs concurrently 
up-regulated in both tumor types, including the HCC serum marker Afp (α-fetoprotein), Slpi 
(secretory leukocyte proteinase inhibitor) which has recently been found to be up-regulated in 
human gastric carcinoma (Cheng et al., 2008), Golm1 (Golgi membrane protein 1) which is 
used as a blood marker for liver cancer (Marrero et al., 2005) and as a tissue and urine marker 
for prostate cancer (Varambally et al., 2008), as well as Gpc3 (glypican 3) which serves as a 
histochemical marker for HCC (Anatelli et al., 2008). Apart from that, the concomitantly up- 
or down-regulated RNAs in the two tumors were very diverse in function, and thus no 
common global changes could be defined. 77 RNAs showed anti-correlated expression, i.e., 
were either up-regulated in Ha-ras- and down-regulated in Ctnnb1-mutated tumors, or vice 
versa. A number of genes associated with xenobiotic metabolism were dysregulated in both 
types of tumors (figure 4.4). Most xenobiotic-metabolizing enzymes and transporters were 
transcriptionally down-regulated in the Ha-ras-mutated tumors whereas they were mostly 
unchanged or up-regulated in the Ctnnb1-mutated ones. mRNA changes with regards to 
energy metabolism are described below. The majority of changes at the mRNA level found in 
the present thesis were also observed in previous studies conducted in our group (Stahl et al., 
2005a; Jaworski et al., 2007).  
In contrast to mRNA, only few miRNAs were significantly dysregulated (log-ratio >1.0, p-
values <0.05; see volcano plot in figure 4.3B), whereas the statistically less stringent Venn 
diagram showed that 28 miRNAs were dysregulated in both tumor types, 9 of which showed 
anti-correlated expression. Experimentally validated target mRNAs could be identified for 4 
of the differentially expressed miRNAs in both tumor types and are listed in table 4.2. 
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Table 4.2. Experimentally validated targets of significantly dysregulated miRNAs in Ctnnb1- and Ha-
ras-mutated mouse liver tumors. Target mRNAs were annotated according to the miRecords v3, 
miRTarBase 2.4 and TarBase V5.0c databases. 
 
Of the experimentally confirmed target mRNAs, only Celsr2 in Ha-ras-mutated tumors was 
significantly changed in the present study, probably because only a small number of 
confirmed targets was identified altogether and the mechanisms connecting mRNA and 
miRNA expression are often disrupted in tumors. In addition, bioinformatically predicted 
mRNA targets were identified using the 3 databases ElMMo (Gaidatzis et al., 2007), DIANA 
microT (Maragkakis et al., 2011) and TargetScan (Friedman et al., 2009). Tgfb2 (encoding 
transforming growth factor β2), one of the predicted target mRNAs of miR-199a-5p, was 
highly up-regulated in Ha-ras-mutated tumors, consistent with the decrease of its potential 
Systematic miRNA 
name 
Log-ratio in Ctnnb1-
mutated tumors 
Log-ratio in Ha-ras-
mutated tumors Target mRNAs 
mmu-miR 199a-5p -2.74 -5.45 Sirt1, Hif1a 
mmu-miR 96 1.00 7.21 Odf2, Celsr2, Myrip, Aqp5, Ryk 
mmu-miR 199a-3p -1.25 -1.23 Smad1 
mmu-miR 139-5p -1.91 -1.21 Foxo1 
Figure 4.4. Overview of dysregulated mRNAs involved in xenobiotic metabolism in Ha-ras- and 
Ctnnb1-mutated tumors. Up-regulation is indicated by upward arrows in red cells, down-regulation 
by downward arrows in blue cells.  
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regulatory miRNA. Annotation of predicted targets of miR-680 and miR-425, which were 
induced in Ctnnb1-mutated tumors, resulted in long lists of potential targets, including Myst1 
(Myst histone acetyltransferase 1), Pbrm1 (polybromo-1), Epc1 (enhancer of polycomb 
homolog 1), Phf21a (Phd finger protein 21A) and Cbx6 (chromobox homolog 6), all of which 
play a role in chromatin remodeling. Possible targets of miR-425 included several mRNAs 
involved in either Ras- or Wnt-signaling, i.e. Rap2c (Rap2c, member of RAS oncogene 
family), Smek1 (suppressor of mek1), Mapk6 (mitogen-activated protein kinase 6) and Fzd1 
(frizzled family receptor 1). 
To visualize genome-wide DNA methylation changes with Venn diagrams and volcano plots, 
probes within a region between 2 kbp upstream and 0.5 kbp downstream of the transcription 
start site (TSS) were annotated to the respective gene and then averaged to obtain the mean 
methylation. All in all, more genes were hypermethylated in Ctnnb1- than in Ha-ras-mutated 
tumors, whereas the latter showed more hypomethylated genes than their Ctnnb1-mutated 
counterparts (see Venn diagram in figure 4.3C). Only few genes were concomitantly hyper- or 
hypomethylated (29 of 496 and 9 of 513, respectively) in the two tumor types, and the mean 
methylation of 17 genes showed anti-correlated fold changes. For visualization of DNA 
methylation the novel cross-platform data analysis tool InCroMAP was used (Wrzodek et al., 
2012; http://www.cogsys.cs.uni-tuebingen.de/software/InCroMAP/). It became obvious that, 
regardless of statistical significance, a number of DNA sequences - most of them gene 
promoter regions - showed almost mirror-image methylation patterns in Ha-ras- and Ctnnb1-
mutated tumors. Four of these promoter regions, together with the absolute mRNA expression 
values of the downstream genes, are displayed in figure 4.5. The figure makes it clear that 
mRNA expression was not changed as a result of the detected DNA methylation changes. 
Lack of significant correlation between gene expression and promoter methylation was a 
general finding upon analysis of the data. 
The antibodies used for reverse phase protein microarray analysis were chosen with a focus 
on xenobiotic-metabolizing enzymes and protein kinases with a role in signaling. 
Phosphorylation of several kinases was increased in the Ha-ras-mutated tumors (where 
MAPK signaling is constitutively activated) as compared to normal liver (figure 4.3D). 
Expectedly, since the antibody emphasis was put on signaling kinases, no proteins met the 
criteria of significantly differential expression or phosphorylation in Ctnnb1-mutated tumors 
(log-ratios >1.0, p-values <0.05, see figure 4.3D). 
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Constitutive activation of the β-Catenin and Ha-ras oncoproteins leads to disruption of Wnt- 
and MAPK-signaling and, as a result, to imbalances in a number of downstream processes 
which provide the initiated cell with a specific growth advantage. Most prominently, 
perturbation of metabolism is a common feature of tumors and has frequently been 
investigated as potential therapeutic target. In the following section, the observed changes in 
Wnt and MAPK signaling as well as alterations in central metabolic pathways in Ha-ras- and 
Ctnnb1-mutated tumors will be described. 
Alterations of MAPK and Wnt signaling at the mRNA and protein level are jointly visualized 
in figure 4.6, based on images created with InCroMAP. As the dynamic range of the reverse 
phase protein microarray approach used for the detection of changes in protein expression and 
phosphorylation is smaller than that of the other experimental platforms (Braeuning et al., 
2011), the significance criteria for protein expression and phosphorylation were eased for this 
visualization: Proteins were accepted as differentially expressed or phosphorylated with a log-
ratio >0.5, without considering the p-value. 
Figure 4.5. Highly anti-correlated methylation patterns in Ha-ras- (blue lines) and Ctnnb1-
mutated tumors (red lines) in the promoter regions of four genes. The position of the 
transcribed region is indicated by the green bar („TSS“ = „transcription start site“). The 
absolute mRNA expression values (log-ratios) of the corresponding genes are indicated as 
bar diagrams in the upper left corners. Note that Olfr1353 was not on the mRNA microarray, 
and hence the expression values are not indicated. 
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In Ha-ras-mutated tumors, activating phosphorylation of the effector kinases downstream of 
Ha-ras was increased, which is consistent with the constitutive activation of the MAPK 
pathway in these lesions. The same held true for Akt1 and Stat3, both of which are 
phosphorylation targets of MAPK and can function as transcriptional activators of Ras target 
genes. Accordingly, mRNA expression of the known Ras target genes H19, Egr1, Fos and 
Jun was significantly increased in the Ha-ras-mutated tumors. Ctnnb1-mutated tumors 
showed significant down-regulation of serine 445-phosphorylation of B-raf. Furthermore, an 
increase of the basic MAPK isoforms 8/9/10 but not the phosphorylated active forms was 
detected. Inhibitory phosphorylation of the kinase GSK3β at serine 9 was increased in both 
tumor types. β-Catenin, a target of GSK3β, was hyperphosphorylated in the Ha-ras-mutated 
tumors, which is a signal for proteasomal degradation and thus inactivation of the protein. 
mRNA expression of the Ras target gene Dusp6 (dual specificity phosphatase 6) was 
significantly increased in the Ha-ras-mutated tumors as compared to control tissue. Dusp14 
mRNA was up-regulated in Ctnnb1-mutated tumors by a log-ratio of 1.63 and a p-value of 
0.08, thereby closely missing the threshold of significance. Finally, two mRNAs encoded by 
Wnt-inhibitory genes, namely Wif1 (Wnt inhibitory factor 1) and Nlk (Nemo-like kinase), 
were abundantly expressed in Ctnnb1-mutated tumors. 
To generally elucidate which pathways apart from the Wnt and MAPK signaling cascades 
were affected by the molecular changes in the two tumor types, pathway enrichment analysis 
of the mRNA and miRNA data was conducted using the InCroMAP tool. To this end, 
significantly up- or down-regulated mRNAs and miRNAs were annotated to pathways 
corresponding to the KEGG database (Kanehisa et al., 2006). The enrichments were then 
ranked according to p-values (tables 4.3-4.6). Due to the comparably limited amount of 
significant DNA methylation and protein data, no enrichment analysis was conducted on these 
datasets. 
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Figure 4.6. Visualization of dysregulated mRNA expression, as well as protein expression and 
phosphorylation in the Wnt and MAPK signaling pathways in A) Ha-ras- and B) Ctnnb1-
mutated tumors. Significantly dysregulated mRNAs are indicated by red or blue arrows next to 
the gene name. Protein names in red or blue boxes indicate up- or down-regulated 
protein/phospho-protein. RNAs were considered significantly up- or down-regulated with 
absolute log-ratios >1.0 and p-values <0.05. Protein was considered significantly up- or down-
regulated/hyper- or hypophosphorylated with absolute log-ratios >0.5 regardless of p-value. 
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 Table 4.3. Pathway enrichments of mRNAs in Ha-ras-mutated tumors (top 15 pathways). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
# Name (ID) List 
ratio BG ratio q-value mRNAs 
1 Metabolic pathways (path:mmu01100) 185/1549 1203/18080 9.12E-14 
9130409I23Rik, Galnt12, Abat, Ctps2, Enpp1, Alox5, 
Hao2, Slc27a5, Tk1, Rgn, Plce1, Ak4, Etnk1, Cyp4f14, 
Mthfd2l, Dgkz, Baat, Hpse, Kynu, Cda, Hsd3b7, Akr1c6, 
Phgdh, Cyp4a14, Dpys, Acsl4, Ugt2a3, Mgll, Lipc, 
Cyp2c54, Asl, Acly, Lss, Oat, Aldh18a1, Galntl2, Chpt1, 
Pgd, Haao, Hsd3b2, Nat1, Pold4, Ptgds, Sds, Hexb, 
Hexa, Dhcr7, B3galnt1, Acsl3, Pafah2, NA, Tat, Etnk2, 
Acsm5, Cyp8b1, Acsl5, Bdh1, Rdh16, Alas2, Agmat, 
Cryl1, Rrm2, Sqle, Bdh2, Gss, Csad, Gcnt2, Gcdh, NA, 
Mthfd1l, Me1, Prodh, Cyp1a2, Acadsb, Rdh11, Aldh1b1, 
Hmgcr, Nt5e, Cyp2c50, NA, Chsy3, Hgd, Aass, NA, 
Psat1, Pon1, Pck1, Hibadh, Pycr1, Akr1b7, NA, P4ha2, 
Mgat5, Cpox, Nnmt, Ahcy, Cyp51, Cyp17a1, Smpd3, 
Upp2, Pigq, Uap1l1, Ggt6, Synj2, Dpyd, Lipg, Pafah1b3, 
NA, Cyp2b13, Fdps, Cyp2j5, Aadat, Sardh, Bcmo1, 
Akr1d1, Dmgdh, Sord, Hsd3b5, Cyp4f16, Cyp2b9, Fdft1, 
Pgm1, Gch1, Hpd, G6pdx, Afmid, B4galt6, Hmgcs1, 
Aldh1a7, Pld1, Ces1e, Cyp2c29, Gnpda1, Amy1, Mvd, 
Gmds, Acsl1, Hmgcs2, Inpp1, Ivd, Ddc, Cyp4f15, Cox5b, 
Aox1, Ugt2b1, Pemt, Akr1b3, Cyp4a12a, Isyna1, Cyp2e1, 
Sptlc2, Cth, Ido2, Dct, St6gal1, G6pc, Adh4, Cyp2c37, 
Glul, Cyp2c39, Cmbl, Acsm2, Cyp2c38, Gpam, Chka, 
Idi1, Ppap2c, Ass1, Pnpla3, Gale, Cyp27a1, Psph, Otc, 
Ephx2, Pck2, Nsdhl, Cyp4a31, Aldoc, Ces1d, Agps, 
Galnt6, Aldh1a1, Cyp7a1, Acsm1, Asns 
2 Retinol metabolism (path:mmu00830) 27/1549 78/18080 9.92E-09 
Cyp2c29, NA, Rdh5, Ugt2b1, Cyp4a12a, Rdh16, 
Cyp26a1, Cyp4a14, Retsat, NA, Cyp2b13, Ugt2a3, Adh4, 
Cyp2c54, Cyp2c37, Cyp2c39, Cyp2c38, Bcmo1, NA, 
Cyp2b9, Cyp26b1, Cyp1a2, Cyp4a31, Rdh11, Lrat, 
Cyp2c50, Aldh1a7 
3 
Primary bile acid 
biosynthesis 
(path:mmu00120) 
10/1549 15/18080 2.83E-06 Baat, Hsd3b7, Slc27a5, Cyp39a1, Akr1d1, Cyp8b1, Cyp7a1, Cyp46a1, Cyp7b1, Cyp27a1 
4 
PPAR signaling 
pathway 
(path:mmu03320) 
22/1549 82/18080 3.89E-05 
NA, Pck1, Scd2, Slc27a5, Hmgcs2, Acsl1, Cyp8b1, 
Fabp4, Fabp7, Acsl5, Cyp27a1, Me1, Fabp5, Pck2, 
Fads2, Cyp4a31, Cyp4a12a, Cyp4a14, Acsl4, Cyp7a1, 
Acsl3, Lpl 
5 
Drug metabolism - 
cytochrome P450 
(path:mmu00982) 
22/1549 88/18080 1.09E-04 
Cyp2c39, Cyp2c29, Cyp2c38, Gstk1, Cyp2d9, NA, 
Cyp2b9, Fmo1, Aox1, Ugt2b1, Cyp1a2, Cyp2e1, Gsta2, 
Cyp2c50, NA, Fmo4, Cyp2b13, Ugt2a3, Gsta3, Adh4, 
Cyp2c37, Cyp2c54 
6 
Arachidonic acid 
metabolism 
(path:mmu00590) 
22/1549 91/18080 1.61E-04 
Cyp2c29, Cyp2c39, Cyp2j5, NA, Cyp2c38, Alox5, 
Cyp4f15, Cyp4f14, Cyp4f16, Cyp2b9, Ephx2, Cyp4a31, 
Cyp4a12a, Ptgds, Gpx1, Ggt6, Cyp2e1, Cyp4a14, 
Cyp2c50, Cyp2b13, Cyp2c37, Cyp2c54 
7 Bile secretion (path:mmu04976) 18/1549 71/18080 4.85E-04 
Slc22a7, Slco1a1, Abcb1a, Abcb11, Slc27a5, Abcg5, 
Car2, Baat, Slco1b2, Slco1a4, Aqp9, Adcy1, Atp1b1, 
Hmgcr, Cyp7a1, Slc10a1, Slc10a2, Aqp4 
8 
p53 signaling 
pathway 
(path:mmu04115) 
17/1549 70/18080 0.001265078 
Ccnd1, Igfbp3, Zmat3, Bax, Ccnb1, Ccnb2, Igf1, Cdkn1a, 
Cdk4, Ccne1, Cdk1, Cdkn2a, Cdk6, Thbs1, Gadd45g, 
Serpine1, Rrm2 
9 
Metabolism of 
xenobiotics by 
cytochrome P450 
(path:mmu00980) 
18/1549 78/18080 0.001385637 
Cyp2c39, Cyp2c29, Cyp2c38, Gstk1, Cyp2b9, Ugt2b1, 
Cyp1a2, Cyp2e1, Gsta2, Cyp2f2, Cyp2c50, NA, Cyp2b13, 
Ugt2a3, Gsta3, Adh4, Cyp2c54, Cyp2c37 
10 
Drug metabolism - 
other enzymes 
(path:mmu00983) 
15/1549 59/18080 0.001574954 Ces1e, Ces2g, Tk1, NA, Ces2e, NA, Ugt2b1, Nat1, Ces1d, Cda, Upp2, Dpyd, Dpys, NA, Ugt2a3 
11 
Butanoate 
metabolism 
(path:mmu00650) 
10/1549 31/18080 0.002745114 Acsm2, Abat, Bdh1, L2hgdh, Akr1c6, Acsm5, Hmgcs1, Bdh2, Hmgcs2, Acsm1 
12 
Fatty acid 
metabolism 
(path:mmu00071) 
13/1549 50/18080 0.002999752 NA, Acsl1, Gcdh, Acsl5, Cyp4a31, Cyp4a12a, Acadsb, Cyp4a14, Aldh1b1, Aldh1a1, Acsl4, Acsl3, Adh4 
13 
Tryptophan 
metabolism 
(path:mmu00380) 
12/1549 46/18080 0.004653156 Aox1, Inmt, Cyp1a2, Aadat, Kynu, Afmid, Ido2, Aldh1b1, Aldh1a1, Haao, Ddc, Gcdh 
14 
Glycine, serine and 
threonine metabolism 
(path:mmu00260) 
10/1549 34/18080 0.00488069 Psph, Sds, Sardh, Phgdh, Cth, Gnmt, Alas2, Dmgdh, Srr, Psat1 
15 Nitrogen metabolism (path:mmu00910) 8/1549 23/18080 0.005218605 Glul, Car5a, Car1, Cth, Car3, Car14, Asns, Car2 
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Table 4.4. Pathway enrichments of mRNAs in Ctnnb1-mutated tumors (top 15 pathways). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
# Name (ID) List 
ratio 
BG 
ratio q-value mRNAs 
1 Nitrogen metabolism (path:mmu00910) 11/1077 23/18080 4.31E-06 
Glul, Car5a, Cps1, Car1, Hal, Cth, Car3, Gls2, 
Car4, Car14, Car2 
2 Metabolic pathways (path:mmu01100) 108/1077 
1203/1808
0 4.18E-04 
Atp6v0d2, Hsd17b6, Abat, Ctps2, Hao2, Plce1, 
Ak4, Uck2, Kynu, Cbr3, Gls2, Acsl4, Pmm2, Asl, 
Acly, Gldc, Arg1, Ptgds, Pold4, Sds, Arg2, 
Amdhd1, Sgms1, Crls1, NA, Tat, Cyp8b1, Uroc1, 
NA, Cryl1, Maoa, Rrm2, Rrm1, Mthfd2, Agl, Bdh2, 
Csad, NA, Cds2, Rdh11, Adss, Gyk, Aldh1b1, 
Hmgcr, Nt5e, Got1, Psat1, Aass, Cs, Pck1, Gck, 
Akr1b7, Acacb, Nnmt, Fbp1, Uap1l1, Upp2, Hal, 
Dpyd, Pnliprp1, NA, Fdps, Cyp2j5, Ahcyl1, Sardh, 
Gulo, Hsd3b5, Bhmt, Cyp2b9, Pycr2, St3gal5, 
Cbs, Hsd17b7, Hmgcs1, Acaa2, Ces1e, Cps1, 
Mvd, Ivd, Cyp2c65, Ept1, Aox1, St6galnac6, Pigp, 
Cth, Dct, St6gal1, G6pc, Pi4k2b, Glul, Cyp2c39, 
Aprt, Agxt, Pla2g2a, Ppap2c, Ass1, Ptgis, 
Aldh3a2, Otc, Idh3a, Nsdhl, Prim1, Gapdh, Ftcd, 
Hsd17b12, Cyp2u1, Cyp7a1, Gpat2 
3 
Arginine and proline 
metabolism 
(path:mmu00330) 
13/1077 56/18080 7.96E-04 Glul, Asl, Cps1, Ass1, Aldh3a2, Pycr2, Otc, Arg1, Arg2, Aldh1b1, Gls2, Got1, Maoa 
4 Cell cycle (path:mmu04110) 21/1077 128/18080 0.001034379 
Ccnd1, Mcm6, Plk1, Ywhaq, Bub1b, Cdc6, Pttg1, 
Ccnb1, Cdc20, Ccnb2, Bub1, Myc, Mcm2, Rbl1, 
Wee1, Pcna, Cdkn2c, Cdk1, Ttk, Ccna2, Mad2l1 
5 Thyroid cancer (path:mmu05216) 9/1077 30/18080 0.001506996 
Tpr, Ccnd1, Pparg, Tcf7l1, Tcf7, Cdh1, Ctnnb1, 
Tpm3, Myc 
6 
Glutathione 
metabolism 
(path:mmu00480) 
12/1077 54/18080 0.001732835 Ggct, Gsr, Gstm6, Mgst3, Gstm4, Gpx7, Gstk1, Gstm3, Gsta4, Gstm2, Rrm2, Rrm1 
7 
Alanine, aspartate and 
glutamate metabolism 
(path:mmu00250) 
9/1077 34/18080 0.002705406 Asl, Glul, Cps1, Abat, Adss, Agxt, Gls2, Ass1, Got1 
8 
Glycine, serine and 
threonine metabolism 
(path:mmu00260) 
9/1077 34/18080 0.003091892 Bhmt, Cbs, Sds, Sardh, Gldc, Cth, Agxt, Maoa, Psat1 
9 
Drug metabolism - 
cytochrome P450 
(path:mmu00982) 
15/1077 88/18080 0.003339641 
Cyp2c39, Gstk1, Cyp2c65, NA, Cyp2b9, Aox1, 
Gstm6, Mgst3, Gstm4, Gstm3, NA, Gsta4, Fmo3, 
Maoa, Gstm2 
10 Bile secretion (path:mmu04976) 13/1077 71/18080 0.003929205 
Slc22a7, Slco1a1, Abcc4, Aqp1, Abcb1a, Car2, 
Slco1b2, Aqp9, Hmgcr, Cyp7a1, Atp1a2, Slc10a2, 
Aqp4 
11 
PPAR signaling 
pathway 
(path:mmu03320) 
14/1077 82/18080 0.004345159 NA, Pparg, Cd36, Pck1, Scd2, Apoa5, Fabp2, Cyp8b1, Fabp7, Aqp7, Gyk, Cyp7a1, Acsl4, Lpl 
12 Pathways in cancer (path:mmu05200) 35/1077 326/18080 0.004791806 
Smo, Cdh1, Ikbkg, Myc, Col4a1, Ikbkb, Pdgfra, 
Pdgfa, Fgf21, Dapk1, Lama3, Araf, Wnt2, Bmp2, 
Tcf7l1, Tcf7, Axin2, Tpm3, Hsp90aa1, Fgfr2, 
Rad51, Tpr, Ccnd1, Itga6, Pparg, Casp3, Crk, 
Igf1, Birc5, Egfr, Tgfbr2, Ctnnb1, Zbtb16, Casp8 
13 Histidine metabolism (path:mmu00340) 7/1077 28/18080 0.013665238 
Uroc1, Amdhd1, Hal, Ftcd, Aldh1b1, Maoa, 
Aldh3a2 
14 
Metabolism of 
xenobiotics by 
cytochrome P450 
(path:mmu00980) 
12/1077 78/18080 0.021782572 Cyp2b9, Cyp2c39, Gstm6, Mgst3, Gstm4, Gstk1, Gstm3, Cyp2c65, Cyp2f2, NA, Gsta4, Gstm2 
15 Prostate cancer (path:mmu05215) 13/1077 90/18080 0.023279291 
Ccnd1, Ikbkg, Ikbkb, Pdgfra, Pdgfa, Igf1, Araf, 
Egfr, Tcf7l1, Tcf7, Ctnnb1, Hsp90aa1, Fgfr2 
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Table 4.5. Pathway enrichments of miRNAs in Ctnnb1-mutated tumors. 
 
# Name (ID) List ratio BG ratio q-value miRNAs 
1 MAPK signaling pathway (path:mmu04010) 4/43 269/18080 0.18610429 mmu-miR-31, mmu-miR-143, mmu-let-7d*, mmu-miR-495 
2 
Neurotrophin signaling 
pathway 
(path:mmu04722) 
3/43 132/18080 0.098679509 mmu-miR-152, mmu-let-7d*, mmu-miR-495 
3 Glioma (path:mmu05214) 2/43 66/18080 0.191258049 mmu-miR-31, mmu-miR-152 
4 Focal adhesion (path:mmu04510) 3/43 200/18080 0.148574037 mmu-miR-31, mmu-miR-143, mmu-miR-29c* 
5 Huntington's disease (path:mmu05016) 3/43 200/18080 0.11885923 mmu-miR-199b*, mmu-let-7d*, mmu-miR-495 
6 Chronic myeloid leukemia (path:mmu05220) 2/43 74/18080 0.118241193 mmu-miR-31, mmu-miR-199b* 
7 ErbB signaling pathway (path:mmu04012) 2/43 87/18080 0.136273222 mmu-miR-143, mmu-miR-152 
8 Prostate cancer (path:mmu05215) 2/43 90/18080 0.126782994 mmu-miR-31, mmu-miR-139-5p 
9 GnRH signaling pathway (path:mmu04912) 2/43 99/18080 0.133726383 mmu-miR-143, mmu-miR-152 
10 Melanogenesis (path:mmu04916) 2/43 101/18080 0.124720215 mmu-miR-31, mmu-miR-152 
11 Pathways in cancer (path:mmu05200) 3/43 326/18080 0.17730514 mmu-miR-31, mmu-miR-199b*, mmu-miR-139-5p 
12 Tight junction (path:mmu04530) 2/43 137/18080 0.176589314 mmu-miR-31, mmu-miR-143 
13 Insulin signaling pathway (path:mmu04910) 2/43 138/18080 0.165024713 mmu-miR-143, mmu-miR-139-5p 
14 Wnt signaling pathway (path:mmu04310) 2/43 154/18080 0.184108224 mmu-miR-31, mmu-miR-152 
 
Table 4.6. Pathway enrichments of miRNAs in Ha-ras-mutated tumors (top 15 pathways). 
 
# Name (ID) List 
ratio 
BG 
ratio q-value miRNAs 
1 Pathways in cancer (path:mmu05200) 10/41 326/18080 1.73E-07 
mmu-miR-21, mmu-miR-199b*, mmu-miR-31, mmu-
miR-27a, mmu-miR-486, mmu-miR-139-5p, mmu-miR-
324-5p, mmu-miR-34a, mmu-miR-30c-2*, mmu-miR-31* 
2 Prostate cancer (path:mmu05215) 6/41 90/18080 2.06E-06 
mmu-miR-21, mmu-miR-31, mmu-miR-34a, mmu-miR-
486, mmu-miR-31*, mmu-miR-139-5p 
3 Focal adhesion (path:mmu04510) 7/41 200/18080 7.97E-06 
mmu-miR-21, mmu-miR-31, mmu-miR-34a, mmu-miR-
143, mmu-miR-29c*, mmu-miR-486, mmu-miR-31* 
5 Chronic myeloid leukemia (path:mmu05220) 5/41 74/18080 1.10E-05 
mmu-miR-31, mmu-miR-199b*, mmu-miR-30c-2*, mmu-
miR-27a, mmu-miR-31* 
4 Tight junction (path:mmu04530) 6/41 137/18080 1.24E-05 
mmu-miR-21, mmu-miR-31, mmu-miR-34a, mmu-miR-
143, mmu-miR-486, mmu-miR-31* 
6 Glioma (path:mmu05214) 4/41 66/18080 2.02E-04 
mmu-miR-21, mmu-miR-31, mmu-miR-486, mmu-miR-
31* 
8 Melanoma (path:mmu05218) 4/41 72/18080 2.14E-04 
mmu-miR-21, mmu-miR-31, mmu-miR-486, mmu-miR-
31* 
7 p53 signaling pathway (path:mmu04115) 4/41 70/18080 2.19E-04 
mmu-miR-21, mmu-miR-31, mmu-miR-486, mmu-miR-
31* 
9 Endometrial cancer (path:mmu05213) 3/41 52/18080 0.002013602 mmu-miR-21, mmu-miR-143, mmu-miR-486 
10 Basal cell carcinoma (path:mmu05217) 3/41 55/18080 0.002137743 mmu-miR-31, mmu-miR-324-5p, mmu-miR-31* 
11 Acute myeloid leukemia (path:mmu05221) 3/41 57/18080 0.002158356 mmu-miR-199b*, mmu-miR-30c-2*, mmu-miR-27a 
12 MAPK signaling pathway (path:mmu04010) 5/41 269/18080 0.002169301 
mmu-miR-21, mmu-miR-31, mmu-miR-143, mmu-let-
7d*, mmu-miR-31* 
13 Small cell lung cancer (path:mmu05222) 3/41 87/18080 0.006209577 mmu-miR-21, mmu-miR-34a, mmu-miR-486 
14 
Chagas disease (American 
trypanosomiasis) 
(path:mmu05142) 
3/41 101/18080 0.008801126 mmu-miR-21, mmu-miR-31, mmu-miR-31* 
15 
Neurotrophin signaling 
pathway 
(path:mmu04722) 
3/41 132/18080 0.017294091 mmu-miR-21, mmu-miR-34a, mmu-let-7d* 
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As expected, mRNAs coding for proteins involved in nitrogen and amino acid metabolism 
ranked very high in Ctnnb1-mutated tumors. In Ha-ras-mutated tumors, several mRNAs 
encoding phase I and II enzymes of xenobiotic metabolism were enriched in different 
pathways. mRNAs involved in general metabolic and signaling pathways associated with 
various cancers were significantly dysregulated in both tumor types, and only few miRNAs 
that regulate a number of mRNAs in different pathways were enriched. No significant 
enrichments of methylated DNA or protein could be detected in any pathway. 
To investigate the characteristic tumor-specific perturbations in metabolism, InCroMAP was 
used to to visualize the data analyzed in the course of this thesis and to integrate the different 
datasets where applicable. First, visualizations of the changes in mRNA expression in central 
metabolic pathways in Ha-ras- or Ctnnb1-mutated tumors as compared to non-tumor control 
tissue were created (figure 4.7). These images illustrate considerable differences between the 
two types of tumors concerning the transcriptional regulation of genes encoding enzymes 
involved in energy metabolism. In the Ha-ras-mutated tumors, mRNA expression of G6pc 
(glucose-6-phosphatase), which catalyzes the last step of gluconeogenesis, was reduced as 
compared to non-tumor control tissue. Expression of Pck1, which encodes the rate-controlling 
gluconeogenic enzyme phosphoenol pyruvate carboxykinase, was decreased in Ctnnb1-
mutated tumors. Citrate synthase (Cs) and a subunit of isocitrate dehydrogenase (Idh3a), 
which is the rate-limiting enzyme of the TCA cycle, were divergently expressed in the two 
tumor types. Both mRNAs were up-regulated in the Ctnnb1-mutated but down-regulated in 
the Ha-ras-mutated tumors; the fold changes in Ha-ras-mutated tumors were slightly below 
the required significance levels of +/-1.0 (-0.71 for Idh3a and -0.73 for Cs), but with 
significant p-values <0.04. The results of proteome analysis recently conducted in our group 
furthermore show that the flavoprotein subunit of succinate dehydrogenase, which represents 
the key interface between the TCA cycle and the respiratory chain, as well as several other 
proteins of the respiratory chain were down-regulated in Ha-ras-mutated tumors (Rignall et 
al., 2009). 
The key enzymes of cholesterol biosynthesis were significantly dysregulated at the mRNA 
level in Ha-ras- and Ctnnb1-mutated tumors. The mRNA of HMG-CoA synthase 1 (Hmgcs1) 
was up-regulated in both tumor types, whereas HMG-CoA reductase (Hmgcr) mRNA was 
increased only in the Ha-ras-mutated ones (figure 4.7). In Ctnnb1-mutated tumors, the 
mRNA levels of cholesterol 7α-hydroxylase (Cyp7a1), which catalyzes the rate-limiting step 
Results  Page 50 
of bile acid biosynthesis from cholesterol, were elevated, while they were decreased in Ha-
ras-mutated tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Changes in mRNA expression in the metabolism of A) Ctnnb1-mutated and B) Ha-ras-mutated 
tumors. Reactions catalyzed by individual enzymes are indicated by arrows and enzyme codes. Dotted 
arrows stand for a series of enzymatic reactions. Red arrows indicate significantly up-regulated, blue 
arrows significantly down-regulated mRNAs (p-value <0.05, log-ratio >1.0). For corresponding enzyme 
names and gene symbols see table 4.7. 
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Table 4.7. Enzyme names and gene symbols corresponding to the enzyme codes in figure 4.7.  
Entries written in bold letters indicate rate-controlling or -limiting steps. 
 
In agreement with earlier observations (Stahl et al., 2005b), a number of mRNAs involved in 
amino acid catabolism were differentially expressed in the Ctnnb1-mutated tumors (figure 
4.7). Among these were Ftcd (formiminotransferase cyclodeaminase), which catalyzes a step 
in histidine degradation, and Sds (serine dehydratase), which converts serine into pyruvate. 
Both genes were decreased in transcription. Down-regulation of  Ftcd in Ctnnb1-mutated 
tumors at the protein level has also been shown previously by our group (Strathmann et al., 
2007). Furthermore, an isoform of glutaminase normally expressed in kidney (Gls1) was up-
regulated in the Ha-ras-mutated tumors (log-ratio 0.97, p-value= 0.01). Two key enzymes of 
Enzyme code Enyme Name Gene symbol 
 1.1.1.95 3-Phosphoglycerate dehydrogenase Phgdh 
 4.2.1.3 Aconitase 2 Aco2 
3.3.1.1 Adenosylhomocysteinase  Ahcy 
2.4.2.7 Adenine phosphoribosyltransferase Aprt 
 3.5.3.1 Arginase Arg 
 4.3.2.1 Argininosuccinate lyase Asl 
 6.3.4.5 Argininosuccinate synthase Ass 
 6.3.4.16 Carbamoyl phosphate synthetase I CpsI 
 2.3.3.1 Citrate synthase Cs 
 1.14.13.17 CYP7A1 Cyp7a1 
 4.4.1.1 Cystathionine γ-lyase Cth 
 2.6.1.3 Cysteine transaminase Got1 
 2.3.1.85 Fatty acid synthase Fasn 
 3.1.3.11 Fructose 1,6-bisphosphatase Fbp1 
  2.7.1.2 Glucokinase Gck 
 3.1.3.9 Glucose 6-phosphatase G6pc 
 5.3.1.9 Glucose-phosphate isomerase Gpi1 
 2.7.2.11 Glutamate 5-kinase Aldh18a1 
 1.4.1.3 Glutamate dehydrogenase Glud 
 2.1.2.5 Glutamate formimino transferase (Formiminotransferase cyclodeaminase) Ftcd 
 3.5.1.2 Glutaminase 2 Gls2 
 6.3.1.2 Glutamine synthetase Glul 
2.4.1.14 Glutamine-PRPP-Amidotransferase  Ppat 
 1.4.4.2 Glycine dehydrogenase Gldc 
2.4.1.1 Glycogen phosphorylase Pygl 
 2.4.1.11 Glycogen synthase Gys2 
 4.3.1.2 Histidine ammonia lyase Hal 
 1.1.1.34 HMG-CoA-reductase Hgcr 
 2.3.3.10 HMG-CoA-synthase Hgcs 
2.4.2.8 Hypoxanthine phosphoribosyltransferase Hprt 
 1.1.1.42 Isocitrate dehydrogenase 2 Idh2 
 2.1.3.3 Ornithine transcarbamoylase Otc 
 1.14.16.1 Phenylalanine hydroxylase Pah 
 4.1.1.32 Phosphoenolpyruvate carboxykinase Pck1 
 1.5.99.8 Proline dehydrogenase Prodh 
 4.3.1.17 Serine dehydratase Sds 
 1.3.5.1 Succinate dehydrogenase Sdha/b/c/d 
 3.1.2.3 Succinyl-CoA hydrolase Acot4 
 1.13.11.11 Tryptophan 2,3-dioxygenase Tdo2 
 2.6.1.5 Tyrosine aminotransferase Tat 
 1.2.4.2 α-ketoglutarate dehydrogenase complex Ogdh, Dlst, Dld 
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the urea cycle were transcriptionally down-regulated in both tumor types, namely 
argininosuccinate synthase (Ass) and argininosuccinate lyase (Asl). Consistently, decreased 
Asl expression in Ha-ras- and Ctnnb1-mutated tumors has been shown at the protein level in a 
previous study conducted in our group (Strathmann et al., 2007). Liver-type arginase (Arg1) 
was not changed at the mRNA level in either of the tumor types, however, previous studies 
have shown down-regulation of arginase 1 at the protein level in Ctnnb1-mutated tumors 
(Strathmann et al., 2007). 
The research group of Christine Perret (Inserm, U1016, Institut Cochin, Paris, France) has 
identified several genes which are subject to direct control by β-Catenin via deep-sequencing 
of chromatin-immunoprecipitation products (unpublished data, manuscript by Torre et al. in 
preparation). Metabolic mRNAs that were significantly dysregulated in the Ctnnb1-mutated 
tumors in the present thesis were compared with the gene lists generated by Torre et al., and 
those that were identified as directly regulated by β-Catenin are listed in table 4.8 
 
Table 4.8. Genes encoding metabolic enzymes that are differentially expressed in Ctnnb1-mutated 
tumors, identified as direct β-Catenin target genes by Torre et al. 
 
EC Enzyme name Gene 
symbol 
Log-ratio in 
Ctnnb1-
mutated 
tumors 
Log-ratio in 
Ha-ras-
mutated 
tumors 
Transcriptional 
regulation by β-
Catenin* 
3.5.3.1 Arginase 1 Arg1 -2.95 - ↓ 
2.1.3.3 Ornithine transcarbamoylase Otc -1.50 -1.31 ↓ 
6.3.4.16 Carbamoylphosphate 
synthetase 1 Cps1 -2.17 - ↓ 
1.4.4.2 Glycine dehydrogenase Gldc -3.53 - ↓ 
4.3.1.17 Serine dehydratase Sds -4.60 - ↓ 
3.5.1.2 Glutaminase 2 Gls2 -4.18 - ↓ 
2.1.2.5 
Glutamate formimino 
transferase 
(Formiminotransferase 
cyclodeaminase) 
Ftcd -1.47 - ↓ 
4.3.1.2 Histidine ammonia lyase Hal -4.35 - ↓ 
4.1.1.32 Phosphoenolpyruvate 
carboxykinase 1 Pck1 -3.02 -0.22 ↓ 
4.3.2.1 Argininosuccinate lyase Asl -1.25 -1.47 ↓ 
1.1.1.105 Retinol dehydrogenase 9 Rdh9 1.79 1.08 ↑ 
1.2.1.3 Aldehyde dehydrogenase family 3, subfamily A2 Aldh3a2 1.86 - ↑ 
1.2.3.1 Aldehyde oxidase 1 Aox1 1.05 -1.47 ↑ 
1.1.1.41 Isocitrate dehydrogenase 3 (NAD+) alpha Idh3a 1.24 - ↑ 
2.4.1.1 Carbonic anhydrase 2 Car2 1.85 1.26 ↑ 
*...as identified by Torre et al., manuscript in preparation 
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4.3. Determination of the expression levels of imprinted Dlk1-Dio3 gene cluster RNAs 
Recent work developed in cooperation with Lempiäinen and colleagues showed that several 
RNAs encoded on the imprinted Dlk1-Dio3 gene cluster were up-regulated in wild-type 
mouse liver upon PB-treatment (Lempiainen et al., 2013). The role of these RNAs in PB-
promoted tumor formation was further examined in the course of the present thesis. To this 
end, the expression levels of 6 RNAs, Meg3/Gtl2, Dio3, Mirg, Rian, Dlk1 and Rtl1, all of 
which are Dlk1-Dio3 cluster RNAs, were determined via LightCycler-PCR in tissue samples 
of Ctnnb1- and Ha-ras-mutated tumors, as well as adjacent non-tumor control tissue samples 
(figure 4.8). The Dlk1 transcript could not be detected in any of the examined tissues, 
although it has previously been reported to be expressed in HCC and fetal liver (Yanai et al., 
2010). RNA levels of Meg3/Gtl2 were significantly higher in Ctnnb1-mutated tumors than in 
Ha-ras-mutated tumors (by a factor of 20.5) and control tissue from non-PB-treated animals 
(by a factor of 18.7), respectively, and expression of Dio3 showed a significant decrease in 
Ctnnb1-mutated tumors as compared to their Ha-ras-mutated counterparts (by a factor of 5.9). 
For the other three RNAs, no significant transcriptional differences were detected between the 
individual tissue groups.  
The PB-induced increase in Meg3/Gtl2 transcription does not occur in livers of PB-treated 
mice with a liver-specific Ctnnb1-knockout or CAR/PXR double knockout (Lempiainen et 
al., 2013). Based on the knowledge that PB is a CAR agonist and selects for Ctnnb1-mutated 
cells, it was hypothesized that Meg3/Gtl2 represents a link between the promoting agent and 
the resulting tumor genotype, and thus the following experiments focused on Meg3/Gtl2. To 
further characterize the potential role of Meg3/Gtl2 in PB-mediated tumor promotion, 
Meg3/Gtl2 RNA levels were determined via LightCycler-PCR in a number of normal tissues 
from different transgenic mouse models and various mouse tumor tissues: 1) liver tissue from 
mice with a liver-specific tamoxifen-inducible APC-knockout (Zeller et al., 2012), where β-
Catenin is constitutively activated (figure 4.9), 2) liver tissue from Connexin32 (Cx32)-
knockout mice (Moennikes et al., 2000a) which are not susceptible to tumor promotion by PB 
(figure 4.9), 3) mouse liver tumors isolated from entirely untreated male mice between 75 and 
77 weeks of age (figure 4.10), and 4) mouse liver tumors from DEN-initiated mice which 
were promoted with PB for 25 weeks and then kept on a PB-free control diet for another 25 
weeks before killing (figure 4.11). Liver samples of untreated mice and mice treated with PB 
for 12 weeks, respectively, were used as control tissues. 
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Figure 4.8. Relative expression of imprinted Dlk1-Dio3 cluster RNAs in Ha-ras- and Ctnnb1-
mutated tumors, as well as adjacent normal liver („NL plus/minus PB“). 
Sample numbers: Ctnnb1 tumors = 7; Ha-ras tumors = 3; NL plus PB  = 2; NL minus PB = 3. 
*... p-value <0.05 
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In APC-knockout liver, in which β-Catenin is constitutively active, Meg3/Gtl2 RNA was up-
regulated by a factor of 27.1 as compared to untreated control tissue and by a factor of 8.0 as 
compared to PB-treated control tissue (figure 4.9). PB-treated Cx32-knockout liver, which is 
insensitive to PB-promotion, showed an increase in Meg3/Gtl2 by a factor of 3.0 as compared 
to untreated Cx32-knockout tissue. In this respect, tissue from Cx32-knockout mice behaved 
very similarly to that of wild-type mice, in which Meg3/Gtl2 RNA was increased 3.4-fold in 
comparison with untreated wild-type tissue.  
From the livers of two DEN-initiated mice which received a PB-containing diet for 25 weeks 
and were then kept on a PB-free control diet for another 25 weeks, two tumors mutated in Ha-
ras and 3 tumors mutated in Ctnnb1 were isolated. In both Ha-ras- and Ctnnb1-mutated 
tumors, Meg3/Gtl2 was up-regulated as compared to PB-treated and untreated controls (figure 
4.10), although the increase was much higher in the Ctnnb1-mutated (factor 441.1 as 
compared to untreated control) than in the Ha-ras-mutated tumors (factor 123.9 as compared 
to untreated control). 
All of the tumors isolated from untreated male C3H mice of 75 to 77 weeks of age harbored 
Ha-ras-mutations. Interestingly, two tumors (tumors 2 and 6) showed increased Meg3/Gtl2 
levels as compared to untreated control, by factors of 39.9 and 5.0, respectively (figure 
4.11A). To clarify the phenotypes of these two samples, mRNA levels of H19 and Glul as 
typical markers for Ha-ras- and Ctnnb1-mutation, respectively, were determined via 
LightCycler-PCR. As expected, H19 was strongly up-regulated in both samples (figure 
4.11B), whereas tumor 2 showed an increase in Glul mRNA by a factor of 29.2 as compared 
to untreated control tissue (figure 4.11C). 
To examine the intracellular localization of the Meg3/Gtl2 transcript in tumors, in situ 
hybridization experiments were carried out in the laboratory of Valérie Dubost, Novartis 
Institutes for Biomedical Research, Basel. The experiments were conducted in fixed and 
embedded liver tissue from DEN-initiated mice which had either been unpromoted or 
promoted with PB (figure 4.12). Meg3/Gtl2-expressing nuclei were detected in GS-positive, 
Ctnnb1-mutated tumors but not in the GS-negative tissue surrounding the tumors. In contrast, 
the Meg3/Gtl2 transcript could not be detected in nuclei of E-Cadherin-positive, Ha-ras-
mutated tumors. 
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Figure 4.9. Relative expression of Meg3/Gtl2 in normal liver from untreated wild-type mice 
(WT minus PB) and mice treated with PB for 12 weeks (WT plus PB), in Cx32-knockout 
liver with and without PB-treatment (Cx32-KO plus/minus PB), and in untreated APC-
knockout liver (APC-KO minus PB). 
Sample numbers: WT minus PB, WT plus PB, Cx32-KO minus PB, Cx32-KO plus PB = 4 
each; APC-KO minus PB = 5. 
*... p-value <0.05 
Figure 4.10. Relative expression of Meg3/Gtl2 in Ha-ras- and Ctnnb1-mutated tumors isolated 
from DEN-initiated mice which were first promoted with PB for 25 weeks and then kept on a PB-
free diet for 25 weeks (Ha-ras/Ctnnb1 tumor (PB withdrawn)), and in normal liver from untreated 
wild-type mice (WT minus PB) and mice treated with PB for 12 weeks (WT plus PB). 
Sample numbers: WT minus PB, WT plus PB = 4 each; Ha-ras tumor (PB withdrawn) = 2; 
Ctnnb1 tumor (PB withdrawn) = 3.  
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Figure 4.11. A) Relative expression of Meg3/Gtl2 in individual spontaneous liver tumors 
isolated from untreated aged mice; B) relative expression of the Ctnnb1-mutation marker 
Glul in tumors 2 and 6; C) relative expression of the Ha-ras-mutation marker H19 in 
tumors 2 and 6. Normal liver from untreated wild-type mice (WT minus PB) and mice 
treated with PB for 12 weeks (WT plus PB) were used as controls in A), B) and C). 
Sample numbers: WT minus PB, WT plus PB = 4 each. 
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Figure 4.12. Demonstration of Meg3/Gtl2 transcript via in situ-hybridization in A) GS 
(glutamine synthetase)-positive and B) E-Cadherin-positive tumors (fixed and embedded liver 
tissue). Abundantly expressed GS and E-Cadherin points to Ctnnb1- and Ha-ras- or B-raf-
mutations, respectively. Note that Meg3/Gtl2 is transcribed in the nuclei of GS- but not of E-
Cadherin-positive tumor. 
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4.4. Determination of 5’-methylation and 5’-hydroxymethylation at cytidine in Ha-ras- 
and Ctnnb1-mutated tumors 
DNA methylation is probably the most important epigenetic mechanism in mammals, and its 
role in the formation and treatment of cancer has been extensively studied (for reviews see 
Ehrlich, 2002; Esteller, 2005; McCabe et al., 2009). 5’-methylcytosine is a well-characterized 
modification in CpG islands (Ehrlich et al., 1981), and 5’-hydroxmethylcytosine is meanwhile 
referred to as the sixth DNA base (Kriaucionis et al., 2009; Tahiliani et al., 2009). As 
phenobarbital has been reported to cause global DNA methylation changes in the mouse liver 
(Watson et al., 2002; Phillips et al., 2007), the 5’-methylation and 5’-hydroxymethylation 
status of cytosine in Ha-ras- and Ctnnb1-mutated tumors was determined via 
immunohistochemstry to investigate if these modifications could serve as additional markers 
to stratify the two phenotypes. To this end, sections of fixed and embedded mouse livers 
bearing both types of tumors were stained with antibodies against 5’-mC and 5’-hmC. The 
results are summarized in table 4.9 and exemplified in figures 4.13 and 4.14. 
Table 4.9. Immunohistochemical characterization of PB-promoted and unpromoted tumors. 
Overexpression of GS indicates Ctnnb1-mutations, overexpression of E-Cadherin indicates Ha-ras- or 
B-raf-mutations. 
 
 
 
 
 
 
In the immunohistochemical specimens, both GS-positive and E-Cadherin-positive tumors 
showed reduced contents of 5’-mC and 5’-hmC as compared to surrounding non-tumor tissue. 
The decrease was pronounced to roughly the same extent in both tumors, although 
macroscopically, it appeared that in some tumors, 5’-mC was marginally less reduced that 5’-
hmC, regardless of the mutation status. In the sections from mice which were promoted with 
PB, a slight zonation of both modifications could be detected, with increased levels of 5’-mC 
and 5’-hmC around the portal triad and thus directly opposed to the zonation of GS (see figure 
4.13). 
 
 
Treatment Plus DEN, plus PB Plus DEN, minus PB 
Number of animals 4 3 
Total tumors 5 2 
GS-positive tumors 5 0 
E-Cadherin-positive tumors 0 2 
Other tumors 0 0 
Tumors with decreased 5‘-hmC 5 2 
Tumors with decreased 5‘mC 5 2 
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Figure 4.13. Immunohistochemical demonstration of A) GS (glutamine synthetase)-
positive and B) pMAPK-positive tumors in serial sections of fixed and embedded liver 
tissue. Abundantly expressed GS and pMAPK points to Ctnnb1- and Ha-ras-mutations, 
respectively. Note the nuclear localization of 5’-mC and 5’-hmC. 
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4.4.1 5’-methylation and 5’-hydroxymethylation in livers of Connexin32-deficient mice 
To further investigate the role of DNA methylation in tumorigenesis, 5’-mC and 5’-hmC 
levels were determined in tumors from Cx32-knockout mice. From a study which had 
previously been conducted in our group, livers of mice partly deficient in the gap junction 
protein connexin32 (Cx32), which is encoded by a gene located on the X-chromosome  
(Moennikes et al., 2000b), were available. In brief, male Cx32 knockout mice (Cx32Y/-) were 
crossed with female Cx32+/+-mice, which led to a heterozygous Cx32 genotype (X+/X- or X-
/X+) in the females among the resulting offspring. After initiation with a single dose of DEN, 
the female offspring developed tumors with three different phenotypes: homogenous Cx32 
expression (48% of all lesions), complete Cx32-deficiency (25% of all lesions), and mosaic-
like Cx32 expression patterns with Cx32-positive and -negative cells within the same tumor 
(27% of all lesions). Assuming that in the Cx32-negative cells of completely Cx32-deficient 
tumors and those with the mosaic phenotype, the allele expressing Cx32 is inactivated by 
cytosine methylation at the 5’-position in the course of tumor formation, one would expect to 
find increased 5’-mC levels in these cells as compared to Cx32-expressing cells. This 
distribution of 5’-mC-positive cells in the tumors would again result in a mosaic-like pattern, 
but perfectly opposed to that of Cx32 expression. To investigate if methylation changes are 
responsible for the patchy Cx32-phenotype, sections of fixed and embedded mouse livers 
bearing tumors were stained with antibodies against 5’-mC and 5’-hmC, as well as GS and E-
Cadherin as indicators for the tumors’ mutation status. Cx32-stainings were carried out with 
an antibody in sections of frozen tissue from the same animals but different liver lobes. The 
results are summarized in table 4.10 and exemplified for the patchy phenotype in figure 4.14. 
 
 
Treatment Plus DEN 
Number of animals 4 
Total tumors 23 
GS-positive tumors 0 
E-Cadherin-positive tumors 23 
Tumors with decreased 5‘-hmC 23 
Tumors with decreased 5‘-mC 23 
 
 
Table 4.10. Immunohistochemical analysis of female Cx32+/- mice, harboring the patchy Cx32-
phenotype. Overexpression of GS indicates Ctnnb1-mutations, overexpression of E-Cadherin 
indicates Ha-ras- or B-raf-mutations. 
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In all tumors of the female Cx32+/- mice investigated, the content of 5’-hmC and 5’-mC was 
homogenously reduced as compared to surrounding non-tumor tissue, and no patchy 
distribution was observed. 
Figure 4.14. (A) Immunohistochemical demonstration of E-Cadherin, 5’-mC and 5’-hmC in liver 
tumors of female Cx32+/- mice. Stainings were carried out in parallel sections of fixed and 
embedded liver tissue. (B) Immunohistochemical demonstration of the patchy Cx32-phenotype in 
frozen tissue from the same animal but a different liver lobe. Open arrows indicate the tumor 
boundary. Closed arrows point towards the Cx32-positive area within the tumor. 
E-Cadherin 5‘-mC 5‘-hmC 
Cx32 
A 
B 
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5. Discussion 
Activation of the Ha-ras or Ctnnb1 proto-oncogenes results in characteristically different 
molecular programs which manifest themselves in tumor-specific changes on several levels, 
including gene expression, protein expression and modification and miRNA expression, as 
well as epigenetic alterations in the form of DNA methylation. As Ctnnb1-mutated cells are 
selected for by PB and no established short-term assays exist to assess the contribution of 
tumor promoters to carcinogenesis, the molecular stratification of tumors induced by different 
treatments bears a potential for predictive biomarker identification and is thus highly relevant. 
The present doctoral thesis comprised three projects, all of which aimed at identifying 
molecular markers that would allow for stratification of Ha-ras- and Ctnnb1-mutated tumors 
in the mouse model. In project 1, four datasets assessing mRNA expression, miRNA 
expression, DNA methylation and protein expression/phosphorylation obtained from the two 
tumor types were globally analyzed and compared. Furthermore, the datasets were integrated 
using a new bioinformatic tool with a focus on signaling cascades and metabolism. Project 2 
aimed at characterizing the role of the lncRNA Meg3/Gtl2, which is a transcript encoded on 
the imprinted Dlk1-Dio3 gene cluster. Since a correlation between Meg3/Gtl2 expression and 
PB-treatment had previously been observed in the rodent liver, a potential role of the lncRNA 
in PB-mediated tumor promotion was investigated. To this end, expression of Meg3/Gtl2 was 
measured and localization of the Meg3/Gtl2 transcript was examined in Ha-ras- and Ctnnb1-
mutated tumor tissue. The goal of project 3 was to elucidate whether the two tumor types 
differ with regards to DNA methylation. Using immunohistochemical techniques, their 
methylation and hydroxymethylation status at the 5’-position of cytidine (5’-mC and 5’-hmC) 
was determined and compared. To further examine the role of DNA methylation in 
tumorigenesis, it was investigated if changes in 5’-mC and 5’-hmC correlate with the 
observed reactivation of Cx32 in a subpopulation of tumor cells in livers from Cx32-knockout 
mice. 
5.1 Global integrated molecular profiling of Ha-ras- and Ctnnb1-mutated tumors 
The reverse phase protein microarray data presented in this thesis are a substantial supplement 
to the previous finding that signaling pathways regulated by Ras or Wnt were differently 
perturbed in Ha-ras- or Ctnnb1-mutated tumors at the mRNA level (Stahl et al., 2005a). A 
key characteristic of Ha-ras-mutated tumors is constitutive activation of MAPK signaling, 
and accordingly, the main kinases mediating downstream effects of Ha-ras were activated in 
these lesions, whereas they were unchanged or down-regulated in Ctnnb1-mutated tumors 
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(figure 4.6). Expectedly, mRNAs of the prominent Ras-target genes Jun and Fos were 
unchanged in Ctnnb1-mutated but up-regulated in Ha-ras-mutated tumors. Activating 
phosphorylation of the two proteins Stat3 (S727) and Rsk1 (T573), which act as mediators of 
Ras signaling, was specifically detected in Ha-ras- but not in Ctnnb1-mutated tumors (figure 
4.6). In this context, a recent work by Yeh et al. has shown that phosphorylation of Stat3 at 
S727 mediated by Ha-ras enhances the oncogenic potential of cancer cells in culture (Yeh et 
al., 2009). Both tumor types investigated in the present thesis showed increased mRNA levels 
of one Dusp isoform: Dusp14 in Ctnnb1-mutated and Dusp6 in Ha-ras-mutated tumors, with 
the p-value for Dusp14 expression only slightly higher than the required significance cutoff. 
In Ctnnb1-mutated tumors, the up-regulation of Dusp14 could be explained by the activation 
of Ras-inhibitory mechanisms by Wnt signaling (Zeller et al., 2012). The up-regulation of 
Dusp6 in Ha-ras-mutated tumors on the other hand indicates a feedback loop negatively 
regulating MAPK signaling in these lesions (Camps et al., 2000; Zhang et al., 2010). 
Similarly, the increased mRNA levels of the Wnt-interfering genes Wif1 and Nlk (Stahl et al., 
2005a), point to a negative feedback mechanism in Ctnnb1-mutated cells. Together with these 
findings, the increase of phosphorylated and thus inactivated β-Catenin and of catalytically 
active GSK3β in Ha-ras-mutated tumors, as well as the down-regulation of activating Braf 
kinase phosphorylation in Ctnnb1-mutated tumors underline that MAPK and Wnt signaling 
function antagonistically in HCC. 
The integration of different “omics” datasets using the InCroMAP tool is a powerful approach 
to gain new insights into the regulation of tumor metabolism at transcriptional, translational 
and epigenetic levels. Global mRNA profiling of Ctnnb1- and Ha-ras-mutated tumors has 
already been conducted in the past (Stahl et al., 2005a), but the data analyzed in the course of 
the present doctoral thesis are substantially stronger as they were generated using more 
Ctnnb1-mutated tumor samples (7 instead of 3) and more appropriate control tissues. The use 
of adjacent non-tumor samples from PB-promoted and unpromoted mice as controls for the 
respective tumors allowed for the distinction between treatment effects caused by DEN alone 
or in combination with PB and dysregulations specifically taking place in the tumors. 
Moreover, this thesis presents entirely new data on DNA methylation, as well as miRNA and 
protein expression.  
A variety of pathways were perturbed in both tumor types, as could be shown by pathway-
specific enrichment of dysregulated mRNAs and miRNAs. Most notably, metabolism of 
nitrogen and a number of amino acids was altered at the mRNA level in Ctnnb1-mutated 
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tumors as compared to control tissue, consistently with previous results (Stahl et al., 2005a; 
Stahl et al., 2005b). In Ha-ras-mutated tumors, mRNAs coding for proteins with a role in 
lipid and bile acid metabolizing pathways were among those changed most in expression. The 
reader must bear in mind that pathway enrichments are generalizations in that genes or other 
regulatory molecules often have far-reaching effects in a large number of processes in the cell. 
Therefore, annotation to a specific pathway always harbors the risk of producing a huge 
amount of superficial information and is no replacement for detailed analysis of every single 
enriched molecule. Nevertheless, as to analyzing large microarray-based datasets, pathway 
enrichment analysis is extremely useful in providing a global overview of the processes 
perturbed in the examined tissue.  
Comparison of the mRNA expression data presented in this thesis with the results of deep-
sequencing of chromatin-immunoprecipitation products conducted by Torre et al. (2013, 
manuscript in preparation) revealed that a number of genes encoding metabolic enzymes 
altered in mRNA expression in the Ctnnb1-mutated tumors are direct targets of the β-
Catenin/TCF4 transcription factor complex (table 4.7). Generally, fundamental metabolic 
changes were found upon analysis of the mRNA data in the course of the present study (figure 
4.7). Together with the frequent observation that glucose-6-phosphatase activity is reduced in 
liver tumors at the enzyme level, the decreased mRNA expression of phosphoenolpyruvate 
carboxykinase (Pck1) in Ctnnb1-mutated tumors and of glucose-6-phosphatase (G6pc) in Ha-
ras-mutated tumors indicates a global down-regulation of gluconeogenesis in both tumor 
types. This is supported by the fact that the rate-limiting enzyme of glycogen synthesis in the 
cytosol, glycogen synthase (Gys2), was unchanged in both tumors at the mRNA level. 
Consistently with the observed reduction of gluconeogenesis in Ctnnb1-mutated tumors, 
Chafey and colleagues have identified several gluconeogenic genes as negatively regulated by 
Wnt signaling in mouse liver (Chafey et al., 2009). In the Ha-ras-mutated tumors investigated 
in the present thesis, a substantial decrease in glycogen storage could be detected via periodic 
acid-Schiff staining (figure 5.1A), another indication for lowered gluconeogenesis rates. A 
mechanism for the inhibition of glucose synthesis from pyruvate recently demonstrated in 
human HCCs (Wang et al., 2012a) could also be identified in Ha-ras-mutated mouse tumors 
via integration of mRNA, miRNA and protein data (figure 5.1B): Stat3, which was activated 
in these lesions, blocks translation of the G6pc transcript by inducing the expression of miR-
23a, which was increased by a log-ratio of 1.08 and only closely missed the significance 
cutoff with a p-value of 0.63. As G6pc mRNA is a target transcript of miR-23a, its conversion 
into a functional enzyme is inhibited, which is in accordance with the previously described 
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observations. As mentioned above, loss of mRNA expression and enzyme activity of glucose-
6-phosphatase is a common yet poorly understood feature of many liver tumors, and these 
interactions between protein, miRNA and mRNA provide possible mechanisms in Ha-ras-
mutated tumors. However, miR-23a could only be found to be up-regulated in Ha-ras-
mutated tumors, which indicates that alternative mechanisms exist in Ctnnb1-mutated lesions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transcription of genes involved in the central metabolic processes of amino acid degradation, 
urea cycle and gluconeogenesis is zonated in normal liver, where it mainly takes place in 
periportal hepatocytes (Gebhardt, 1992). The list of negative β-Catenin target genes in table 
4.7, all of which play a role in the mentioned metabolic pathways, is thus consistent with the 
observation that Ctnnb1-mutated tumor tissue corresponds to the perivenous phenotype and 
periportal gene expression is inhibited in these tumors, whereas the periportal phenotype is 
stimulated in Ha-ras-mutated tumors (Braeuning et al., 2007a).  
In Ha-ras-mutated tumors, expression of the mRNAs encoding the two key enzymes of 
cholesterol biosynthesis, Hmgcs1 and Hmgcr, was significantly increased, and expression of 
Figure 5.1. A) Histochemical demonstration of glycogen in a pMAPK-positive, Ha-ras-mutated 
tumor via periodic acid-Schiff-staining. B) Proposed mechanism for down-regulation of G6pc 
transcription in Ha-ras-mutated tumors via Stat3 and miRNA 23a. 
B 
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Hmgcs1 was elevated also in Ctnnb1-mutated tumors (figure 4.7). At the protein level, 
Hmgcs1 could neither be detected by immunohistochemical staining nor by Western Blot 
using commercially available antibodies. However, two previously conducted studies confirm 
the up-regulation of Hmgcs1 in Ha-ras-mutated tumors versus normal liver at the mRNA 
level (Stahl et al., 2005a; Jaworski et al., 2007). Ha-ras- and Ctnnb1-mutated tumors differed 
with regards to mRNA expression of the gene encoding the key enzyme of bile acid 
biosynthesis, Cyp7a1, which was up-regulated at the mRNA level in Ctnnb1-mutated (figure 
5.3.B) and transcriptionally down-regulated in Ha-ras-mutated tumors. Accordingly, 
accumulation of cholesterol in Ha-ras-mutated but not in Ctnnb1-mutated mouse liver tumors 
has been shown previously by our group (Jaworski et al., 2007). These findings indicate that 
usage of cholesterol for bile acid synthesis is regulated differently in Ha-ras- and Ctnnb1-
mutated tumors (figure 5.3). Strikingly, most mRNAs encoding proteins involved in bile acid 
biosynthesis were down-regulated in Ha-ras-mutated tumors, except for Cyp39a1, which was 
increased in transcription (table 5.1). In addition to the present study, these results were found 
consistently in two other experiments of our group (Stahl et al., 2005a; Jaworski et al., 2007). 
Previous mRNA expression measurements showed that Cyp39a1 transcription is repressed in 
perivenous as compared to periportal hepatocytes (Braeuning et al., 2006). As Ha-ras-
mutated tumors show a periportal phenotype, this is in consistence with the selective up-
regulation of Cyp39a1 in these tumors. In Ctnnb1-mutated tumors, mRNAs coding for 
enzymes of bile acid synthesis were largely unchanged in the present study and the study 
conducted by Stahl et al. (Stahl et al., 2005a), with the exception of the key enzyme Cyp7a1 
(figure 4.7, table 5.1), as well as Cyp46a1 and Cyp8b1 (table 5.1). The fact that bile acid 
biosynthesis is significantly down-regulated at the mRNA level in Ha-ras-mutated tumors 
corresponds to the observed storage of cholesterol in these lesions (Jaworski et al., 2007). 
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Table 5.1. Significantly dysregulated mRNAs involved in bile acid biosynthesis. Study 1 = Stahl et al., 
2005a; study 2 = Jaworski et al., 2007; pv vs. pp = perivenous versus periportal hepatocytes 
(Braeuning et al., 2006). For scheme of bile acid biosynthesis see figure 5.2. 
 
 
Hmgcs1 and Hmgcr are known target genes of the transcription factor EGR1 (early growth 
response protein 1) (Gokey et al., 2011). In Ha-ras-mutated tumors in the present study, Egr1 
mRNA was found up-regulated, and increased levels of the protein were detected 
immunohistochemically in the tumors but not in adjacent non-tumor tissue (figure 5.3B). On 
its part, Egr1 mRNA expression is induced by SRF (serum response factor) and other 
transcription factors which act as downstream mediators of MAPK signaling and bind to a 
serum response element in the promoter region of the Egr1 gene (Qureshi et al., 1991; Gregg 
et al., 2011; Gregg et al., 2012). This is consistent with the detected increase of activated 
MAPK protein and up-regulated Egr1 mRNA expression in Ha-ras-mutated tumors, and, 
consequently, explains the increase of Hmgcs at the mRNA level in this tumor type. 
Enzyme name Gene 
symbol 
Enzyme 
code 
Ha-ras-mutated 
tumor 
pv vs. 
pp 
Ctnnb1- 
mutated tumor 
Study 
1 
Study 
2 
Present 
study  
Study 
1 
Present 
study 
cytochrome P450, 
family 7, subfamily a, 
polypeptide 1 
Cyp7a1 1.14.15.6 -6.74 -3.23 -3.21; 
-3.13 3.42 - 
2.36; 
1.62 
cytochrome P450, 
family 46, subfamily a, 
polypeptide 1 
Cyp46a1 1.14.13.30 -3.74 -2.33 -3.30 - -2.92 -3.32 
cytochrome P450, 
family 27, subfamily a, 
polypeptide 1 
Cyp27a1 4.2.1.92 -3.42 -2.60 -2.47 - - - 
cytochrome P450, 
family 39, subfamily a, 
polypeptide 1 
Cyp39a1 4.2.1.92 1.59 5.09 2.28 -2.38 - - 
cytochrome P450, 
family 7, subfamily b, 
polypeptide 1 
Cyp7b1 1.14.13.30 -6.18; 
-6.36 
-4.39; 
-6.01 
-3.68; 
-3.72 - - - 
hydroxy-delta-5-steroid 
dehydrogenase, 3 
beta- and steroid delta-
isomerase 7 
Hsd3b7 5.1.3.3 - -1.67 -1.18 - - - 
cytochrome P450, 
family 8, subfamily b, 
polypeptide 1 
Cyp8b1 1.14.15.4 -5.74 -5.20 -3.57 - - -1.20 
aldo-keto reductase 
family 1, member D1 Akr1d1 1.3.99.6 
-3.49; 
-1.88 
-1.72; 
-1.88 
-1.22; 
-1.10 - - - 
solute carrier family 27 
(fatty acid transporter), 
member 5, bile acyl 
CoA synthase 
Slc27a5 6.3.2.20 -1.19 -1.16 -1.09 - - - 
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Several observations support the idea that the Cyp7a1 gene is regulated by β-Catenin. 
Comparison of Cyp7a1 mRNA levels in wild-type mouse liver and liver tissue from mice 
harboring a Ctnnb1-knockout (Rignall et al., 2010) shows significantly decreased Cyp7a1 
expression in the knockout (log-ratio = -1.25). Furthermore, Cyp7a1 is a pericentrally 
expressed gene (figure 1.2), and accordingly, its mRNA expression was up-regulated by a 
log-ratio of 3.42 in enriched populations of pericentral as compared to periportal hepatocytes 
(figure 5.3B; Braeuning et al., 2006). Pericentral gene expression patterns are maintained in 
Ctnnb1-mutated tumors, which is consistent with the up-regulation of Cyp7a1 in these lesions 
in the present study. Interaction between the transcription factor HNF4 and Wnt-signaling has 
recently been shown to regulate zonal gene expression in liver (Colletti et al., 2009). In that 
work, it was shown that expression of the model pericentral gene Cyp1a1 was induced by 
joint binding of the HNF4 and TCF-4 transcription factors in the gene’s promoter region upon 
activation of Wnt-signaling. In the present study, bioinformatic analysis of the Cyp7a1 gene 
promoter using the ModuleMaster tool (Wrzodek et al., 2010) revealed binding sites for 
HNF4 and TCF-4 in close proximity to one another, about 240 bp and 150 bp upstream of the 
transcription start site, respectively. To confirm the theory that Cyp7a1 transcription is 
directly activated by β-Catenin, mRNA levels of Cyp7a1 were determined by qPCR 
measurements in cultured 70.4 and 53.2b hepatoma cells which had been treated with LiCl to 
Figure 5.2. Schematic demonstration of bile acid synthesis from cholesterol (modified from 
Schwarz, 2004). 
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stimulate β-Catenin. It was not possible to detect Cyp7a1 mRNA in cell culture at all (data not 
shown). However, the presence of a TCF binding site in the promoter and the fact that 
Cyp7a1 transcription is decreased in murine Ctnnb1-knockout liver tissue strongly indicate a 
regulatory function of β-Catenin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An interaction between MAPK-signaling and Cyp7a1 transcription has previously been 
proposed (De Fabiani et al., 2001). In this model, Cyp7a1 transcription is subject to feedback 
regulation, whereby bile acids lead to activation of the MAP-kinase Jun. Jun then activates 
transcription of the nuclear receptor SHP (small heterodimer partner), which represses 
Cyp7a1 transcription. Activation of Jun via phosphorylation was detected in Ha-ras-mutated 
tumors in a previous study conducted in our group (Thomas Knorpp, University of Tübingen, 
unpublished data). However, no dysregulation of the potential downstream effectors in the 
model mentioned above could be detected in the present study. Thus, a MAPK-stimulatory 
Figure 5.3. A) Demonstration of cholesterol synthesis in Ha-ras-mutated tumors by 
integration of mRNA, protein and metabolite data. mRNAs are written in italics, proteins in 
regular capitals. B) (1) Detection of pMAPK and pMEK in Ha-ras-mutated tumors via 
Western Blot; (2) Immunohistochemical demonstration of transcription factor EGR1 in 
pMAPK-positive (Ha-ras-mutated tumors); (3) Cyp7a1 mRNA expression in Ctnnb1- and Ha-
ras-mutated tumors; (4) absolute Cyp7a1 mRNA expression values in Ctnnb1-wildtype and 
knockout tissue, as well as in periportal and perivenous hepatocytes; (5) Cholesterol levels 
in Ha-ras-mutated tumors and normal liver, obtained from Jaworski et al., 2007. 
1
…data obtained from Rignall et al., 2010 
2
…data obtained from Braeuning et al., 2006 
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feedback mechanism mediated by bile acids does not provide sufficient molecular explanation 
for the down-regulation of Cyp7a1 in Ha-ras-mutated tumors. 
The sodium/bile acid cotransporter Slc10a1 (solute carrier 10 familiy member 1), which 
mediates the reabsorption of bile acids into hepatocytes via the basolateral membrane was 
down-regulated at the mRNA level in Ha-ras-mutated tumors (figure 4.7). As bile salts have 
previously been reported to activate MAPK signaling (Kurz et al., 2000), this might indicate 
another negative feedback mechanism in these lesions. Acetyl-CoA is the precursor of 
cholesterol biosynthesis and provided in the cytosol in the form of citrate subtracted from the 
TCA cycle via the citrate-pyruvate shuttle system in the mitochondrial membrane (figure 4.7). 
Since citrate synthase is slightly down-regulated at the mRNA level in the Ha-ras-mutated 
tumors, the question arises if in this case acetyl-CoA is really obtained from the mitochondria. 
To definitely clarify this, one would have to collect and analyze enzyme activity data for 
citrate synthase, ATP citrate lyase, which catalyzes the formation of Acetyl-CoA from citrate, 
as well as the carriers involved in the mitochondrial shuttle system. The abundant synthesis of 
cholesterol on the one hand and the lack of “drainage” into bile acid synthesis on the other 
leads to the observed accumulation in the cell, where it can be used as a precursor for the 
biosynthesis of cellular structures, such as membranes. Furthermore, several tumors are 
dependent on the presence of isoprenoids (Gibbs et al., 1997; Larner et al., 1998), which are 
formed as intermediates in the pathway leading to cholesterol, the mevalonate pathway, and 
are used for prenylation of proteins. Interactions between cholesterol metabolism and Ras, 
which itself is anchored in the cell membrane with, among others, a prenyl anchor, have been 
described previously (Shack et al., 1999; Clendening et al., 2010). The observations made in 
the course of the present study indicate that by up-regulation of Hmgcs and Hmgcr Ha-ras-
mutated tumors are provided with a selective proliferation advantage. The potential use of 
statins, which inhibit the major regulatory step in cholesterol biosynthesis catalyzed by 
Hmgcr, as chemotherapeutics is currently a prominent topic of research and has been so for 
several years (Lonardo et al., 2012). The data shown in the present thesis corroborate that this 
approach is promising for Ha-ras-mutated but not for Ctnnb1-mutated tumors. The fact that 
cholesterol production is increased in Ha-ras-mutated but not in Ctnnb1-mutated tumors 
shows that the metabolic adaptations contributing to a tumor cell’s growth advantage can be 
very diverse. All in all, this underlines the fundamental differences between the two types of 
lesions analyzed here. 
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In the beginning of the 20th century, Otto Warburg postulated that, regardless of oxygen 
supply, proliferating tumor cells would metabolize glucose via conversion to lactate and 
subsequent anaerobic fermentation, rather than generating pyruvate, which feeds into the TCA 
cycle and oxidative phosphorylation in the mitochondria (Warburg, 1956). This theory is 
commonly known as the Warburg Hypothesis and attributes the metabolic shift observed in 
tumors to mitochondrial dysfunction. In neither of the two tumor types analyzed in the course 
of this thesis, the mRNA levels of the enzyme catalyzing the conversion of pyruvate into 
lactate, lactate dehydrogenase (Ldh), was significantly changed. While the mRNA levels of 
two key enzymes of the TCA cycle, isocitrate dehydrogenase (Idh3a) and citrate synthase 
(Cs), were slightly decreased in Ha-ras-mutated lesions, transcriptional up-regulation of these 
two genes was observed in Ctnnb1-mutated tumors. Contrary to Warburg’s hypothesis, the 
latter finding rather points to oxidative glucose metabolism than to lactate fermentation in 
Ctnnb1-mutated lesions. At the protein and metabolite level, these results are supported by a 
recent report by Yuneva and colleagues who conducted metabolic profiling of MET-induced 
mouse liver tumors which contain activated β-Catenin, similar to the system investigated in 
the present thesis. They were unable to detect elevated lactate levels in these tumors, despite 
an increase in enzyme activity of lactate dehydrogenase (Yuneva et al., 2012). Furthermore, it 
was recently shown that Ldh enzyme activity is increased in mice harboring a liver-specific 
APC-knockout, which results in constitutive activation of β-Catenin (Chafey et al., 2009). 
Overall, these observations indicate that Ctnnb1-mutated prefer the energetically more 
efficient pathway of oxidative phosphorylation for glucose catabolism to lactate fermentation, 
while Ha-ras-mutated cells, showing a repression of the TCA cycle and the respiratory chain, 
carry out glycolysis in the cytosol only, without involving the mitochondria. Do these 
observations allow the conclusion that Ctnnb1-mutated tumors function contrary to the 
Warburg Hypothesis?  As a matter of fact, our current knowledge demands that Warburg’s 
model be viewed in a more differentiated manner, looking beyond the aspect of efficiency of 
ATP production. In most tumors, the functionality of mitochondria is not impaired but, on the 
contrary, essential for highly proliferating cells (Schulze et al., 2012; Ward et al., 2012). They 
require an enormous amount of biomolecules and depend on the mitochondria as key 
biosynthesis organelles. The present study indicates that Ha-ras- and Ctnnb1-mutated tumors 
have developed very different strategies to meet these requirements. Ha-ras-mutated tumors 
carried out massive cholesterol synthesis (figure 5.3), they increasingly produced glycine and 
serine as C1 and C3 components for further biosyntheses and, finally, they degraded 
glutamine via kidney-type glutaminase (Gls), while the mRNA levels of glutamine synthetase 
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(Glul) were down-regulated. Glutamine could fulfill the function of a key energy source, as 
ATP is gained from the oxidation of its degradation product α-ketoglutarate in the 
mitochondria. It could also play an important role in the tumor’s defense against oxidative 
stress by being deaminated to glutamate, which is part of the antioxidative tripeptide 
glutathione. Furthermore, glutamine is required for a number of biosyntheses, including that 
of purines. With the transcriptional down-regulation of glutamine synthesis (Glul) and up-
regulation of its degradation (Gls), the question arises as to where glutamine is obtained from 
in the first place. The liver‘s main glutamine transporter Slc38a1 was unchanged at the 
mRNA level, so it remains unclear if the tumor still withdraws glutamine from the blood 
stream, if the transporter is activated at the protein level, or if the tumor receives glutamine 
via some other mechanism, such as protein degradation. Ctnnb1-mutated tumors differed from 
their Ha-ras-mutated counterparts in that they showed elevated mRNA levels of enzymes 
forming TCA-cycle intermediates from glucose and excessively synthesized glutamine. The 
fact that bile acid biosynthesis from cholesterol was increased in the Ctnnb1-mutated tumors 
(Cyp7a1) indicates that, in contrast to the Ha-ras-mutated ones, excessive storage of 
cholesterol does not result in a specific proliferation advantage for these tumor cells. Both 
tumor types investigated in this study showed lowered mRNA levels of genes encoding some 
key enzymes of amino acid degradation. Accordingly, some mRNAs of genes involved in the 
urea cycle, where amino acid-derived ammonia is detoxified, were down-regulated. This 
could be a sign of increased protein synthesis, which would make perfect sense for 
proliferating cells. 
The results discussed here underline that the Warburg Hypothesis as such is a too simplistic 
model to describe the energetic and metabolic adaptations a cell undergoes in the course of 
transformation. According to this model, most tumor cells, regardless of their genetic 
modification or phenotype, reprogram their metabolism to follow one specific route with the 
priority objective of maximizing ATP-production. The comparison between Ctnnb1- and Ha-
ras-mutated mouse liver tumors provides evidence that cancer cells in fact develop very 
diverse metabolic strategies, not all of which exclude oxidative glucose metabolism in the 
mitochondria. Whether the metabolic alterations are a transcriptional consequence of changes 
in upstream signaling or in fact an initial feature selected for during tumorigenesis is unclear. 
There is currently an ever-growing body of evidence for a direct interaction between signaling 
proteins and metabolism, without transcriptional mechanisms being activated (Ward et al., 
2012). However, as exemplified for cholesterol synthesis in Ha-ras-mutated tumors (figure 
5.3), regulation of gene expression by transcription factors is still a valid mechanism. In 
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conclusion, the results of data set-spanning analysis and comparison of the two tumor types 
emphasize that altered metabolism is a mutation-specific fingerprint of tumor cells.  
 
5.2 The role of the imprinted Dlk1-Dio3-Cluster in the formation of Ha-ras- and 
Ctnnb1-mutated tumors 
The relevance of epigenetic mechanisms such as genomic imprinting, histone modification or 
ncRNAs during carcinogenesis is commonly recognized, although their effects appear to be 
more complex than originally thought. While miRNA-mediated regulation of gene expression 
is well-established, the function and mechanism of lncRNAs remains enigmatic. The 
imprinted Dlk1-Dio3 gene cluster plays a pivotal role in developmental processes (Kagami et 
al., 2008) and encodes a number of protein-coding RNAs, miRNAs and lncRNAs, the latter 
including Meg3/Gtl2. A connection between Meg3/Gtl2 and carcinogenesis has been observed 
in a number of tumor cells and tissues from different species (Zhou et al., 2007; Anwar et al., 
2012; Wang et al., 2012b; Ying et al., 2013), but the reported findings are in part inconsistent 
and have so far failed to present a mechanism for this lncRNA. One of the goals of the present 
thesis was to investigate a potential function of Meg3/Gtl2 as a biomarker for PB-promoted 
tumors. 
A recent study conducted in cooperation with the Novartis Institutes for Biomedical Research 
in Basel has shown that Meg3/Gtl2 is expressed in the GS-positive, hypertrophic hepatocytes 
surrounding the central vein in normal mouse liver tissue treated with PB (Lempiainen et al., 
2013). Together with the observation that the induction of Meg3/Gtl2 and other cluster 
ncRNAs is genetically dependent on CAR and β-Catenin, these findings provide strong 
evidence of a potential role of this locus in PB-promoted tumor formation. This is 
corroborated by the specific increase in Meg3/Gtl2 expression in Ctnnb1- but not Ha-ras-
mutated mouse liver tumors, demonstrated on the basis of qPCR measurements and 
histochemical experiments in this work (figures 4.8 and 4.12). A potential link between 
Meg3/Gtl2 and β-Catenin is further emphasized by transcriptional induction of the gene in 
APC knockout tissue where β-Catenin is constitutively active (figure 4.9). Interestingly, PB 
had a very similar effect on Meg3/Gtl2 expression in the liver of transgenic mice lacking the 
major gap junction protein Cx32 and wild-type mice, leading to a moderate but significant 
increase of expression. This was unexpected in the light of the outcome of an initiation-
promotion experiment with Cx32 knockout mice previously conducted in our group, which 
showed that Cx32 is essential for liver tumor promotion by PB (Moennikes et al., 2000a). The 
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results of both experiments allow the conclusion that for PB-mediated transactivation of 
Meg3/Gtl2, CAR and β-Catenin but not Cx32 is required. Furthermore, if the Meg3/Gtl2 
transcript is a mediator of PB in the course of tumor formation in the mouse liver, its effects 
are dependent on the presence of functional Cx32 and cannot circumvent gap junctional 
intercellular communication. 
In normal mouse liver, the up-regulation of Meg3/Gtl2 is completely reversible when PB-
treatment is abandoned (Lempiainen et al., 2013). However, in tumors which were promoted 
with PB for 25 weeks and then proliferated for another 25 weeks in the absence of PB before 
they were isolated, the levels of Meg3/Gtl2 remained increased as compared to untreated and 
PB-treated normal liver (figure 4.10). Interestingly, this was the case both in Ctnnb1- and Ha-
ras-mutated tumors, while Ha-ras-mutated tumors that had formed in non-PB-treated animals 
showed no induction of Meg3/Gtl2 (figure 4.8). Under the assumption that PB-treatment 
stimulates the outgrowth of Ctnnb1-mutated and inhibits proliferation of Ha-ras-mutated 
cells, it is imaginable that during the 25 PB-free weeks the Ha-ras-mutated cells regained the 
capacity to proliferate and form a tumor (figure 5.4). Since Meg3/Gtl2 was detected in the PB-
treated Ha-ras-mutated tumors, the activating effect of PB on this lncRNA appears to not be 
exclusive to Ctnnb1-mutated cells but takes place in Ha-ras-mutated cells as well, at least 
when treated with PB over a longer period of time.  
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Scheme of proliferation of Ctnnb1- and Ha-ras-mutated cells during PB-
promotion and when PB-treatment is abandoned. 
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All of the spontaneously formed tumors isolated from untreated aged male C3H mice were 
Ha-ras-mutated, and most of them showed similar or slightly lower levels of Meg3/Gtl2 
mRNA than untreated control tissue (figure 4.11A). In two tumors, however, Meg3/Gtl2 
expression was increased by factors of 40 and 9, respectively, as compared to the untreated 
control and was thus even higher than in the PB-treated control samples. As expected, these 
two samples showed up-regulated mRNA levels of the Ha-ras-mutation marker gene H19 as 
compared to non-tumor control tissue (figure 4.11C). Interestingly however, the Ha-ras-
mutated tumor with the 40-fold induction of Meg3/Gtl2 showed a significant increase in the 
expression of Glul, which is characteristically up-regulated in Ctnnb1-mutated tumors (figure 
4.11B). In consideration of the finding that unpromoted Ha-ras-mutated tumors usually do 
not overexpress Meg3/Gtl2, the question arose as to why this particular spontaneous tumor 
sample did anyway. The percentage of Ctnnb1-mutated tumors in the livers of non-PB-
promoted mice is very low, and no activating point mutations were detected in the 
spontaneous tumors. However, aside from single base substitutions in codons 32, 33, 37 and 
41, which predominate under the experimental conditions used, larger deletions in the 
Ctnnb1-gene, which also lead to activation of β-Catenin, may occur rarely. Thus, in addition 
to the Ha-ras-mutated cells that were identified via RFLP-analysis, the spontaneous tumor 
isolated from untreated mice could contain a population of cells harboring large deletions in 
Ctnnb1 which were not detected with the primers used in this study. Another explanation for 
the elevated Meg3/Gtl2 levels in the Ha-ras-mutated tumor would be that it harbored 
additional unknown mutations which lead to a stabilization of β-Catenin, for instance in the 
Apc gene. The results gained from spontaneous tumors and from those which developed under 
the regimen with PB-promotion and subsequent PB-withdrawal must be regarded with 
reservations as the sample numbers were very small. This made it impossible to statistically 
assess the effects seen in these tissues in a reasonable manner. 
All in all, the investigation of Meg3/Gtl2 showed that its activation can neither be assigned 
exclusively to one specific type of mutation nor to treatment with PB. This is consistent with 
the outcomes of other studies, which have shown Meg3/Gtl2 to be dysregulated in a variety of 
tissues and tumors. However, two facts still strongly support its role as a potential early and 
predictive biomarker for PB as a tumor promoter: first, up-regulation of Meg3/Gtl2 can be 
observed in normal liver after only two weeks of PB-treatment and thus long before a tumor 
has actually formed, and second, it is significantly increased in PB-promoted tumors.  
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The data presented in this work point to a tumor-driving function of Meg3/Gtl2 as it is always 
up-regulated in the context of PB-treatment or tumor formation. This is in contrast to other 
studies showing that Meg3/Gtl2 is significantly down-regulated in human liver cancer cell 
lines as compared to non-tumor cells (Braconi et al., 2011), inhibits cell proliferation in 
glioma cells in vitro (Wang et al., 2012b), induces apoptosis via activation of p53 (Zhou et al., 
2007), and has thus been suggested as a tumor suppressor (Zhou et al., 2012). However, the 
data from PB-driven Ctnnb1-mutated tumors provide a strong body of evidence that 
Meg3/Gtl2 functions as a promoter in these tumors, or at least is an essential component of 
PB-mediated tumor promotion in mouse liver. To definitely test this hypothesis, one would 
have to run an initiation-promotion experiment using DEN and PB in mice with a liver-
specific Meg3/Gtl2 knockout and check if tumor formation is impaired in these animals. 
5.3 5’-methylation and 5’-hydroxymethylation of cytidine in Ha-ras- and Ctnnb1-
mutated tumors 
The 5’-hmC patterns in murine and human brain are subject to defined dynamics in the course 
of postnatal neurodevelopment (Szulwach et al., 2011), which indicates that 5’-hmC is a self-
contained epigenetic modification and not a mere intermediate in the demethylation of 5’-mC. 
However, the functional significance of 5’-hmC is currently unknown. Impaired methylation 
at the 5’-position of cytosine is a frequently found feature in many cancer cell lines and 
tumors (Goelz et al., 1985; Barciszewska et al., 2007; Braconi et al., 2011), and a number of 
human cancers show a global decrease in 5’-hmC (Yang et al., 2012). Correspondingly, a 
comprehensive reduction of both 5’-mC and 5’-hmC was detected in Ha-ras- and Ctnnb1-
mutated tumors as compared to surrounding non-tumor tissue in the present work. The 
decrease in 5’-hmC has been reported to be accompanied by a down-regulation of Tet (ten-
eleven translocation) gene expression in various human cancers (Yang et al., 2012); however, 
no differential expression of the Tet genes was found in the two tumor types investigated in 
this study. The fact that Ctnnb1-mutated tumors showed reduced 5’-mC and 5’-hmC levels 
along with up-regulated expression of Meg3/Gtl2 indicates a causal relationship between 
these two phenomena. This is corroborated by a recent work by Braconi and colleagues, who 
have shown that decreased expression of Meg3/Gtl2 in human cancer cell lines could be re-
induced by treatment with a methylation inhibitor or siRNAs targeting the transcripts of 
Dnmt1 and 3b (DNA methyltransferases 1 and 3b) (Braconi et al., 2011). 
In the livers of both unpromoted and PB-promoted mice, 5’-hmC and 5’-mC were zonated in 
a periportally dominated pattern. Affymetrix® mRNA datasets of enriched populations of 
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periportal and pericentral mouse hepatocytes were available from an earlier experiment 
(Braeuning et al., 2006). To determine if the zonated methylation pattern was due to zonated 
expression of the enzymes that synthesize 5’-mC (Tet) or convert it to 5’-hmC (Dnmt), it was 
checked if these genes were differentially expressed in either of the cell types, but this was not 
the case. It is, however, possible that the catalytic activity of these enzymes is subject to 
differential regulation at the protein level in periportal and pericentral hepatocytes.  
To further analyze how DNA methylation influences the phenotype of a tumor, an interesting 
unpromoted tumor type with patchy Cx32-expression was investigated with regards to its 5’-
mC and 5’-hmC status. These analyses aimed at elucidating if DNA methylation is 
responsible for inactivation of the functional Cx32 allele in liver tumors of Cx32-
heterozygous female mice (X+/X- or X-/X+). Immunohistochemical stainings showed no 
correlation between cytidine methylation or hydroxymethylation and the expression of Cx32 
in the tumors harboring the mixed Cx32-phenotype. The determination of the global contents 
of 5’-mC and 5’-hmC in tissue sections is a rather unspecific method and does not allow an 
exact-to-the-nucleotide identification of local methylation changes in a specific genetic 
region. If the Cx32 promoter is very selectively methylated in only the Cx32-negative 
subpopulation of cells in the investigated tumors, these changes may not be visible in an 
antibody staining. In the course of integrated data analysis of Ha-ras- and Ctnnb1-mutated 
tumors, no significant correlation between methylation of a promoter region and expression of 
the downstream gene was detected (see figure 4.3 and section 4.2). This indicates that 
regulation of mRNA expression by DNA methylation is a more complex mechanism than 
described in textbooks and might work indirectly via intermediate steps, which could be 
another explanation for the lack of a direct correspondence between Cx32-expression and 
DNA methylation. 
The data discussed in this section show that Ha-ras- and Ctnnb1-mutated tumors cannot be 
stratified by means of global visual assessment of their 5’-mC and 5’-hmC contents. 
Nevertheless, it is known that PB causes significant changes in 5’-hydroxymethylation and 
5’-methylation in the promoter regions of selected genes in normal mouse liver (Thomson et 
al., 2012), which cannot be detected by immunohistochemical staining. This implies that PB 
as a NGC does in fact mediate specific epigenetic mechanisms that contribute to the 
substantial molecular differences between Ha-ras- and Ctnnb1-mutated tumors.  
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5.4 Conclusions and outlook 
Comprehensive molecular characterization of Ha-ras- and Ctnnb1-mutated tumors, with a 
focus on metabolism and signaling, revealed distinctive differences, but also similarities 
between the two tumor types. The identified tumor-specific features, especially in 
combination with further metabolite data, may be a valuable contribution to the development 
of future cancer therapies as they provide very selective drug targets. 
The function of Meg3/Gtl2 is not fully understood, and its characterization is complicated by 
ambivalent results: Does it function as a tumor suppressor or an oncogene? Whatever its 
mechanism may be, Meg3/Gtl2 definitely qualifies as a predictive biomarker for PB-promoted 
tumor formation. An in vivo carcinogenesis experiment in a Meg3/Gtl2-knockout mouse 
model would bring clarity to the question of this lncRNA’s mechanism and relevance in 
tumorigenesis. The generation of such a mouse model, however, poses a challenge since the 
Dlk1-Dio3 locus is subject to genomic imprinting and thus needs to be deleted allele-
specifically, and furthermore, the locus is essential for embryonic development. In situ 
knockdown techniques, at which siRNAs complementary to the target transcript are 
administered to a wild-type animal via tail vein injection, could serve as alternative to stable 
genetic modification (Zhang et al., 1999).  
The global reduction in methylation and hydroxymethylation is a common feature of many 
tumors, and visualization of 5’-mC and 5’-hmC in fixed and embedded liver specimens does 
not allow a distinction between Ha-ras- and Ctnnb1-mutated tumors. Nevertheless, PB causes 
very specific epigenetic changes in rodent liver, and it is thus likely that PB-promoted and 
unpromoted tumors diverge in that each tumor type shows a different DNA methylation 
fingerprint. Current technology provides the possibility of high resolution DNA methylation 
analysis (Akalin et al., 2012; Llamas et al., 2012). A detailed, exact-to-the-nucleotide 
methylation chart of Ha-ras- and Ctnnb1-mutated tumors would allow for precise localization 
of hyper- or hypomethylated regions respective to transcription factor binding sites and other 
important regulatory sequences in the genome. Thus, the tumors could be characterized more 
accurately with regards to their DNA methylation status and the consequences thereof.  
The results of the analyses presented here also bear a methodic relevance with respect to 
personalized tumor therapy. Screening for specific markers is already a frequently used 
technique in tumor patients to evaluate the necessity and predict the effectiveness of 
chemotherapy and, if possible, to spare the patients a long and arduous treatment. 
Bioinformatic tools like InCroMAP could allow for fast and easy integration of large datasets 
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obtained from isolated tumor specimens and thus for more targeted and efficient therapeutic 
measures for the individual patient. 
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Summary 
Oncogene mutations in chemically induced mouse liver tumors strongly depend on the 
experimental regimen. Treatment of mice with a single dose of the genotoxin DEN mainly 
gives rise to Ha-ras- (~50%) or B-raf- (~20%) mutated tumors, in which the mitogen-
activated protein kinase (MAPK) pathway is permanently activated. However, if DEN-
treatment is followed by continuous application of the tumor promoter PB, selective 
proliferation of cells harboring activating mutations in Ctnnb1, which results in constitutive 
activation of the Wnt/β-Catenin signaling pathway, is observed. The mechanisms of tumor 
promotion are still widely unsolved. Comprehensive molecular characterization of Ctnnb1- 
and Ha-ras-mutated mouse liver tumors was conducted with the goal of identifying tumor-
specific differences that could help elucidate the molecular mechanism of PB and PB-like 
promoters. 
Analysis of large mRNA and miRNA (microRNA) expression, DNA methylation and protein 
expression/phosphorylation datasets using the novel bioinformatic data integration tool 
InCroMAP revealed characteristic changes in metabolism and signaling in the tumors, as well 
as tumor-specific differences. Most notably, mRNA data in Ctnnb1- but not Ha-ras-mutated 
tumors indicated that glucose is oxidatively metabolized in the TCA cycle. In contrast to 
Ctnnb1-mutated tumors, Ha-ras-mutated lesions displayed excessive production and trapping 
of cholesterol in the cell. Integration of miRNA, mRNA and protein data provided a possible 
mechanism for the down-regulation of glucose-6-phosphatase at the transcription and enzyme 
level in Ha-ras-mutated tumors, by which the transcription factor Stat3 transactivates miR-
23a, which on its part targets and inhibits G6pc mRNA. Joint analysis of mRNA and protein 
data showed that Ha-ras-mutated tumors activate feedback mechanisms, which negatively 
regulate MAPK signaling, while Ctnnb1-mutated tumors show an activation of Wnt-inhibitory 
genes. Furthermore, the data supported a previously proposed crosstalk between the two 
signaling cascades mediated by dual-specificity phosphatases. 
The relevance of the lncRNA Meg3/Gtl2 in PB-mediated tumor promotion was investigated 
by qPCR measurements and in situ hybridization in Ctnnb1- and Ha-ras-mutated tumors as 
well as non-tumor control tissues. The main result of these experiments is that Meg3/Gtl2 was 
consistently and reproducibly up-regulated in all Ctnnb1-mutated tumors from PB-promoted 
mice but in none of the Ha-ras-mutated lesions from unpromoted animals. Together with the 
previous observation that Meg3/Gtl2 is increased in pericentral hypertrophic hepatocytes in 
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PB-treated normal mouse liver, the described findings corroborate the relevance of this 
lncRNA as a predictive biomarker for PB-mediated tumor promotion. 
Ha-ras- and Ctnnb1-mutated tumors showed a ubiquitous reduction of methylation and 
hydroxymethylation at the 5’-position of cytidine relative to normal liver tissue, as 
determined by immunohistochemical staining. This suggests that global visual assessment of 
the DNA methylation and hydroxymethylation status is not suited as a means of stratification 
between the two tumor types. 
In conclusion, the data presented in this thesis underline that tumors harboring different 
oncogene mutations develop in part fundamentally different survival strategies. 
Comprehensive analysis of these substantial differences, including bioinformatic integration 
of large “omics” datasets, is extremely helpful in understanding the molecular processes that 
drive tumorigenesis and has led to identification of at least one promising new predictive 
biomarker for PB-mediated tumor formation.  
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Zusammenfassung 
Der Onkogen-Mutationsstatus in chemikalieninduzierten Mauslebertumoren wird stark vom 
vorangegangen Behandlungsschema bestimmt. Werden Mäuse mit einer Einzeldosis des 
gentoxischen Initiators DEN behandelt, führt dies hauptsächlich zu Ha-ras- (~50%) oder B-
raf- (~20%) mutierten Tumoren, in welchen der MAPK-Signalweg dauerhaft aktiviert ist. 
Folgt jedoch auf die DEN-Einzeldosis eine kontinuierliche Behandlung mit dem 
Tumorpromotor PB, wird selektives Auswachsen von Tumoren mit aktivierenden Mutationen 
im Ctnnb1-Gen beobachtet, welche zur konstitutiven Aktivierung des Wnt/β-Catenin-
Signalwegs führen. Da die genaue Wirkungsweise von Tumorpromotoren weitgehend 
unbekannt ist, wurden Ctnnb1- und Ha-ras-mutierte Mauslebertumoren einer umfassenden 
molekularen Charakterisierung unterzogen. Ziel dessen war es, tumorspezifische 
Unterschiede aufzuzeigen, die ein genaueres Verständnis des molekularen Mechanismus von 
PB und PB-ähnlichen Promotoren ermöglichen. 
Mit Hilfe der neuentwickelten Datenintegrations-Software InCroMAP wurden große 
Datensätze, die mRNA- und miRNA (microRNA)-Expression, DNA-Methylierung sowie 
Proteinexpression und -phosphorylierung umfassten, zusammenhängend analysiert. Dabei 
wurden in den Tumoren charakteristische Veränderungen und tumorspezifische Unterschiede 
im Bezug auf Stoffwechsel und Signaltransduktion gefunden. Die mRNA-Daten deuteten 
insbesondere darauf hin, dass in Ctnnb1- aber nicht in Ha-ras-mutierten Tumoren Glucose 
oxidativ im Citratzyklus abgebaut wird. Außerdem zeigten Ha-ras-mutierte im Gegensatz zu 
Ctnnb1-mutierten Tumoren eine deutlich erhöhte Produktion und Speicherung von 
Cholesterin. Aus der Integration von miRNA-, mRNA- und Proteindaten ergab sich ein 
möglicher Mechanismus für die Inhibierung der Glucose-6-Phosphatase (G6pc) in Ha-ras-
mutierten Tumoren auf Transkriptions- und Enzymnebene, im Zuge dessen der 
Transkriptionsfaktor Stat3 die Expression von miR-23a aktiviert, die ihrerseits das  G6pc-
Transkript und damit dessen Translation blockiert. In Ha-ras-mutierten Tumoren konnte auf 
mRNA- und Proteinebene die Aktivierung von Rückkopplungsmechanismen, die den MAPK-
Signalweg negativ regulieren, gezeigt werden. In Ctnnb1-mutierten Tumoren wurde 
wiederum die Transaktivierung Wnt-inhibitorischer Gene festgestellt. Die Daten stützten des 
Weiteren das Modell einer durch dual-specificity-Phosphatasen vermittelten Wechselwirkung 
zwischen diesen beiden Signalwegen. 
Die Bedeutung der lncRNA Meg3/Gtl2 in der PB-vermittelten Tumorpromotion wurde mittels 
qPCR-Messungen und In-situ-Hybridisierung in Ctnnb1- und Ha-ras-mutierten Tumoren 
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sowie nicht-mutierten Kontrollgeweben untersucht. Der eindeutige und reproduzierbare 
Befund dieser Experimente war, dass Meg3/Gtl2 in PB-promovierten Ctnnb1-mutierten, 
jedoch nicht in unpromovierten Ha-ras-mutierten Tumoren induziert wird. In Anbetracht 
vorangegangener Experimente, in denen Meg3/Gtl2-Transkription durch PB-Behandlung in 
den perizentralen hypertrophen Zellen in Mäusenormalleber aktiviert werden konnte, 
untermauern die beschriebenen Ergebnisse die Bedeutung dieser lncRNA als prädiktiven 
Biomarker für PB-vermittelte Tumorpromotion. 
In immunhistochemischen Färbungen wurde eine flächendeckende Reduktion der 
Methylierung und Hydroxymethylierung an der 5’-Position von Cytidin sowohl in Ha-ras- als 
auch Ctnnb1-mutierten Tumoren demonstriert. Dies deutet darauf hin, dass die globale 
visuelle Erfassung von DNA-Methylierung und -Hydroxymethylierung sich nicht zur 
Unterscheidung von Ha-ras- und Ctnnb1-mutierten Tumoren eignet. 
Zusammenfassend unterstreichen die in dieser Arbeit präsentierten Daten die Tatsache, dass 
Tumore mit unterschiedlichen Onkogenmutationen teilweise grundlegend verschiedene 
Überlebensstrategien entwickeln. Die umfassende Analyse dieser beträchtlichen 
Unterschiede, unter anderem durch bioinformatische Integration großer “-omik”-Datensätze, 
ist extrem hilfreich für das Verständnis der molekularen Vorgänge, welche die Tumorgenese 
antreiben, und hat zur Identifikation mindestens eines neuen vielversprechenden prädiktiven 
Biomarkers für PB-vermittelte Tumorbildung geführt. 
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Appendix 
A) Genes significantly dysregulated in Ctnnb1-mutated tumors vs. adjacent non-tumor 
tissue (log-ratio >1.0, p-value <0.05). 
Gene symbol EntrezGene ID Log-ratio  p-value Gene name 
Abca8a 217258 -1.09 0.05 
ATP-binding cassette, sub-family A 
(ABC1), member 8a 
Abcb1a 18671 1.84 0.01 
ATP-binding cassette, sub-family B 
(MDR/TAP), member 1a 
Abcc4 239273 2.78 0.03 
ATP-binding cassette, sub-family C, 
member 4 
Abcc9 20928 -1.40/-1.01 0.01 
ATP-binding cassette, sub-family C, 
member 9 
Abhd12 76192 1.67 0.01 Abhydrolase domain containing 12 
Abi3bp 320712 -1.71 0.00 
ABI family, member 3 (NESH) binding 
protein 
Acacb 100705 -1.09 0.02 Acetyl-CoA carboxylase beta 
Accn5 58170 -1.24 0.02 
Amiloride-sensitive cation channel 5, 
intestinal 
Acly 104112 -1.00 0.01 ATP citrate lyase 
Acot9 56360 1.59 0.01 Acyl-CoA thioesterase 
Acsl4 50790 1.35/1.01/1.63 0.02 Long-chain-fatty-acid-CoA ligase 4 
Adam23 23792 -1.99 0.01 
Disintegrin and metalloproteinase domain-
containing protein 23 
Adamdec1 58860 -2.04 0.00 
A disintegrin and metalloproteinase 
domain-like protein decysin-1 
Adamtsl1 77739 -1.47 0.00 
A disintegrin and metalloproteinase with 
thrombospondin motifs)-like 1 
Adamtsl4 229595 2.60 0.00 
A disintegrin and metalloproteinase with 
thrombospondin motifs)-like 4 
Adra2b 11552 -1.04 0.01 alpha-2B adrenergic receptor 
Adss 11566 1.11 0.00 Adenylosuccinate synthase 
Afp 11576 3.61/4.33/4.35 0.01/0.01/0.00 Alpha-Fetal Protein 
Agfg1 15463 1.00 0.01 
Arf-GAP domain and FG repeats-
containing protein 1 
Agl 77559 1.11/1.01/1.09 0.01/0.02/0.01 Glycogen debranching enzyme 
Agxt 11611 -1.53 0.01 Serine—pyruvate aminotransferase 
Agxt2l1 71760 -5.23/-4.91 0.00 
Alanine-glyoxylate aminotransferase 2-
like 1 
Ahr 11622 1.44 0.00 Aryl hydrocarbon receptor 
AI413582 106672 1.20 0.04 N/A 
Airn 104103 1.96 0.00 Antisense of IGF2R 
Ak4 11639 -2.80/-2.75 0.00/0.01 Adenylate kinase 4 
Akap7 432442 -1.11 0.02 A-kinase anchor protein 7 
Akr1b7 11997 2.02 0.01 Aldo-keto reductase family 1, member B7 
Akr1e1 56043 1.29 0.03 Aldo-keto reductase family 1, member E1 
Aldh1b1 72535 -3.61 0.01 
Aldehyde dehydrogenase 1 family, 
member B1 
Aldh3a2 11671 1.86 0.00 
Aldehyde dehydrogenase 3 family, 
member A2 
Amdhd1 71761 -2.90/-2.69 0.00/0.01 Amidohydrolase domain containing 1 
Amigo1 229715 -1.01 0.01 Adhesion molecule with Ig-like domain 1 
Angptl6 70726 -1.09 0.01 Angiopoietin-like 6 
Ankrd33b 67434 -1.12 0.03 Ankyrin repeat domain 33B 
Anln 68743 1.46 0.02 Actin-binding protein anillin 
Anxa13 69787 -1.48 0.01 Annexin A13 
Anxa2 12306 2.28 0.00 Annexin A2 
Anxa7 11750 1.04 0.01 Annexin A7 
Anxa9 71790 1.31 0.01 Annexin A9 
Aox1 11761 1.05 0.02 Aldehyde oxidase 1 
Aph1b 208117 1.06 0.01 Anterior pharynx defective 1 homolog B 
Aplnr 23796 3.60 0.01 Apelin receptor 
Apoa5 66113 -1.16 0.02 Apolipoprotein A-V 
Aprt 11821 1.01 0.02 Adenine phosphoribosyltransferase 
Aqp4 11829 -3.76 0.00 Aquaporin 4 
Aqp7 11832 1.19/1.79 0.02/0.03 Aquaporin 7 
Arf6 11845 1.44 0.05 ADP-ribosylation factor 6 
Arg2 11847 2.99/3.43 0.03/0.01 Arginase 2 
Arhgap11a 228482 1.49 0.01 Rho GTPase activating protein 11A 
Arhgef2 16800 1.19/1.01 0.00/0.02 
Rho guanine nucleotide exchange factor 
2 
Arl2bp 107566 1.07 0.05 
ADP-ribosylation factor-like 2 binding 
protein 
Armcx3 71703 -1.24 0.00 
Armadillo repeat-containing X-linked 
protein 3 
As3mt 57344 -1.51 0.04 
Arsenic (+3 oxidation state) 
methyltransferase 
Asl 109900 -1.25 0.00 Argininosuccinate lyase 
Aspg 104816 -3.73 0.00 Asparaginase homolog 
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Aspm 12316 2.10 0.00 
Abnormal spindle-like microcephaly-
associated protein 
Ass1 11898 -1.66/-1.27 0.01/0.04 Argininosuccinate synthase 1 
Atp2b2 11941 1.41 0.04 Ca(2+)-pumping ATPase isoform PMCA2 
Atp6v0d2 242341 1.29 0.04 
ATPase, H+ transporting, lysosomal 
38kDa, V0 subunit d2 
Atrnl1 226255 -1.89 0.01 Attractin-like 1 
Aurka 20878 1.59 0.01 Aurora kinase a 
Aurkb 20877 1.11 0.05 Aurora kinase b 
Avpr1a 54140 1.93/2.19 0.01/0.01 Arginine vasopressin receptor 1A 
Bace2 56175 1.37 0.01 beta-site APP-cleaving enzyme 2 
Bag4 67384 -1.03 0.00 
BAG family molecular chaperone 
regulator 4 
Bche 12038 -1.09 0.01 Butyrylcholinesterase 
Bdh2 69772 -2.96 0.00 3-hydroxybutyrate dehydrogenase, type 2 
Bgn 12111 -1.41/-1.38/-1.27 0.01/0.01/0.00 biglycan 
Bik 12124 -1.79 0.02 Bcl-2-interacting killer 
Birc5 11799 1.90 0.02 Baculoviral IAP repeat containing 5 
Blvrb 233016 1.86 0.00 
biliverdin reductase B (flavin reductase 
(NADPH)) 
Bmp2 12156 -1.76 0.01 Bone morphogenetic protein 2 
Bmp5 12160 -1.52 0.01 Bone morphogenetic protein 5 
Btc 12223 1.25 0.02 Betacellulin 
Btg1 12226 -1.03 0.04 
B-cell translocation gene 1, anti-
proliferative 
Bub1 12235 1.81 0.01 
Budding uninhibited by benzimidazoles 1 
homolog 
C8a 230558 -1.47 0.03 
Bomplement component 8, alpha 
polypeptide 
Cadm1 54725 -1.08 0.02 Cell adhesion molecule 1 
Cadps2 320405 -3.19 0.01 
Ca2+-dependent activator protein for 
secretion 2 
Calcrl 54598 -1.12 0.01 Calcitonin receptor-like 
Calml4 75600 3.52 0.00 Calmodulin-like 4 
Camkk2 207565 -1.80/-1.33/-1.10 0.00/0.00/0.01 
Calcium/calmodulin-dependent protein 
kinase kinase 2, beta 
Car14 23831 -1.43 0.04 Carbonic anhydrase 14 
Car2 12349 1.85 0.00 Carbonic anhydrase 2 
Casp1 12362 2.09 0.01 Caspase 1 
Casp12 12364 2.35/2.38 0.01/0.01 Caspase 12 
Casp4 12363 1.11 0.05 Caspase 4 
Cav1 12389 1.06 0.02 Caveolin 1 
Cbs 12411 -1.28 0.04 Cystathionine-β-synthase 
Ccbe1 320924 -1.45 0.00 
Collagen and calcium binding EGF 
domains 1 
Ccdc120 54648 1.76 0.01 Coiled-coil domain containing 120 
Ccdc28b 66264 -1.08 0.02 Coiled-coil domain containing 28b 
Ccdc99 70385 1.20 0.01 Coiled-coil domain containing 99 
Ccna2 12428 1.20/1.30 0.04/0.01 Cyclin-A2 
Ccnb1 268697 1.79/2.23/2.28 0.02/0.00/0.01 Cyclin-B1 
Ccnb2 12442 2.27 0.00 Cyclin-B2 
Ccnl2 56036 -1.04 0.01 Cyclin-L2 
Cd163 93671 -1.67 0.01 Cluster of Differentiation 163 
Cd200 17470 1.28 0.04 Cluster of Differentiation 200 
Cd2ap 12488 1.05/1.47/1.71 0.00/0.00/0.00 CD2-associated protein 
Cd34 12490 1.24 0.04 
Hematopoietic progenitor cell antigen 
CD34 
Cd5l 11801 -1.43 0.04 CD5 antigen-like 
Cd9 12527 1.24 0.03 CD9 antigen 
Cd93 17064 1.14/1.17 0.01/0.01 CD93 antigen 
Cdc20 107995 1.43 0.03 Cell-division cycle protein 20 
Cdc6 23834 1.04 0.03 Cell-division cycle protein 6 
Cdca3 14793 1.53 0.02 Cell division cycle associated 3 
Cdca8 52276 1.08/1.14/1.84 0.02/0.02/0.00 Cell division cycle associated 8 
Cdhr2 268663 2.11 0.02 Cadherin-related family member 2 
Cdk1 12534 1.71 0.01 Cyclin-dependent kinase 1 
Cdkn2c 12580 1.50 0.00 Cyclin-dependent kinase 4 inhibitor C 
Cdkn3 72391 1.96 0.01 Cyclin-dependent kinase 3 inhibitor 
Cds2 110911 1.13 0.00 
CDP-diacylglycerol synthase 
(phosphatidate cytidylyltransferase) 2 
Celsr1 12614 -1.43 0.02 
Cadherin EGF LAG seven-pass G-type 
receptor 1 
Cenpa 12615 1.08 0.04 Centromere protein A 
Cenpf 108000 1.51 0.03 Centromere protein F 
Cenpi 102920 1.20 0.02 Centromere protein I 
Cenpl 70454 1.90 0.00 Centromere protein L 
Cenpp 66336 1.13/1.51 0.04/0.01 Centromere protein P 
Cenpt 320394 1.12 0.01 Centromere protein T 
Cep192 70799 1.31 0.04 Centrosomal protein of 192 kDa 
Cep55 74107 1.83 0.01 Centrosomal protein of 55 kDa 
Ces1e 13897 -2.67 0.00 Carboxylesterase 1E 
Ces1f 234564 -2.15 0.04 Carboxylesterase 1F 
Cfhr2 545366 -1.12 0.00 Complement factor H-related protein 2 
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Cgrrf1 68755 1.03 0.03 
Cell growth regulator with ring finger 
domain 1 
Chrna4 11438 -1.15 0.01 
Neuronal acetylcholine receptor subunit 
alpha-4 
Cib2 56506 2.12 0.02 
Calcium and integrin binding family 
member 2 
Cisd1 52637 -1.13 0.02 CDGSH iron sulfur domain 1 
Ckap2 80986 1.71 0.02 Cytoskeleton-associated protein 2 
Cldn2 12738 1.14 0.02 Claudin-2 
Clec1b 56760 -1.10 0.01 C-type lectin domain family 1 member B 
Clec4b1 69810 1.09 0.05 C-type lectin domain family 1 member B1 
Clec4f 51811 -1.95 0.02 C-type lectin domain family 4, member F 
Clmn 94040 -1.69/-1.67 0.01/0.01 Calmin (calponin-like, transmembrane) 
Cln6 76524 1.24 0.03 Ceroid-lipofuscinosis neuronal protein 6 
Cmah 12763 -1.14 0.01 
Putative cytidine monophosphate-N-
acetylneuraminic acid hydroxylase-like 
protein 
Col13a1 12817 -1.06 0.00 Collagen, type XIII, alpha 1 
Col14a1 12818 -1.15 0.02 Collagen, type XIV, alpha 1 
Col27a1 373864 -1.23/-1.18 0.00/0.01 Collagen, type XXVII, alpha 1 
Col4a1 12826 1.01 0.03 Collagen, type IV, alpha 1 
Col4a3bp 68018 1.11 0.05 Collagen type IV alpha-3-binding protein 
Colec10 239447 -3.14 0.02 Collectin sub-family member 10 
Colec11 71693 -1.79/-1.34 0.00/0.01 Collectin sub-family member 11 
Cox7a1 12865 -1.13 0.03 
Cytochrome c oxidase polypeptide 7A1, 
mitochondrial 
Cps1 227231 -2.17 0.02 Carbamoyl-phosphate synthase 1 
Crem 12916 -1.08 0.04 cAMP responsive element modulator 
Crim1 50766 1.32 0.02 Cysteine-rich motor neuron 1 protein 
Crls1 66586 1.16 0.05 Cardiolipin synthase 1 
Cryl1 68631 -3.14/-2.83/-1.55 0.00/0.00/0.00 Crystallin, lambda 1 
Cs 12974 1.08 0.01 Citrate synthase 
Csad 246277 1.58 0.03 Cysteine sulfinic acid decarboxylase 
Csn3 12994 1.30 0.02 Kappa-casein 
Csprs 114564 1.04 0.01 Component of Sp100-rs 
Csrp2 13008 1.43 0.03 Cysteine and glycine-rich protein 2 
Cstb 13014 1.45/1.92 0.00/0.00 Cystatin B 
Ctbs 74245 1.28/1.37 0.03/0.02 Di-N-acetylchitobiase 
Cth 107869 -1.10 0.02 Cystathionine gamma-lyase 
Ctnnbip1 67087 -1.46/-1.44 0.00/0.00 Beta-catenin-interacting protein 1 
Ctps2 55936 1.51 0.01 CTP synthase 2 
Ctsc 13032 -1.57 0.01 Cathepsin C 
Cttn 13043 1.01 0.03 Cortactin 
Cxcl10 15945 1.79 0.02 C-X-C motif chemokine 10 
Cxcl12 20315 -1.80/-1.51 0.01/0.01 C-X-C motif chemokine 12 
Cyfip2 76884 -2.36/-2.41 0.01/0.01 Cytoplasmic FMR1-interacting protein 2 
Cyp2f2 13107 -4.19 0.03 Cytochrome P450 2F2 
Cyp2j5 13109 -1.49 0.04 Cytochrome P450 2J5 
Cyp2u1 71519 -1.28 0.00 Cytochrome P450 2U1 
Cyp46a1 13116 -3.32 0.00 Cytochrome P450 46A1 
Cyp7a1 13122 1.62/2.36 0.03/0.00 
Cytochrome P450 7A1 (Cholesterol 7 
alpha-hydroxylase) 
Cyp8b1 13124 -1.20 0.01 Cytochrome P450 8B1 
Dab2ip 69601 1.08 0.01 Disabled homolog 2-interacting protein 
Dach2 93837 -1.42 0.04 Dachshund homolog 2 
Dapk1 69635 -1.23 0.01 Death-associated protein kinase 1 
Dcdc2a 195208 -1.25 0.00 Doublecortin domain containing 2a 
Dclk3 245038 -1.79 0.00 Doublecortin-like kinase 3 
Dcn 13179 -2.04 0.01 Decorin 
Dct 13190 -3.25 0.02 Dopachrome tautomerase 
Ddi2 68817 -1.35/-1.02 0.00/0.00 DNA-damage inducible 1 homolog 2 
Dhrs1 52585 1.09 0.02 
Dehydrogenase/reductase SDR family 
member 1 
Dhx32 101437 1.08 0.04 
Putative pre-mRNA-splicing factor ATP-
dependent RNA helicase 
Dmrta1 242523 -1.74 0.00 DMRT-like family A1 
Dnajc10 66861 1.01 0.01 DnaJ homolog subfamily C member 10 
Dnajc24 99349 1.01 0.01 DnaJ homolog subfamily C member 24 
Dnase1l3 13421 -1.37 0.02 Deoxyribonuclease gamma 
Dnase2a 13423 1.04 0.03 Deoxyribonuclease II alpha 
Dpp7 83768 1.21 0.00 Dipeptidyl-peptidase 2 
Dpt 56429 -2.01 0.01 Dermatopontin 
Dpyd 99586 -1.12 0.01 
Dihydropyrimidine dehydrogenase 
[NADP+] 
Dynll1 56455 1.24 0.00 Dynein light chain 1, cytoplasmic 
Dyrk3 226419 2.00 0.00 
Dual specificity tyrosine-phosphorylation-
regulated kinase 3 
E130308A19Rik 230259 -1.02 0.05 N/A 
Ecm1 13601 -1.51 0.01 Extracellular matrix protein 1 
Ect2 13605 2.11 0.01 
Epithelial cell transforming sequence 2 
oncogene 
Efemp1 216616 -2.36 0.01 
EGF containing fibulin-like extracellular 
matrix protein 1 
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Efna5 13640 -1.36 0.01 Ephrin-A5 
Egfr 13649 -1.80/-1.62 0.00/0.00 Epidermal growth factor receptor 
Ehd4 98878 1.33 0.02 EH-domain containing 4 
Emcn 59308 1.77 0.01 Endomucin 
Emp1 13730 1.18 0.04 Epithelial membrane protein 1 
Emp2 13731 1.38 0.03 Epithelial membrane protein 2 
Enah 13800 -1.14 0.01 Protein enabled homolog 
Endod1 71946 1.18/1.44/1.59/1.74/1.82 0.01/0.01/0.00/0.01/0.00 Endonuclease domain containing 1 
Enho 69638 -1.42/-1.18 0.02/0.03 Energy homeostasis associated 
Entpd5 12499 1.41/1.05/1.20 0.01/0.01/0.00 
ctonucleoside triphosphate 
diphosphohydrolase 5 
Epcam 17075 -1.35 0.01 Epithelial cell adhesion molecule 
Erp27 69187 -1.47 0.00 Endoplasmic reticulum protein 27 
Esco2 71988 2.52 0.01 Establishment of cohesion 1 homolog 2 
Esm1 71690 1.31 0.05 Endothelial cell-specific molecule 1 
Etl4 208618 1.02 0.01 Enhancer trap locus 4 
Ets2 23872 1.04 0.00 Protein C-ets-2 
Fam101b 76566 1.30 0.00 
Family with sequence similarity 101, 
member B 
Fam171a1 269233 1.92 0.00 
Family with sequence similarity 171, 
member A1 
Fam198b 68659 1.16 0.03 
Family with sequence similarity 198, 
member B 
Fam25c 69134 1.51 0.05 
Family with sequence similarity 25, 
member C 
Fam46a 212943 -1.56 0.04 
Family with sequence similarity 46, 
member A 
Fam46c 74645 -1.63 0.03 
Family with sequence similarity 46, 
member C 
Fam47e 384198 -1.63 0.03 
Family with sequence similarity 47, 
member E 
Fam55b 78252 2.59 0.01 
Family with sequence similarity 55, 
member B 
Fam89a 69627 1.12 0.03 
Family with sequence similarity 89, 
member A 
Fbp1 14121 -1.26 0.01 Fructose-1,6-bisphosphatase 1 
Fbxo31 76454 -1.12 0.00 F-box protein 31 
Fcna 14133 -1.15 0.05 Ficolin A 
Fdps 110196 1.52 0.05 Farnesyl diphosphate synthase 
Fez2 225020 1.03 0.00 
Fasciculation and elongation protein zeta-
2 
Fgf21 56636 1.87 0.05 Fibroblast growth factor 21 
Fgfr2 14183 -2.30/-1.36 0.00/0.03 Fibroblast growth factor 2 
Fhl1 14199 -1.06 0.04 Four and a half LIM domains 1 
Fkbp11 66120 1.29 0.01 FK506 binding protein 11 
Fkbp1a 14225 1.14 0.01 Peptidyl-prolyl cis-trans isomerase 
Fn3k 63828 -1.09 0.00 Fructosamine-3-kinase 
Folh1 53320 1.75 0.02 
Folate hydrolase (prostate-specific 
membrane antigen) 1 
Folr2 14276 -1.42 0.01 Folate receptor beta 
Foxp1 108655 -1.20/-1.00 0.03/0.03 Forkhead box protein P1 
Foxp2 114142 -1.21 0.02 Forkhead box protein P2 
Frk 14302 1.11/1.66 0.00/0.01 Fyn-related kinase 
Ftcd 14317 -1.47 0.03 Formiminotransferase cyclodeaminase 
Fundc1 72018 1.08 0.01 FUN14 domain containing 1 
Gabra3 14396 -1.53 0.02 
Gamma-aminobutyric acid receptor 
subunit alpha-3 
Gars 353172 1.10 0.00 Glycyl-tRNA synthetase 
Gas1 14451 -2.85/-1.75 0.00/0.00 Growth arrest-specific protein 1 
Gas7 14457 1.36 0.02 Growth arrest-specific protein 7 
Gca 227960 1.45/1.54 0.00/0.01 Grancalcin 
Gdf10 14560 -2.34 0.00 Growth differentiation factor 10 
Gdf2 12165 -1.42 0.00 Growth differentiation factor 2 
Gins2 272551 1.38 0.02 GINS complex subunit 2 (Psf2 homolog) 
Gipc2 54120 3.67 0.01 
GIPC PDZ domain containing family, 
member 2 
Gldc 104174 -3.53 0.01 Glycine dehydrogenase (decarboxylating) 
Gls2 216456 -4.18 0.00 Glutaminase 2 
Golm1 105348 1.95 0.01 Golgi membrane protein 1 
Got1 14718 -3.17 0.04 Aspartate aminotransferase, cytoplasmic 
Gpat2 215456 -1.09 0.00 
glycerol-3-phosphate acyltransferase 2, 
mitochondrial 
Gpc3 14734 4.06 0.00 Glypican-3 
Gpm6a 234267 -1.70 0.00 Glycoprotein M6A 
Gpx7 67305 1.63 0.00 Glutathione peroxidase 7 
Gramd1b 235283 1.65/1.55 0.01/0.01 GRAM domain containing 1B 
Grhl1 195733 1.21 0.01 Grainyhead-like 1 
Grm8 14823 -2.11 0.00 Glutamate receptor, metabotropic 8 
Gsn 227753 -2.12/-2.06/-2.05/-1.40 0.00/0.00/0.01/0.00 Gelsolin 
Gsr 14782 1.33 0.05 Glutathione reductase 
Gsta4 14860 1.08 0.03 Glutathione S-transferase A4 
Gstk1 76263 -1.04 0.01 Glutathione S-transferase kappa 1 
Gstm2 14863 1.79 0.00 Glutathione S-transferase Mu 2 
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Gstm3 14864 2.00 0.00 Glutathione S-transferase Mu 3 
Gstm4 14865 1.18 0.01 Glutathione S-transferase Mu 4 
Gstm6 14867 1.86 0.02 Glutathione S-transferase Mu 6 
Gulo 268756 1.45 0.01 L-gulonolactone oxidase 
Gyg 27357 1.44 0.00 Glycogenin 1 
Gyk 14933 1.54 0.01 Glycerol kinase 
Gypc 71683 -1.19 0.01 Glycophorin C 
Hal 15109 -4.35 0.00 Histidine ammonia lyase 
Hamp 84506 -3.23/-3.20 0.01/0.01 Hepcidin 
Hamp2 66438 -3.61 0.00 Hepcidin 2 
Hand2 15111 -1.83 0.00 
Heart- and neural crest derivatives-
expressed protein 2 
Hfe2 69585 1.28 0.01 Hemochromatosis type 2 
Hist1h1c 50708 1.27/1.58 0.05/0.00 Histone cluster 1, H1c 
Hmgb2 97165 1.31 0.03 High-mobility group protein B2 
Hmgcs1 208715 1.37/1.45 0.01/0.03 
3-hydroxy-3-methylglutaryl-CoA synthase 
1 
Hmmr 15366 1.22/1.22/1.46 0.01/0.05/0.01 Hyaluronan-mediated motility receptor 
Hn1 15374 1.26 0.00 
Hematological and neurological 
expressed 1 protein 
Hsd17b13 243168 -1.63/-1.31 0.01/0.02 
Hydroxysteroid (17-beta) dehydrogenase 
13 
Hsd17b7 15490 1.07 0.04 
Hydroxysteroid (17-beta) dehydrogenase 
7 
Hsf2bp 74377 1.93 0.01 
Heat shock transcription factor 2 binding 
protein 
Iars 105148 1.26 0.04 Isoleucyl-tRNA synthetase 
Ica1 15893 1.51 0.03 Islet cell autoantigen 1 
Icos 54167 -1.04 0.00 Inducible T-cell co-stimulator 
Idh3a 67834 1.24 0.01 
Isocitrate dehydrogenase [NAD] subunit 
alpha 
Ifi27l2b 217845 1.39 0.00 
Interferon, alpha-inducible protein 27 like 
2B 
Ifitm1 68713 -1.87 0.00 
Interferon-induced transmembrane protein 
1 
Ifngr1 15979 1.40 0.00 Interferon gamma receptor 1 
Ifngr2 15980 1.10 0.03 Interferon gamma receptor 2 
Igf1 16000 -2.15/-1.90 0.04/0.05 Insulin-like growth factor 1 
Igf2r 16004 1.55 0.00 Insulin-like growth factor 2 receptor 
Igfbp1 16006 1.55 0.00 Insulin-like growth factor-binding protein 1 
Ikbkb 16150 1.26 0.02 
Inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase beta 
Ikbkg 16151 1.01 0.05 
Inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase gamma 
Il13ra1 16164 -1.42/-1.17 0.01/0.02 Interleukin 13 receptor, alpha 1 
Il1rap 16180 -1.09 0.02 Interleukin-1 receptor accessory protein 
Impact 16210 1.10 0.01 Impact homolog 
Irf2 16363 -1.17 0.00 Interferon regulatory factor 2 
Islr 26968 -1.15 0.03 
Immunoglobulin superfamily containing 
leucine-rich repeat 
Itga6 16403 1.06 0.01 Integrin alpha-6 
Ivd 56357 -1.09 0.04 Isovaleryl-CoA dehydrogenase 
Jub 16475 2.08 0.02 Ajuba 
Kalrn 545156 -1.43 0.00 Kalirin 
Kcnk1 16525 2.01/2.12 0.01/0.00 Potassium channel subfamily K member 1 
Kcnt2 240776 -1.75 0.00 
Potassium channel subfamily T, member 
2 
Kctd12b 207474 1.01 0.03 
Kctd12b potassium channel 
tetramerisation domain containing 12b 
Kif11 16551 1.05/1.41 0.02/0.01 Kinesin family member 11 
Kif20a 19348 1.95 0.01 Kinesin family member 20A 
Kif20b 240641 1.39 0.04 Kinesin family member 20B 
Kif22 110033 1.09/1.32 0.03/0.01 Kinesin family member 22 
Klf10 21847 -1.37 0.01 Krueppel-like factor 10 
Klf6 23849 1.39/1.80 0.02/0.01 Krueppel-like factor 6 
Kpnb1 16211 1.06 0.04 Karyopherin (importin) beta 1 
Krt4 16682 3.80/2.96 0.00/0.01 Keratin 4 
Kynu 70789 -1.88/-1.77 0.01/0.00 Kynureninase 
Lama3 16774 -1.57 0.01 Laminin, alpha 3 
Lats2 50523 1.08 0.03 Large tumor suppressor, homolog 2 
Lcn2 16819 2.96 0.01 Lipocalin-2 
Lect2 16841 1.59 0.01 Leukocyte cell-derived chemotaxin- 
Lepr 16847 -1.77 0.01 Leptin receptor 
Lgals3 16854 2.23 0.02 Galectin-3 
Lgr5 14160 2.57 0.05 
Leucine-rich repeat-containing G-protein 
coupled receptor 5 
Lhx2 16870 -1.61 0.00 LIM homeobox 2 
Lix1l 280411 -1.02 0.00 Lix1 homolog (mouse)- like 
Lmod3 320502 -1.65 0.02 Leiomodin-3 
Lpin2 64898 1.27 0.00 Lipin 2 
Lpl 16956 2.00/1.33 0.00/0.01 Lipoprotein lipase 
Lrat 79235 -2.13 0.01 Lecithin retinol acyltransferase 
Lrrc39 109245 1.50 0.03 Leucine-rich repeat-containing protein 39 
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Lrtm1 319476 -1.68 0.00 
Leucine-rich repeats and transmembrane 
domains 1 
Lum 17022 -1.29 0.04 Lumican 
Ly6d 17068 3.40 0.01 Lymphocyte antigen 6 complex, locus D 
Ly75 17076 1.00 0.04 Lymphocyte antigen 75 
Mab21l3 242125 2.03 0.01 Mab-21-like 3 
Macrod1 107227 -1.45 0.01 MACRO domain containing 1 
Mad2l1 56150 1.64 0.00 MAD2 mitotic arrest deficient-like 1 
Maf 17132 -1.03 0.05 
V-maf musculoaponeurotic fibrosarcoma 
oncogene homolog 
Mafb 16658 -1.42 0.01 
V-maf musculoaponeurotic fibrosarcoma 
oncogene homolog B 
Maged2 80884 1.06 0.04 Melanoma-associated antigen D2 
Mamdc2 71738 -2.11 0.00 Melanoma-associated antigen C2 
Maoa 17161 2.33/2.50 0.02/0.01 Monoamine oxidase A 
Mapre2 212307 -1.47/-1.46 0.00/0.03 
Microtubule- associated protein, RP/EB 
family, member 2 
Mark1 226778 -1.11 0.00 
MAP/microtubule affinity -regulating 
kinase 1 
Marveld3 73608 -1.85 0.00 MARVEL domain containing 3 
Masp1 17174 -1.26/-1.24 0.01/0.05 Mannan-binding lectin serine protease 1 
Mcart1 230125 -2.82/-1.63/-1.62 0.00/0.00/0.00 Mitochondrial carrier triple repeat 1 
Mcm10 70024 -1.43 0.04 
Minichromosome maintenance complex 
component 10 
Mcm2 17216 1.18 0.01 
Minichromosome maintenance complex 
component 2 
Mcm6 17219 1.38 0.02 
Minichromosome maintenance complex 
component 6 
Mfsd2a 76574 -3.41 0.01 
Major facilitator superfamily domain-
containing protein 2 
Mgst3 66447 1.47 0.01 Microsomal glutathione S-transferase 3 
Mis18bp1 217653 1.02/1.24 0.04/0.03 MIS18 binding protein 1 
Mki67 17345 1.50 0.03 
Antigen identified by monoclonal antibody 
Ki-67 
Mmd2 75104 -1.29 0.02 
Monocyte to macrophage differentiation-
associated 2 
Mmgt1 236792 1.10 0.05 Membrane magnesium transporter 1 
Mmp13 17386 1.79 0.01 Matrix metallopeptidase 13 
Mmp15 17388 -1.16 0.04 Matrix metallopeptidase 15 
Mn1 433938 -2.59 0.00 
Meningioma (disrupted in balanced 
translocation) 1 
Mosc1 66112 -2.22 0.00 
MOCO sulphurase C-terminal domain 
containing 1 
Mpp1 17524 1.23 0.00 
Membrane protein, palmitoylated 1, 
55kDa 
Mrps18a 68565 1.07 0.03 Mitochondrial ribosomal protein S18A 
Ms4a4d 66607 -1.73 0.00 
Membrane-spanning 4-domains, 
subfamily A, member 4D 
Msi2 76626 -1.07 0.01 Musashi homolog 2 
Mt1 17748 -1.22 0.05 Melatonin receptor 1A 
Mthfd2 17768 1.53 0.01 
Methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 2 
Mtmr11 194126 1.86 0.00 Myotubularin related protein 11 
Mup10 100039008 -3.68 0.03 Major urinary protein 10 
Mup3 17842 -2.74 0.02 Major urinary protein 3 
Mup5 17844 -1.71 0.01 Major urinary protein 5 
Mustn1 66175 -1.02 0.01 
Musculoskeletal, embryonic nuclear 
protein 1 
Mybl1 17864 1.36 0.02 
V-myb myeloblastosis viral oncogene 
homolog (avian)-like 1 
Myc 17869 1.64 0.00 
V-myc myelocytomatosis viral oncogene 
homolog 
Mycn 18109 2.17 0.00 
V-myc myelocytomatosis viral related 
oncogene, neuroblastoma derived 
Myo15b 217328 1.04 0.00 Myosin XVB pseudogene 
N6amt2 68043 1.24 0.02 
N-6 adenine-specific DNA 
methyltransferase 2 (putative) 
Nap1l1 53605 1.03 0.02 Nucleosome assembly protein 1-like 1 
Napepld 242864 1.22 0.00 
N-acyl phosphatidylethanolamine 
phospholipase D 
Ncapg2 76044 1.55 0.00 
Non-SMC condensin II complex, subunit 
G2 
Ndn 17984 -1.20/-1.20/-1.18 0.00/0.00/0.00 Necdin 
Ndrg1 17988 1.37/1.47/1.93 0.03/0.04/0.01 N-myc downstream regulated 1 
Neat1 66961 1.65 0.00 Nuclear enriched abundant transcript 1 
Neb 17996 -2.24 0.01 Nebulin 
Nek2 18005 1.53 0.01 
NIMA (never in mitosis gene a)-related 
kinase 2 
Nek6 59126 1.17 0.00 
NIMA (never in mitosis gene a)-related 
kinase 6 
Net1 56349 1.23 0.01 Neuroepithelial cell transforming 1 
Nfia 18027 -1.14 0.01 Nuclear factor I/A 
Nhp2 52530 1.13 0.01 NHP2 ribonucleoprotein homolog 
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Nid1 18073 1.33/1.98 0.03/0.00 Nidogen 1 
Nlk 18099 1.36 0.03 Nemo-like kinase 
Nnmt 18113 -3.59 0.02 Nicotinamide N- methyltransferase 
Npc1l1 237636 1.91 0.05 Niemann-Pick C1-like protein 1 
Npdc1 18146 1.94 0.00 
Neural proliferation, differentiation and 
control, 1 
Nptx1 18164 1.59/3.18 0.01/0.00 Neuronal pentraxin I 
Nqo1 18104 1.96 0.04 NAD(P)H dehydrogenase , quinone 1 
Nsdhl 18194 1.33 0.03 
Sterol-4-alpha-carboxylate 3-
dehydrogenase 
Nt5e 23959 2.55/1.69 0.01/0.02 5'-nucleotidase 
Ntn1 18208 -1.60 0.00 Netrin-1 
Nubp1 26425 1.02 0.04 Nucleotide binding protein 1 
Nudt7 67528 -1.03 0.01 
Nudix (nucleoside diphosphate linked 
moiety X)-type motif 7 
Nusap1 108907 2.46 0.00 
Nucleolar and spindle associated protein 
1 
Odf3b 70113 -1.59 0.00 Outer dense fiber of sperm tails 3B 
Olfm1 56177 -1.27 0.01 Olfactomedin 1 
Olfm3 229759 -4.04/-4.03 0.00/0.00 Olfactomedin 3 
Ostc 66357 1.04 0.01 
Oligosaccharyltransferase complex 
subunit 
Otc 18416 -1.46/-1.53 0.03/0.03 Ornithine carbamoyltransferase 
Pbk 52033 1.65 0.02 PDZ binding kinase 
Pbld2 67307 -1.24 0.01 
Phenazine biosynthesis-like protein 
domain containing 2 
Pcdh17 219228 1.74/1.76 0.00/0.00 Protocadherin-17 
Pck1 18534 -3.02 0.02 
Phosphoenolpyruvate carboxykinase 1 
(soluble) 
Pclo 26875 -1.03 0.00 Piccolo (presynaptic cytomatrix protein) 
Pcolce2 76477 -1.38 0.02 Procollagen C- endopeptidase enhancer 2 
Pde7b 29863 -1.48 0.01 Phosphodiesterase 7B 
Pdgfa 18590 1.03/1.05 0.02/0.02 Platelet-derived growth factor subunit A 
Pdgfra 18595 -1.66 0.00 
Alpha-type platelet-derived growth factor 
receptor 
Pdk1 228026 -1.30/-1.22/-2.13 0.00/0.00/0.00 
Pyruvate dehydrogenase lipoamide 
kinase isozyme 1, mitochondrial 
Pdlim7 67399 1.17 0.01 PDZ and LIM domain protein 7 
Pdp1 381511 1.24 0.02 
Pyruvate dehyrogenase phosphatase 
catalytic subunit 1 
Peli2 93834 -1.26 0.03 Pellino homolog 2 
Pes1 64934 1.08 0.01 
Pescadillo homolog 1, containing BRCT 
domain 
Pgm3 109785 1.33 0.00 Phosphoglucomutase 3 
Phlda2 22113 1.79 0.00 
Pleckstrin homology-like domain family A 
member 2 
Pi4k2b 67073 1.06 0.03 Phosphatidylinositol 4- kinase type 2 beta 
Pigp 56176 1.04 0.03 
Phosphatidylinositol glycan anchor 
biosynthesis, class P 
Pigr 18703 -2.67/-2.65 0.01/0.02 Polymeric immunoglobulin receptor 
Pir 69656 1.30 0.01 Pirin 
Plagl1 22634 -1.48 0.04 Pleiomorphic adenoma gene-like 1 
Plbd1 66857 1.27 0.00 Phospholipase B domain containing 1 
Plce1 74055 -1.85 0.00 Phospholipase C, epsilon 1 
Plcxd1 403178 -1.17 0.01 
Phosphatidylinositol- specific 
phospholipase C, X domain containing 1 
Plk1 18817 1.03 0.01 Polo-like kinase 1 
Plk4 20873 1.01 0.01 Polo-like kinase 4 
Pls1 102502 1.87 0.00 Plastin 1 
Plscr1 22038 1.03/1.07 0.01/0.01 Phospholipid scramblase 1 
Pold4 69745 1.24 0.02 DNA polymerase delta subunit 4 
Ppap2c 50784 1.07 0.00 Phosphatidic acid phosphatase type 2C 
Pparg 19016 1.49 0.03 
Peroxisome proliferator-activated receptor 
gamma 
Ppargc1b 170826 -1.80 0.01 
Peroxisome proliferator-activated receptor 
gamma coactivator 1-beta 
Ppl 19041 1.22 0.00 Periplakin 
Ppm1l 242083 -1.09 0.03 
Protein phosphatase, Mg2+/Mn2+ 
dependent, 1L 
Prc1 233406 1.33 0.02 Protein regulator of cytokinesis 1 
Prickle1 106042 -1.01 0.01 Prickle homolog 1 
Prkcdbp 109042 1.19 0.00 Protein kinase C, delta binding protein 
Psmd8 57296 1.40 0.00 
Proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 8 
Psmd9 67151 -1.52 0.03 
Proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 9 
Ptbp1 19205 -2.18 0.01 Polypyrimidine tract binding protein 1 
Ptgds 19215 -1.54/-1.15 0.03/0.04 Prostaglandin D2 synthase 21kDa (brain) 
Ptger2 19217 -1.37 0.01 
Prostaglandin E receptor 2 (subtype EP2), 
53kDa 
Ptgis 19223 -1.01 0.02 Prostaglandin I2 ( prostacyclin) synthase 
Pth1r 19228 -1.87 0.00 Parathyroid hormone 1 receptor 
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Ptplb 70757 1.28/1.20 0.01/0.00 
Protein tyrosine phosphatase-like (proline 
instead of catalytic arginine), member b 
Ptpn14 19250 2.57 0.01 
Protein tyrosine phosphatase, non-
receptor type 14 
Pttg1 30939 1.98 0.01 Pituitary tumor- transforming 1 
Pycr2 69051 -1.04 0.01 
Pyrroline-5-carboxylate reductase family, 
member 2 
Rab27b 80718 -1.26 0.00 RAB27B, member RAS oncogene family 
Racgap1 26934 1.60 0.01 Rac GTPase activating protein 1 
Rad51 19361 1.54 0.01 RAD51 homolog 
Rad51ap1 19362 1.07 0.01 RAD51 associated protein 1 
Ralgps2 78255 1.32 0.00 
Ral GEF with PH domain and SH3 
binding motif 2 
Ramp1 51801 -1.35 0.01 Receptor activity modifying protein 1 
Ranbp3l 223332 -1.57 0.00 RAN binding protein 3-like 
Rasgef1b 320292 -1.69 0.01 RasGEF domain family, member 1B 
Rasgrp2 19395 -1.19 0.01 RAS guanyl-releasing protein 2 
Rbbp8 225182 1.06 0.01 Retinoblastoma binding protein 8 
Rbl1 19650 1.56 0.00 Retinoblastoma-like 1 
Rbm24 666794 1.08 0.01 RNA binding motif protein 24 
Rbms3 207181 -2.27/-1.55 0.00/0.00 
RNA binding motif, single stranded 
interacting protein 3 
Rbp1 19659 1.48 0.00 Retinol binding protein 1 
Rbp7 63954 1.74 0.03 Retinol binding protein 7 
Rdh9 103142 1.79 0.01 Retinol dehydrogenase 9 
Reck 53614 -2.46 0.00 
Reversion-inducing- cysteine-rich protein 
with kazal motifs 
Rfc4 106344 1.05 0.02 
Replication factor C ( activator 1) 4, 
37kDa 
Rgs2 19735 -1.05 0.01 Regulator of G-protein signaling 2 
Rgs4 19736 -1.85 0.01 Regulator of G-protein signaling 4 
Rgs5 19737 -2.10/-1.19/-1.72 0.00/0.03/0.04 Regulator of G-protein signaling 5 
Rhoc 11853 1.08 0.02 Ras homolog gene family, member C 
Rian 75745 2.65 0.01 
RNA imprinted and accumulated in 
nucleus 
Rnf14 56736 1.16 0.04 Ring finger protein 14 
Rnf43 207742 1.23 0.03 Ring finger protein 43 
Rnpep 215615 1.24 0.00 
Arginyl aminopeptidase (aminopeptidase 
B) 
Rp2h 19889 1.26/1.46 0.00/0.03 Retinitis pigmentosa 2 homolog 
Rpl12 269261 1.01 0.03 Ribosomal protein L12 
Rpl22l1 68028 1.21 0.00 Ribosomal protein L22- like 1 
Rps4y2 66184 -2.16 0.00 Ribosomal protein S4, Y-linked 2 
Rras 20130 1.31 0.01 
Related RAS viral (r-ras) oncogene 
homolog 
Rrm1 20133 1.36 0.02 Ribonucleotide reductase M1 
Rrm2 20135 1.42/1.63 0.02/0.03 Ribonucleotide reductase M2 
Rspo3 72780 -2.12 0.00 R-spondin 3 
Rtn4 68585 1.54 0.03 Reticulon 4 
S100a10 20194 1.30 0.01 S100 calcium binding protein A10 
S100a11 20195 2.10 0.03 S100 calcium binding protein A11 
Samd4 74480 1.34 0.02 Sterile alpha motif domain containing 4A 
Sardh 192166 -1.09 0.01 Sarcosine dehydrogenase 
Scamp5 56807 1.22 0.00 Secretory carrier membrane protein 5 
Scara3 219151 -1.81 0.03 Scavenger receptor class A, member 3 
Scara5 71145 1.65 0.02 Scavenger receptor class A, member 5 
Sco2 100126824 -1.33 0.00 
SCO cytochrome oxidase deficient 
homolog 2 
Scoc 56367 1.37 0.02 Short coiled-coil protein 
Sdc1 20969 -1.07 0.01 Syndecan 1 
Sds 231691 -4.57 0.00 Serine dehydratase 
Sdsl 257635 -2.38 0.00 Serine dehydratase-like 
Sectm1a 209588 1.89 0.01 Secreted and transmembrane 1A 
Sema3b 20347 1.53 0.02 Semaphorin-3B 
Sema3d 108151 -1.42 0.01 Semaphorin-3D 
Sema3e 20349 -1.83/-1.73/-1.36 0.03/0.01/0.01 Semaphorin-3E 
Serpina4-ps1 321018 -2.52/-2.30/-1.58 0.01/0.01/0.02 
Serine (or cysteine) peptidase inhibitor, 
clade A, member 4, pseudogene 1 
Serpinb6a 20719 1.98 0.01 
Serine (or cysteine) peptidase inhibitor, 
clade B, member 6a 
Setd7 73251 -1.05 0.01 
SET domain containing (lysine 
methyltransferase) 7 
Sftpd 20390 -1.25 0.03 Surfactant protein D 
Sfxn1 14057 -3.33/-3.09 0.00/0.00 Sideroflexin 1 
Sfxn2 94279 -1.42/-1.31 0.01/0.03 Sideroflexin 2 
Sgms1 208449 1.04/1.16 0.02/0.02 Sphingomyelin synthase 1 
Sgol2 68549 1.18 0.03 Shugoshin-like 2 
Shcbp1 20419 1.41 0.00 SHC SH2-domain binding protein 1 
Sidt1 320007 2.03 0.02 SID1 transmembrane family, member 1 
Slc10a2 20494 2.00 0.00 
Solute carrier family 10 (sodium/bile acid 
cotransporter family), member 2 
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Slc11a1 18173 1.30 0.03 
Solute carrier family 11 (proton-coupled 
divalent metal ion transporters), member 
1 
Slc12a2 20496 -1.05 0.02 
Solute carrier family 12 
(sodium/potassium/chloride transporters), 
member 2 
Slc13a2 20500 -1.26 0.00 
Solute carrier family 13 (sodium-
dependent dicarboxylate transporter), 
member 2 
Slc13a3 114644 2.06/2.24 0.02/0.00 
Solute carrier family 13 (sodium-
dependent dicarboxylate transporter), 
member 3 
Slc16a7 20503 1.12 0.05 
Solute carrier family 16, member 7 
(monocarboxylic acid transporter 2) 
Slc1a4 55963 1.94/2.37/2.90 0.00/0.00/0.00 
Solute carrier family 1 (glutamate/neutral 
amino acid transporter), member 4 
Slc22a7 108114 -1.33 0.04 
Solute carrier family 22 (organic anion 
transporter), member 7 
Slc25a15 18408 -1.14 0.00 
Solute carrier family 25 (mitochondrial 
carrier; ornithine transporter) member 15 
Slc25a25 227731 -1.00 0.04 
Solute carrier family 25 (mitochondrial 
carrier; phosphate carrier), member 25 
Slc25a30 67554 1.57 0.03 
Solute carrier family 25 (mitochondrial 
carrier; phosphate carrier), member 30 
Slc36a1 215335 1.00 0.00 
Solute carrier family 36 (proton/amino 
acid symporter), member 1 
Slc37a4 14385 -1.00 0.02 
Solute carrier family 37 (glucose-6-
phosphate transporter), member 4 
Slc38a3 76257 -1.51 0.00 
Solute carrier family 38 (sodium-coupled 
neutral amino acid transporter), member 3 
Slc39a2 214922 2.21 0.04 
Solute carrier family 39 (zinc transporter), 
member 2 
Slc39a4 72027 1.48 0.01 
Solute carrier family 39 (zinc transporter), 
member 4 
Slc48a1 67739 1.10/1.21 0.04/0.01 
Solute carrier family 48 (heme 
transporter), member 1 
Slc5a3 53881 -1.24 0.01 
Solute carrier family 5 (sodium/myo-
inositol cotransporter), member 3 
Slc7a2 11988 -1.96/-1.50 0.00/0.01 
Solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 2 
Slc7a4 224022 -1.17 0.01 
Solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 4 
Slc8a3 110893 -1.18 0.01 
Solute carrier family 8 (sodium/calcium 
exchanger), member 3 
Slco2a1 24059 -1.68 0.03 
Solute carrier organic anion transporter 
family, member 2A1 
Slpi 20568 2.20 0.03 Secretory leukocyte peptidase inhibitor 
Smc2 14211 1.02 0.03 
Structural maintenance of chromosomes 
protein 2 
Smo 319757 -1.10 0.02 Smoothened, frizzled family receptor 
Snhg11 319317 1.45 0.03 
Small nucleolar RNA host gene 11 (non-
protein coding) 
Snhg8 69895 -1.07 0.03 
Small nucleolar RNA host gene 8 (non-
protein coding) 
Sntg2 268534 -1.60 0.00 Syntrophin, gamma 2 
Socs5 56468 -1.00 0.02 Suppressor of cytokine signaling 5 
Sod3 20657 -1.06 0.03 Superoxide dismutase 3, extracellular 
Spa17 20686 1.06 0.04 Sperm autoantigenic protein 17 
Sparcl1 13602 2.17 0.01 SPARC-like 1 
Spc25 66442 1.30 0.01 
NDC80 kinetochore complex component, 
homolog 
Sprr1a 20753 2.54 0.01 Small proline-rich protein 1A 
Srxn1 76650 2.11/2.29 0.04/0.04 Sulfiredoxin 1 
St3gal5 20454 -1.58/-1.49 0.01/0.01 
ST3 beta-galactoside alpha-2,3-
sialyltransferase 5 
Steap2 74051 -1.78 0.00 
STEAP family member 2, 
metalloreductase 
Stmn1 16765 1.25 0.04 Stathmin 1 
Strbp 20744 1.47 0.04 
Spermatid perinuclear RNA binding 
protein 
Sulf2 72043 -1.42/-1.35 0.00/0.00 Sulfatase 2 
Sult5a1 57429 -1.85 0.02 Sulfotransferase family 5A, member 1 
Susd1 634731 -1.46 0.02 Sushi domain containing 1 
Susd4 96935 -2.62/-2.32 0.00/0.00 Sushi domain containing 4 
Syde2 214804 -1.47 0.00 
Synapse defective 1, Rho GTPase, 
homolog 2 
Synpo 104027 1.09 0.01 Synaptopodin 
Tat 234724 -1.57 0.02 Tyrosine aminotransferase 
Tbc1d8 54610 -1.01 0.04 
TBC1 domain family, member 8 (with 
GRAM domain) 
Tbcel 272589 1.02 0.02 Tubulin folding cofactor E-like 
Tbx20 57246 -1.30 0.01 T-box 20 
Tcf21 21412 -1.71 0.01 Transcription factor 21 
Tcf7 21414 1.32 0.02 Transcription factor 7 
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Tcf7l1 21415 -1.49 0.00 Transcription factor 7-like 1 
Tead1 21676 -1.42 0.01 TEA domain family member 1 
Tes 21753 1.05 0.01 Testis derived transcript 
Tgfbi 21810 -1.33/-1.12/-1.08/-1.17 0.03/0.04/0.01/0.01 
Transforming growth factor, beta-induced, 
68kDa 
Tgfbr2 21813 1.01 0.01 
Transforming growth factor, beta receptor 
II 
Tgfbr3 21814 -1.32 0.02 
Transforming growth factor, beta receptor 
III 
Them5 66198 -1.80 0.00 Thioesterase superfamily member 5 
Tiam2 24001 -1.93 0.03 
T-cell lymphoma invasion and metastasis 
2 
Timd4 276891 -1.15 0.05 
T-cell immunoglobulin and mucin domain 
containing 4 
Timm8a1 30058 1.25 0.01 
Translocase of inner mitochondrial 
membrane 8 homolog a1 
Timp2 21858 -1.07 0.05 TIMP metallopeptidase inhibitor 2 
Tinag 26944 2.92 0.00 Tubulointerstitial nephritis antigen 
Tle4 21888 -1.03 0.03 Transducin-like enhancer of split 4 
Tmem204 407831 -1.03 0.05 Transmembrane protein 204 
Tmem25 71687 -1.37 0.02 Transmembrane protein 25 
Tmem37 170706 1.18 0.05 Transmembrane protein 37 
Tmem43 74122 1.06 0.02 Transmembrane protein 43 
Tmem45a 56277 -1.40 0.03 Transmembrane protein 45A 
Tmem47 192216 -1.26 0.01 Transmembrane protein 47 
Tmem63a 208795 -1.10 0.00 Transmembrane protein 63A 
Tmem97 69071 1.20 0.01 Transmembrane protein 97 
Tmpo 21917 1.05 0.02 Thymopoietin 
Tmprss2 50528 1.16/1.21 0.00/0.00 Transmembrane protease, serine 2 
Tmprss4 214523 -1.09 0.03 Transmembrane protease, serine 4 
Tmtc2 278279 -1.12 0.02 
Transmembrane and tetratricopeptide 
repeat containing 2 
Tmtc4 70551 1.49/1.70 0.01/0.01 
Transmembrane and tetratricopeptide 
repeat containing 4 
Tnfrsf11b 18383 -1.08 0.01 
Tumor necrosis factor receptor 
superfamily, member 11b 
Tnfrsf12a 27279 1.35/1.48 0.03/0.02 
Tumor necrosis factor receptor 
superfamily, member 12a 
Tnfrsf19 29820 1.67 0.01 
Tumor necrosis factor receptor 
superfamily, member 19 
Tns1 21961 -1.17 0.00 Tensin 1 
Tnxb 81877 -1.26 0.00 Tenascin XB 
Top2a 21973 1.86 0.00 DNA topoisomerase 2-alpha 
Tpd52 21985 1.22 0.01 Tumor protein D52 
Tpm1 22003 1.30/1.58 0.00/0.00 Tropomyosin 1 (alpha) 
Tpr 108989 1.13/1.24 0.01/0.01 
Translocated promoter region (to 
activated MET oncogene) 
Tpx2 72119 1.35 0.02 Targeting protein for Xklp2 
Trim2 80890 1.01/1.48 0.01/0.03 Tripartite motif containing 2 
Trpm7 58800 1.18 0.04 
Transient receptor potential cation 
channel, subfamily M, member 7 
Tshz2 228911 -1.76/-1.03 0.01/0.01 Teashirt zinc finger homeobox 2 
Tspan33 232670 -1.32 0.01 Tetraspanin 33 
Tspyl4 72480 -1.62 0.03 TSPY-like 4 
Tstd1 226654 -2.63 0.00 
Thiosulfate sulfurtransferase (rhodanese)-
like domain containing 1 
Ttc39a 230603 1.46 0.01 Tetratricopeptide repeat domain 39A 
Ttk 22137 1.68 0.01 TTK protein kinase 
Tubb4b 227613 1.35 0.02 Tubulin, beta 4B class IVb 
Uap1l1 227620 1.63 0.00 
UDP-N-acteylglucosamine 
pyrophosphorylase 1-like 1 
Ubd 24108 3.20 0.01 Ubiquitin D 
Ube2c 68612 1.95 0.00 Ubiquitin-conjugating enzyme E2 C 
Ube2t 67196 1.30 0.03 Ubiquitin-conjugating enzyme E2 T 
Uck2 80914 -1.77 0.02 Uridine-cytidine kinase 2 
Uroc1 243537 -2.59/-2.17 0.01/0.01 Urocanase domain containing 1 
Vipr1 22354 -1.38 0.01 
Vasoactive intestinal polypeptide receptor 
1 
Vma21 67048 1.05 0.02 VMA21 vacuolar H+-ATPase homolog 
Vopp1 232023 1.26/1.95 0.01/0.00 
Vesicular, overexpressed in cancer, 
prosurvival protein 1 
Vwf 22371 -1.10 0.02 Von Willebrand factor 
Wdr1 22388 1.05 0.01 WD repeat domain 1 
Wdr67 210544 1.12 0.03 WD repeat domain 67 
Wfdc15b 192201 -1.57 0.01 WAP four-disulfide core domain 15B 
Wfdc2 67701 -2.05 0.00 WAP four-disulfide core domain 2 
Wisp1 22402 2.23/2.41 0.01/0.02 
WNT1-inducible-signaling pathway protein 
1 
Wsb1 78889 -1.89 0.00 WD repeat and SOCS box containing 1 
Zdhhc14 224454 -1.96/-1.90/-1.86 0.01/0.01/0.02 Zinc finger, DHHC-type containing 14 
Zfand2a 100494 1.03/1.22 0.01/0.00 Zinc finger, AN1-type domain 2A 
Zfp259 22687 -1.27 0.00 Zinc finger protein 259 
Zfp54 22712 1.21 0.02 Zinc finger protein 54 
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Zfpm2 22762 -1.09 0.01 Zinc finger protein, multitype 2 
Zswim6 67263 -1.07 0.01 Zinc finger, SWIM-type containing 6 
Zwilch 68014 1.75 0.00 Zwilch, kinetochore associated, homolog 
 
 
 
B) Genes significantly dysregulated in Ha-ras-mutated tumors vs. adjacent non-tumor 
tissue (log-ratio >1.0, p-value <0.05). 
Gene symbol 
EntrezGene 
ID Log-ratio p-value 
Gene name 
Aadat 23923 -2.25 0.00 Aminoadipate aminotransferase 
Aass 30956 -1.26 0.00 Aminoadipate-semialdehyde synthase 
Abat 268860 -1.45 0.00 4-aminobutyrate aminotransferase 
Abca5 217265 1.39 0.00 ATP-binding cassette, sub-family A (ABC1), member 5 
Abcb10 56199 -1.42/-1.13 0.00/0.01 
ATP-binding cassette, sub-family B (MDR/TAP), 
member 10 
Abcb11 27413 -1.40 0.04 
ATP-binding cassette, sub-family B (MDR/TAP), 
member 11 
Abcb1a 18671 1.88/2.17 0.02/0.01 
ATP-binding cassette, sub-family B (MDR/TAP), 
member 1A 
Abcb6 74104 -1.13 0.00 
ATP-binding cassette, sub-family B (MDR/TAP), 
member 6 
Abcc5 27416 1.16 0.00 
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 5 
Abcd2 26874 3.38/3.64/4.74 0.00/0.00/0.00 ATP-binding cassette, sub-family D (ALD), member 2 
Abhd15 67477 -2.07 0.01 Abhydrolase domain containing 15 
Abhd2 54608 1.32/1.43/1.90 0.00/0.00/0.00 Abhydrolase domain containing 2 
Abhd5 67469 1.60/1.74 0.00/0.00 Abhydrolase domain containing 5 
Abi2 329165 2.75/2.78 0.00/0.00 Abl-interactor 2 
Abi3bp 320712 -2.75/-1.54 0.00/0.00 ABI family, member 3 (NESH) binding protein 
Ablim3 319713 -1.96 0.00 Actin binding LIM protein family, member 3 
Acadsb 66885 -1.29 0.00 Acyl-CoA dehydrogenase, short/branched chain 
Acbd3 170760 1.20/1.20/1.42 0.00/0.02/0.02 Acyl-CoA binding domain containing 3 
Accn5 58170 -2.83 0.00 Amiloride-sensitive cation channel 5 
Acot1 26897 -2.37 0.00 Acyl-CoA thioesterase 1 
Acot9 56360 1.07 0.00 Acyl-CoA thioesterase 9 
Acsl1 14081 -1.10/-1.05 0.02/0.01 Acyl-CoA synthetase long-chain family member 1 
Acsl3 74205 1.74/1.85 0.01/0.02 Acyl-CoA synthetase long-chain family member 3 
Acsl4 50790 1.79/1.97/2.03 0.00/0.00/0.00 Acyl-CoA synthetase long-chain family member 4 
Acsl5 433256 1.23 0.00 Acyl-CoA synthetase long-chain family member 5 
Acsm1 117147 -2.06 0.00 Acyl-CoA synthetase medium-chain family member 1 
Acsm2 233799 -1.48 0.00 Acyl-CoA synthetase medium-chain family member 2 
Acsm5 272428 -2.31 0.00 Acyl-CoA synthetase medium-chain family member 5 
Actn1 109711 1.04 0.00 Actinin, alpha 1 
Adam11 11488 -1.10 0.00 ADAM metallopeptidase domain 11 
Adamdec1 58860 -2.05 0.01 ADAM-like, decysin 1 
Adamts5 23794 -1.10 0.03 
ADAM metallopeptidase with thrombospondin type 1 
motif, 5 
Adck3 67426 -1.22 0.04 AarF domain containing kinase 3 
Adck4 76889 2.32 0.00 AarF domain containing kinase 4 
Add3 27360 -1.09 0.01 Adducin 3 (gamma) 
Adh4 26876 -2.19 0.00 Alcohol dehydrogenase 4 (class II), pi polypeptide 
Adhfe1 76187 -1.57/-1.38 0.01/0.01 Alcohol dehydrogenase, iron containing, 1 
Adrbk2 320129 1.27/1.79/2.09 0.00/0.00/0.00 Adrenergic, beta, receptor kinase 2 
Aebp1 11568 1.36/2.00 0.00/0.00 AE binding protein 1 
Afmid 71562 -1.53/-1.12 0.01/0.04 Arylformamidase 
Afp 11576 1.13/3.43/4.17/4.81 0.02/0.00/0.00/0.00 Alpha-fetoprotein 
Agbl3 76223 -1.20 0.00 ATP/GTP binding protein-like 3 
Agfg1 15463 
1.18/1.41/1.47/1.75/
1.92 0.00/0.00/0.00/0.00/0.00 
ArfGAP with FG repeats 1 
Agmat 75986 -1.89 0.00 Agmatine ureohydrolase (agmatinase) 
Agps 228061 1.06 0.01 Alkylglycerone phosphate synthase 
Agxt2l1 71760 -4.50 0.01 Alanine-glyoxylate aminotransferase 2-like 1 
Ahcy 269378 -1.17 0.02 Adenosylhomocysteinase 
AI132709 101494 3.60 0.00 N/A 
AI195470 107131 -1.07 0.02 N/A 
AI464131 329828 -1.19 0.00 N/A 
AI597468 103266 1.31 0.01 N/A 
Aifm3 72168 -1.53 0.00 Apoptosis-inducing factor, mitochondrion-associated, 3 
Aig1 66253 1.40 0.00 Androgen-induced 1 
Airn 104103 1.73 0.00 Antisense of IGF2R RNA (non-protein coding) 
Ak4 11639 1.08 0.02 Adenylate kinase 4 
Akr1b3 11677 1.72/1.82/2.30 0.01/0.00/0.00 Aldo-keto reductase family 1, member B3 
Akr1b7 11997 1.37 0.01 Aldo-keto reductase family 1, member 7 
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Akr1c18 105349 5.04 0.00 Aldo-keto reductase family 1, member C18 
Akr1c19 432720 -1.56 0.03 Aldo-keto reductase family 1, member C19 
Akr1c6 83702 -1.45 0.00 Aldo-keto reductase family 1, member C6 
Akr1d1 208665 -1.22/-1.10 0.02/0.02 
Aldo-keto reductase family 1, member D1 (delta 4-3-
ketosteroid-5-beta-reductase) 
Alas2 11656 -2.31 0.00 Aminolevulinate, delta-, synthase 2 
Alcam 11658 
1.59/1.81/1.92/2.04/
2.09 0.00/0.00/0.00/0.00/0.00 
Activated leukocyte cell adhesion molecule 
Aldh16a1 69748 -1.08 0.00 Aldehyde dehydrogenase 16 family, member A1 
Aldh18a1 56454 1.28/2.34 0.01/0.00 Aldehyde dehydrogenase 18 family, member A1 
Aldh1a1 11668 -1.20 0.01 Aldehyde dehydrogenase 1 family, member A1 
Aldh1a7 26358 -1.18 0.00 Aldehyde dehydrogenase family 1, subfamily A7 
Aldh1b1 72535 1.99 0.00 Aldehyde dehydrogenase 1 family, member B1 
Aldoc 11676 1.37 0.01 Aldolase C, fructose-bisphosphate 
Alox5 11689 2.66 0.00 Arachidonate 5-lipoxygenase 
Amn 93835 1.37 0.01 Amnionless homolog (mouse) 
Amot 27494 1.56 0.00 Angiomotin 
Amy1 11722 -1.29 0.00 Amylase 1, salivary, alpha-amylase 
Ang 11727 -2.76 0.00 Angiogenin, ribonuclease, RNase A family, 5 
Angptl6 70726 -1.16 0.01 Angiopoietin-like 6 
Ankrd33b 67434 -2.08/-1.76 0.00/0.01 Ankyrin repeat domain 33B 
Ano1 101772 -1.03 0.00 Anoctamin 1, calcium activated chloride channel 
Anxa2 12306 2.64 0.00 Annexin A2 
Anxa3 11745 1.55 0.00 Annexin A3 
Anxa4 11746 1.27/1.38 0.00/0.00 Annexin A4 
Anxa5 11747 1.13 0.00 Annexin A5 
Anxa9 71790 1.29 0.00 Annexin A9 
Aox1 11761 -1.47 0.00 Aldehyde oxidase 1 
Aox3 71724 -3.04 0.01 Aldehyde oxidase 3 
Aph1b 208117 1.65/1.83 0.00/0.00 Anterior pharynx defective 1 homolog B (C. elegans) 
Aplnr 23796 3.07 0.04 Apelin receptor 
Apoa4 11808 1.70/2.18 0.00/0.00 Apolipoprotein A-IV 
Apoc2 11813 1.47 0.00 Apolipoprotein C-II 
Apom 55938 1.51 0.00 Apolipoprotein M 
App 11820 1.80/2.01 0.00/0.00 Amyloid beta (A4) precursor protein 
Aqp4 11829 -2.69/-1.97 0.00/0.02 Aquaporin 4 
Aqp9 64008 -1.38/-1.30 0.01/0.00 Aquaporin 9 
Ar 11835 -2.53/-2.46/-1.00 0.00/0.00/0.01 Androgen receptor 
Arhgap12 75415 1.08 0.01 Rho GTPase activating protein 12 
Arhgap22 239027 1.66 0.00 Rho GTPase activating protein 22 
Arhgap42 71544 -1.28 0.01 Rho GTPase activating protein 42 
Arhgef37 328967 -2.43 0.00 Rho guanine nucleotide exchange factor (GEF) 37 
Arl2bp 107566 1.27 0.00 ADP-ribosylation factor-like 2 binding protein 
Armcx3 71703 1.67/1.80 0.00/0.01 Armadillo repeat containing, X-linked 3 
Arntl2 272322 1.61 0.00 Aryl hydrocarbon receptor nuclear translocator-like 2 
Arpc1b 11867 1.78 0.00 Actin related protein 2/3 complex, subunit 1B, 41kDa 
As3mt 57344 1.04 0.01 Arsenic (+3 oxidation state) methyltransferase 
Asl 109900 -1.47 0.00 Argininosuccinate lyase 
Aspa 11484 -1.48 0.01 Aspartoacylase 
Asph 65973 1.16 0.00 Aspartate beta-hydroxylase 
Ass1 11898 -1.45 0.01 Argininosuccinate synthase 1 
Atf3 11910 1.40 0.02 Activating transcription factor 3 
Atp11c 320940 -1.33/-1.21 0.00/0.00 ATPase, class VI, type 11C 
Atp1b1 11931 1.10/1.10/1.14/1.22 0.01/0.00/0.00/0.00 ATPase, Na+/K+ transporting, beta 1 polypeptide 
Atp8b4 241633 -2.06 0.03 ATPase, class I, type 8B, member 4 
Atpif1 11983 1.35 0.00 ATPase inhibitory factor 1 
Atrnl1 226255 -1.59 0.00 Attractin-like 1 
Avpi1 69534 1.33 0.00 Arginine vasopressin-induced 1 
Avpr1a 54140 -1.59 0.04 Arginine vasopressin receptor 1A 
B3galnt1 26879 1.11 0.00 
Beta-1,3-N-acetylgalactosaminyltransferase 1 
(globoside blood group) 
B4galt6 56386 1.77/2.45/2.87/2.93 0.00/0.00/0.00/0.00 
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 6 
Baat 12012 -1.67/-1.49 0.00/0.00 
Bile acid CoA: amino acid N-acyltransferase (glycine 
N-choloyltransferase) 
Bace1 23821 -1.14 0.02 Beta-site APP-cleaving enzyme 1 
Bach1 12013 1.31/1.40 0.01/0.01 
BTB and CNC homology 1, basic leucine zipper 
transcription factor 1 
Bach2 12014 1.02/1.04 0.02/0.02 
BTB and CNC homology 1, basic leucine zipper 
transcription factor 2 
Bag4 67384 -1.50/-1.41 0.000.00 BCL2-associated athanogene 4 
Bax 12028 1.08 0.01 BCL2-associated X protein 
Baz1a 217578 1.00 0.00 Bromodomain adjacent to zinc finger domain, 1A 
BB319198 100503607 1.84 0.00  
Bbox1 170442 -1.04 0.03 
Butyrobetaine (gamma), 2-oxoglutarate dioxygenase 
(gamma-butyrobetaine hydroxylase) 1 
Bcas1 76960 1.50 0.01 Breast carcinoma amplified sequence 1 
Bcl10 12042 1.18/1.37/1.54 0.00/0.00/0.00 B-cell CLL/lymphoma 10 
Bcl2 12043 1.41/1.71 0.00/0.00 B-cell CLL/lymphoma 2 
Bcl2l11 12125 1.03/1.27/1.30/2.00 0.02/0.01/0.01/0.00 BCL2-like 11 (apoptosis facilitator) 
Bcl2l14 66813 1.62/1.73 0.00/0.00 BCL2-like 14 (apoptosis facilitator) 
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Bcmo1 63857 2.23 0.00 Beta-carotene 15,15'-monooxygenase 1 
Bco2 170752 -1.51 0.01 Beta-carotene oxygenase 2 
Bdh1 71911 1.06 0.00 3-hydroxybutyrate dehydrogenase, type 1 
Bdh2 69772 -1.80 0.00 3-hydroxybutyrate dehydrogenase, type 2 
Bdnf 12064 -1.45 0.00 Brain-derived neurotrophic factor 
Bex1 19716 5.23 0.00 Brain expressed, X-linked 1 
Bex2 12069 2.55 0.00 Brain expressed X-linked 2 
Bgn 12111 -1.18/-1.08 0.02/0.01 Biglycan 
Bicc1 83675 1.49/1.68 0.00/0.00 Bicaudal C homolog 1 (Drosophila) 
Blnk 17060 1.94 0.03 B-cell linker 
Bmf 171543 -1.95 0.00 Bcl2 modifying factor 
Bmp4 12159 1.14 0.01 Bone morphogenetic protein 4 
Bmp5 12160 -1.94 0.00 Bone morphogenetic protein 5 
Bmp7 12162 1.49/2.55 0.00/0.00 Bone morphogenetic protein 7 
Bmp8b 12164 1.27/1.56 0.00/0.00 Bone morphogenetic protein 8b 
Btc 12223 1.34/1.44 0.00/0.00 Betacellulin 
Btg2 12227 2.86/3.25 0.00/0.00 BTG family, member 2 
Btnl9 237754 1.46 0.03 Butyrophilin-like 9 
Bub1 12235 1.83 0.05 
Budding uninhibited by benzimidazoles 1 homolog 
(yeast) 
C1ql3 227580 1.05 0.03 Complement component 1, q subcomponent-like 3 
C4b 12268 -1.67 0.00 Complement component 4B (Chido blood group) 
C6 12274 -1.83 0.03 Complement component 6 
C8b 110382 -2.06 0.01 Complement component 8, beta polypeptide 
C9 12279 -1.33 0.01 Complement component 9 
Cab39 12283 1.08 0.01 Calcium binding protein 39 
Cacna1b 12287 2.85/2.94 0.03/0.02 
Calcium channel, voltage-dependent, N type, alpha 1B 
subunit 
Cacna1c 12288 1.51 0.00 
Calcium channel, voltage-dependent, L type, alpha 1C 
subunit 
Calml4 75600 2.79 0.00 Calmodulin-like 4 
Capn10 23830 1.01 0.03 Calpain 10 
Caprin2 232560 1.39 0.00 Caprin family member 2 
Capsl 75568 1.22 0.01 Calcyphosine-like 
Car1 12346 -2.88 0.00 Cysteinyl-tRNA synthetase 
Car14 23831 -1.61 0.05 Carbonic anhydrase 14 
Car2 12349 1,26 0,00 Carbonic anhydrase 2 
Car3 12350 
-2,67/-2,39/-1,82/-
1,35 0,01/0,03/0,03/0,03 
Carbonic anhydrase 3 
Car5a 12352 -2,14 0,00 Carbonic anhydrase 5a, mitochondrial 
Card10 105844 1,32 0,00 Caspase recruitment domain family, member 10 
Cars 27267 1,03 0,01 Cysteinyl-tRNA synthetase 
Casc4 319996 3,88 0,00 Cancer susceptibility candidate 4 
Casp12 12364 1,98/2,27 0,00/0,00 Caspase 12 (gene/pseudogene) 
Casp4 12363 1,76 0,00 Caspase 4, apoptosis-related cysteine peptidase 
Cav1 12389 1,82 0,02 Caveolin 1, caveolae protein, 22kDa 
Cav2 12390 2,54 0,00 Caveolin 2 
Ccbe1 320924 -1,47 0,04 Collagen and calcium binding EGF domains 1 
Ccdc120 54648 2,36 0,00 Coiled-coil domain containing 120 
Ccdc125 76041 1,01 0,02 Coiled-coil domain containing 125 
Ccdc149 100503884 2,07 0,00 Coiled-coil domain containing 149 
Ccdc162 75973 -1,61 0,01 Coiled-coil domain containing 162, pseudogene 
Ccdc164 381738 2,21 0,00 Coiled-coil domain containing 164 
Ccdc25 67179 1,38 0,01 Coiled-coil domain containing 25 
Ccdc51 66658 1,31 0,00 Coiled-coil domain containing 51 
Ccdc68 381175 1,77 0,00 Coiled-coil domain containing 68 
Ccdc88c 68339 1,19 0,02 Coiled-coil domain containing 88C 
Ccdc99 70385 1,08 0,02 Coiled-coil domain containing 99 
Ccna2 12428 1,31/1,98 0,03/0,04 Cyclin A2 
Ccnb1 268697 2,12 0,05 Cyclin B1 
Ccnb2 12442 2,58 0,03 Cyclin B2 
Ccnd1 12443 2,19/2,32/2,43 0,01/0,00/0,01 Cyclin D1 
Ccne1 12447 2,11 0,00 Cyclin E1 
Cd14 12475 3,11 0,00 CD14 molecule 
Cd163 93671 -2,43 0,01 CD163 molecule 
Cd1d2 12480 2,31 0,00 CD1d2 antigen 
Cd209b 69165 -1,32 0,01 N/A 
Cd24a 12484 1,34 0,04 CD24a antigen 
Cd276 102657 1,71 0,01 CD276 molecule 
Cd2ap 12488 1,26/1,43/1,67 0,00/0,00/0,00 CD2-associated protein 
Cd40 21939 2,05/2,06/2,72 0,00/0,00/0,00 CD40 molecule 
Cd9 12527 1,17 0,00 CD9 molecule 
Cd93 17064 1,42/1,55 0,01/0,01 CD93 molecule 
Cd97 26364 1,02 0,01 CD97 molecule 
Cda 72269 1,06 0,00 Cytidine deaminase 
Cdc20 107995 1,29/1,86 0,04/0,02 Cell division cycle 20 homolog (S. cerevisiae) 
Cdca3 14793 1,64 0,03 Cell division cycle associated 3 
Cdca4 71963 1,14 0,00 Cell division cycle associated 4 
Cdca8 52276 1,05/1,28 0,01/0,04 Cell division cycle associated 8 
Cdh1 12550 3,38 0,01 Cadherin 1, type 1, E-cadherin (epithelial) 
Cdh17 12557 3,34 0,00 Cadherin 17, LI cadherin (liver-intestine) 
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Cdhr2 268663 2,59 0,00 Cadherin-related family member 2 
Cdhr5 72040 -1,06 0,01 Cadherin-related family member 5 
Cdk1 12534 1,33 0,05 Cyclin-dependent kinase 1. 
Cdk2ap2 52004 1,05 0,01 Cyclin-dependent kinase 2 associated protein 2 
Cdk4 12567 1,02 0,01 Cyclin-dependent kinase 4 
Cdk6 12571 1,19 0,02 Cyclin-dependent kinase 6 
Cdkn1a 12575 1,59/1,95 0,00/0,00 Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
Cdkn2a 12578 2,65 0,00 
Cyclin-dependent kinase inhibitor 2A (melanoma, p16, 
inhibits CDK4) 
Cdkn2b 12579 4,65 0,00 
Cyclin-dependent kinase inhibitor 2B (p15, inhibits 
CDK4) 
Cdkn2c 12580 2,18 0,00 
Cyclin-dependent kinase inhibitor 2C (p18, inhibits 
CDK4) 
Cdkn3 72391 2,24 0,02 Cyclin-dependent kinase inhibitor 3 
Celf2 14007 -2,14/-1,68/-1,53 0,02/0,04/0,02 CUGBP, Elav-like family member 2 
Celsr2 53883 1,87 0,00 
Cadherin, EGF LAG seven-pass G-type receptor 2 
(flamingo homolog, Drosophila) 
Cenpa 12615 2,07 0,00 Centromere protein A 
Cep170 545389 1,03 0,03 Centrosomal protein 170kDa 
Cep192 70799 1,04 0,00 Centrosomal protein 192kDa 
Cerk 223753 1,38 0,01 Ceramide kinase 
Ces1d 104158 -1,93/-1,78 0,03/0,04 Carboxylesterase 1D 
Ces1e 13897 -3,50 0,00 Carboxylesterase 1E 
Ces1f 234564 -2,46 0,00 Carboxylesterase 1F 
Ces1g 12623 -2,91 0,00 Carboxylesterase 1G 
Ces2a 102022 -1,76 0,01 Carboxylesterase 2A 
Ces2e 234673 2,52 0,00 Carboxylesterase 2E 
Ces2g 72361 1,25 0,00 Carboxylesterase 2G 
Cfhr1 50702 -1,50 0,00 Complement factor H-related 1 
Cgref1 68567 1,90/2,47 0,00/0,00 Cell growth regulator with EF-hand domain 1 
Chka 12660 2,42/2,45 0,04/0,04 Choline kinase alpha 
Chmp2b 68942 1,05/1,21 0,03/0,00 Charged multivesicular body protein 2B 
Chmp4c 66371 1,47/2,26/2,54 0,01/0,00/0,00 Charged multivesicular body protein 4C 
Chmp6 208092 1,24 0,00 Charged multivesicular body protein 6 
Chpt1 212862 
-2,31/-2,24/-2,03/-
1,84 0,00/0,00/0,00/0,00 
Choline phosphotransferase 1 
Chrna2 110902 -1,05 0,00 Cholinergic receptor, nicotinic, alpha 2 (neuronal) 
Chrna4 11438 1,75 0,02 Cholinergic receptor, nicotinic, alpha 4 (neuronal) 
Chsy3 78923 1,67 0,00 Chondroitin sulfate synthase 3 
Cib2 56506 -1,75 0,00 Calcium and integrin binding family member 2 
Cidea 12683 4,72 0,00 Cell death-inducing DFFA-like effector a 
Cidec 14311 2,18 0,01 Cell death-inducing DFFA-like effector c 
Cisd1 52637 -1,03 0,00 CDGSH iron sulfur domain 1 
Ckap2 80986 1,78 0,03 Cytoskeleton associated protein 2 
Cks1b 54124 1,16 0,01 CDC28 protein kinase regulatory subunit 1B 
Clcf1 56708 1,75 0,00 Cardiotrophin-like cytokine factor 1 
Clcn2 12724 -1,95 0,01 Chloride channel 2 
Cldn14 56173 1,40 0,00 Claudin 14 
Cldn15 60363 1,01 0,00 Claudin 15 
Cldn7 53624 1,78 0,04 Claudin 7 
Clec1b 56760 -1,69 0,05 C-type lectin domain family 1, member B 
Clec4f 51811 -2,46 0,04 C-type lectin domain family 4, member F 
Clic5 224796 -1,19/-1,04 0,01/0,04 Chloride intracellular channel 5 
Clint1 216705 1,13 0,01 Clathrin interactor 1 
Cmah 12763 -1,84/-1,55 0,00/0,03 
Cytidine monophospho-N-acetylneuraminic acid 
hydroxylase, pseudogene 
Cmbl 69574 -1,51 0,00 
Carboxymethylenebutenolidase homolog 
(Pseudomonas) 
Cml1 66116 -1,78 0,00 Camello-like 1 
Cml2 93673 -2,72/-2,43/-2,36 0,00/0,00/0,00 Camello-like 2 
Cml5 69049 -1,13 0,00 Camello-like 5 
Cobl 12808 1,79 0,00 Cordon-bleu homolog (mouse) 
Col13a1 12817 -1,06 0,01 Collagen, type XIII, alpha 1 
Col14a1 12818 -1,04/-1,00 0,03/0,02 Collagen, type XIV, alpha 1 
Col27a1 373864 -1,20 0,01 Collagen, type XXVII, alpha 1 
Col4a1 12826 1,14/1,55 0,04/0,01 Collagen, type IV, alpha 1 
Col4a2 12827 1,19 0,03 Collagen, type IV, alpha 2 
Col4a3 12828 2,93/3,17 0,00/0,00 Collagen, type IV, alpha 3 (Goodpasture antigen) 
Col4a4 12829 1,63/2,04 0,00/0,00 Collagen, type IV, alpha 4 
Col4a5 12830 1,54/3,10 0,00/0,00 Collagen, type IV, alpha 5 
Col5a3 53867 -1,35 0,00 Collagen, type V, alpha 3 
Colec10 239447 -3,48 0,02 Collectin sub-family member 10 (C-type lectin) 
Colec11 71693 -1,80/-1,12 0,00/0,02 Collectin sub-family member 11 
Comtd1 69156 1,07 0,00 Catechol-O-methyltransferase domain containing 1 
Copb2 50797 1,07 0,01 Coatomer protein complex, subunit beta 2 (beta prime) 
Coq10a 210582 -1,31 0,00 Coenzyme Q10 homolog A (S. cerevisiae) 
Corin 53419 -3,03 0,00 Corin, serine peptidase 
Cox5b 12859 2,26 0,00 Cytochrome c oxidase subunit Vb 
Cp 12870 1,28/1,63 0,02/0,02 Ceruloplasmin (ferroxidase) 
Cpd 12874 1,10/1,21 0,00/0,01 Carboxypeptidase D 
Cpox 12892 -1,17/-1,07 0,01/0,01 Coproporphyrinogen oxidase 
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Cpsf4l 52670 -1,33 0,00 Cleavage and polyadenylation specific factor 4-like 
Creb3l2 208647 1,14 0,01 cAMP responsive element binding protein 3-like 2 
Crisp2 22024 1,37 0,01 Cysteine-rich secretory protein 2 
Crp 12944 -1,04 0,00 C-reactive protein, pentraxin-related 
Crygn 214301 -2,05 0,02 Crystallin, gamma N 
Cryl1 68631 -1,03 0,01 Crystallin, lambda 1 
Csad 246277 -2,07 0,00 Cysteine sulfinic acid decarboxylase 
Csn3 12994 4,12 0,00 Casein kappa 
Csrp2 13008 -1,93 0,00 Cysteine and glycine-rich protein 2 
Csrp3 13009 -2,61 0,00 
Cysteine and glycine-rich protein 3 (cardiac LIM 
protein) 
Cstb 13014 1,07 0,00 Cystatin B (stefin B) 
Cth 107869 -1,30 0,00 Cystathionase (cystathionine gamma-lyase) 
Ctps2 55936 1,99 0,00 CTP synthase II 
Ctsc 13032 1,42/1,80 0,00/0,00 Cathepsin C 
Cxadr 13052 1,31/1,38/1,61 0,04/0,04/0,00 Coxsackie virus and adenovirus receptor 
Cxcl1 14825 1,11/1,33 0,02/0,01 
Chemokine (C-X-C motif) ligand 1 (melanoma growth 
stimulating activity, alpha) 
Cxcl12 20315 -1,74/-1,48 0,00/0,01 Chemokine (C-X-C motif) ligand 12 
Cxcl14 57266 2,73 0,02 Chemokine (C-X-C motif) ligand 14 
Cxcl17 232983 1,91 0,05 Chemokine (C-X-C motif) ligand 17 
Cyb561 13056 2,99 0,00 Cytochrome b-561 
Cyb5r1 72017 1,41 0,00 Cytochrome b5 reductase 1 
Cyfip2 76884 -1,26 0,02 Cytoplasmic FMR1 interacting protein 2 
Cyp17a1 13074 2,73 0,01 
Cytochrome P450, family 17, subfamily A, polypeptide 
1 
Cyp1a2 13077 -2,62 0,00 Cytochrome P450, family 1, subfamily A, polypeptide 2 
Cyp26a1 13082 -2,13 0,02 
Cytochrome P450, family 26, subfamily A, polypeptide 
1 
Cyp26b1 232174 -1,17 0,02 
Cytochrome P450, family 26, subfamily B, polypeptide 
1 
Cyp27a1 104086 -2,47 0,00 
Cytochrome P450, family 27, subfamily A, polypeptide 
1 
Cyp2b13 13089 3,01 0,00 
Cytochrome P450, family 2, subfamily B, polypeptide 
13 
Cyp2b9 13094 3,69 0,00 Cytochrome P450, family 2, subfamily B, polypeptide 9 
Cyp2c29 13095 -1,16 0,04 
Cytochrome P450, family 2, subfamily C, polypeptide 
29 
Cyp2c37 13096 -3,12 0,00 
Cytochrome P450, family 2. subfamily C, polypeptide 
37 
Cyp2c38 13097 -2,18 0,00 
Cytochrome P450, family 2, subfamily C, polypeptide 
38 
Cyp2c39 13098 -2,91 0,00 
Cytochrome P450, family 2, subfamily C, polypeptide 
39 
Cyp2c50 107141 -2,99 0,00 
Cytochrome P450, family 2, subfamily C, polypeptide 
50 
Cyp2c54 404195 -2,85 0,00 
Cytochrome P450, family 2, subfamily C, polypeptide 
54 
Cyp2d13 68444 -1,70/-1,38 0,01/0,02 
Cytochrome P450, family 2, subfamily D, polypeptide 
13 
Cyp2d9 13105 -1,41 0,02 Cytochrome P450, family 2, subfamily D, polypeptide 9 
Cyp2e1 13106 -1,41 0,02 Cytochrome P450, family 2, subfamily E, polypeptide 1 
Cyp2f2 13107 -2,85 0,01 Cytochrome P450, family 2, subfamily F, polypeptide 1 
Cyp2g1 13108 -2,74 0,01 
Cytochrome P450, family 2, subfamily G, polypeptide 
1 
Cyp2j5 13109 -1,98/-1,75 0,01/0,00 Cytochrome P450, family 2, subfamily J, polypeptide 5 
Cyp39a1 56050 2,28 0,01 
Cytochrome P450, family 39, subfamily A, polypeptide 
1 
Cyp46a1 13116 -3,30 0,00 
Cytochrome P450, family 46, subfamily A, polypeptide 
1 
Cyp4a12a 277753 -3,80 0,00 
Cytochrome P450, family 4, subfamily A, polypeptide 
12a 
Cyp4f14 64385 -3,21 0,00 
Cytochrome P450, family 4, subfamily F, polypeptide 
14 
Cyp4f15 106648 -1,66 0,01 
Cytochrome P450, family 4, subfamily F, polypeptide 
15 
Cyp4f16 70101 1,57 0,00 
Cytochrome P450, family 4, subfamily F, polypeptide 
16 
Cyp4v3 102294 -1,33/-1,12 0,00/0,00 Cytochrome P450, family 4, subfamily V, polypeptide 3 
Cyp51 13121 1,59 0,04 Cytochrome P450, family 51 
Cyp7a1 13122 -3,21/-3,13 0,00/0,02 Cytochrome P450, family 7, subfamily A, polypeptide 1 
Cyp7b1 13123 -3,72/-3,68 0,02/0,03 Cytochrome P450, family 7, subfamily B, polypeptide 1 
Cyp8b1 13124 -3,57 0,00 Cytochrome P450, family 8, subfamily B, polypeptide 1 
Dab1 13131 
1,39/1,40/2,37/3,58/
3,69 0,01/0,01/0,00/0,00/0,00 
Disabled homolog 1 (Drosophila) 
Dach2 93837 -1,98 0,00 Dachshund homolog 2 (Drosophila) 
Dapk2 13143 1,50 0,00 Death-associated protein kinase 2 
Dbndd2 52840 1,01 0,00 
Dysbindin (dystrobrevin binding protein 1) domain 
containing 2 
Dcbld1 66686 1,14/1,33 0,00/0,00 Discoidin, CUB and LCCL domain containing 1 
Dcn 13179 -2,21 0,00 Decorin 
Ddah1 69219 1,04/1,13 0,01/0,02 Dimethylarginine dimethylaminohydrolase 1 
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Ddhd2 72108 -1,49 0,03 DDHD domain containing 2 
Ddit4l 73284 1,47/1,67 0,00/0,00 DNA-damage-inducible transcript 4-like 
Ddr1 12305 1,18/1,91/2,64 0,00/0,00/0,00 Discoidin domain receptor tyrosine kinase 1 
Ddx1 104721 1,07 0,01 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 
Ddx25 30959 1,34 0,04 DEAD (Asp-Glu-Ala-Asp) box polypeptide 25 
Dera 232449 -1,09 0,00 Deoxyribose-phosphate aldolase (putative) 
Det1 76375 1,00 0,01 De-etiolated homolog 1 (Arabidopsis) 
Dgkz 104418 1,15 0,00 Diacylglycerol kinase, zeta 
Dhcr7 13360 1,64 0,01 7-dehydrocholesterol reductase 
Dhtkd1 209692 -2,05 0,01 
Dehydrogenase E1 and transketolase domain 
containing 1 
Dkk4 234130 -1,72 0,00 Dickkopf homolog 4 (Xenopus laevis) 
Dleu2 668253 -1,20/-1,15 0,00/0,01 
Deleted in lymphocytic leukemia 2 (non-protein 
coding) 
Dlgap4 228836 1,01 0,00 
Discs, large (Drosophila) homolog-associated protein 
4 
Dlx4 13394 1,07/1,35 0,01/0,00 Distal-less homeobox 4 
Dmgdh 74129 -1,55 0,00 Dimethylglycine dehydrogenase 
Dmrta1 242523 -1,73 0,00 DMRT-like family A1 
Dmxl2 235380 -1,42 0,02 Dmx-like 2 
Dnajc10 66861 1,03 0,00 DnaJ (Hsp40) homolog, subfamily C, member 10 
Dnase1 13419 -1,31 0,01 Deoxyribonuclease I 
Dnase2a 13423 -1,65 0,01 Deoxyribonuclease II alpha 
Dntt 21673 1,97 0,04 Deoxynucleotidyltransferase, terminal 
Dock8 76088 -2,26 0,00 Dedicator of cytokinesis 8 
Dopey2 70028 -1,00 0,04 Dopey family member 2 
Dpp4 13482 -2,30/-1,84/-1,39 0,01/0,01/0,02 Dipeptidyl-peptidase 4 
Dpy19l1 244745 -1,13/-1,02 0,01/0,01 Dpy-19-like 1 (C. elegans) 
Dpy19l3 233115 -1,94/-1,23 0,00/0,03 Dpy-19-like 3 (C. elegans) 
Dpyd 99586 -1,71/-1,51 0,00/0,00 Dihydropyrimidine dehydrogenase 
Dpys 64705 -2,33/-1,88/-1,84 0,04/0,00/0,01 Dihydropyrimidinase 
Dse 212898 -1,07 0,04 Dermatan sulfate epimerase 
Dusp16 70686 1,26 0,01 Dual specificity phosphatase 16 
Dusp5 240672 1,85 0,00 Dual specificity phosphatase 5 
Dusp6 67603 2,57 0,00 Dual specificity phosphatase 6 
Dynll1 56455 2,19 0,00 Dynein, light chain, LC8-type 1 
E2f8 108961 -1,44 0,01 E2F transcription factor 8 
Ecm1 13601 -1,63 0,01 Extracellular matrix protein 1 
Ednra 13617 -1,18 0,00 Endothelin receptor type A 
Efemp1 216616 -1,36 0,01 
EGF containing fibulin-like extracellular matrix protein 
1 
Efnb2 13642 1,33 0,01 Ephrin-B2 
Egfr 13649 -1,47/-1,11/-1,04 0,00/0,01/0,04 Epidermal growth factor receptor 
Egr1 13653 3,88 0,00 Early growth response 1 
Ehd4 98878 1,47 0,01 EH-domain containing 4 
Eif2c2 239528 1,11 0,01 Eukaryotic translation initiation factor 2C, 2 
Elovl3 12686 -3,12 0,05 ELOVL fatty acid elongase 3 
Elovl7 74559 
1,62/1,76/2,04/2,40/
2,59 0,00/0,01/0,00/0,00/0,00 
ELOVL fatty acid elongase 7 
Emcn 59308 2,02 0,01 Endomucin 
Enc1 13803 1,95/2,45 0,00/0,00 Ectodermal-neural cortex 1 (with BTB-like domain) 
Enpep 13809 -1,37 0,00 Glutamyl aminopeptidase (aminopeptidase A) 
Enpp1 18605 1,05/1,24/1,52 0,00/0,00/0,00 Ectonucleotide pyrophosphatase/phosphodiesterase 1 
Enpp2 18606 1,41 0,00 Ectonucleotide pyrophosphatase/phosphodiesterase 2 
Enpp5 83965 -1,04 0,01 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 5 (putative) 
Entpd2 12496 1,86 0,00 Ectonucleoside triphosphate diphosphohydrolase 2 
Epas1 13819 1,49 0,00 Endothelial PAS domain protein 1 
Ephx2 13850 -1,13 0,01 Epoxide hydrolase 2, cytoplasmic 
Ergic1 67458 -1,09 0,03 
Endoplasmic reticulum-golgi intermediate 
compartment (ERGIC) 1 
Ero1lb 67475 -1,65/-1,07 0,00/0,02 ERO1-like beta (S. cerevisiae) 
Erp27 69187 -1,72 0,01 Endoplasmic reticulum protein 27 
Esm1 71690 4,13 0,00 Endothelial cell-specific molecule 1 
Etl4 208618 1,09 0,00 Enhancer trap locus 4 
Etnk1 75320 1,06 0,04 Ethanolamine kinase 1 
Etnk2 214253 -1,23 0,02 Ethanolamine kinase 2 
Ets2 23872 1,05/1,42 0,02/0,00 
V-ets erythroblastosis virus E26 oncogene homolog 2 
(avian) 
Etv5 104156 1,57 0,00 Ets variant 5 
Exph5 320051 -1,05 0,02 Exophilin 5 
Extl1 56219 -1,00 0,00 Exostoses (multiple)-like 1 
F11r 16456 1,65 0,00 F11 receptor 
F2r 14062 1,24 0,00 Coagulation factor II (thrombin) receptor 
F2rl1 14063 3,81 0,00 Coagulation factor II (thrombin) receptor-like 1 
Fabp4 11770 1,33/2,10/2,24 0,01/0,01/0,00 Fatty acid binding protein 4, adipocyte 
Fabp5 16592 2,16 0,00 Fatty acid binding protein 5 (psoriasis-associated) 
Fabp7 12140 -1,92 0,05 Fatty acid binding protein 7, brain 
Fads1 76267 1,16 0,01 Fatty acid desaturase 1 
Fads2 56473 1,36/1,54/1,88 0,01/0,01/0,00 Fatty acid desaturase 2 
Fam110c 104943 1,56/1,61 0,00/0,00 Family with sequence similarity 110, member C 
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Fam114a1 68303 1,01 0,00 Family with sequence similarity 114, member A1 
Fam118a 73225 1,05 0,00 Family with sequence similarity 118, member A 
Fam126a 84652 1,01 0,00 Family with sequence similarity 126, member A 
Fam176a 232146 -1,07 0,00 Family with sequence similarity 176, member A 
Fam19a5 106014 -1,26 0,00 
Family with sequence similarity 19 (chemokine (C-C 
motif)-like), member A5 
Fam25c 69134 -2,87 0,00 Family with sequence similarity 25, member C 
Fam3c 27999 1,77/1,99 0,00/0,00 Family with sequence similarity 3, member C 
Fam43a 224093 1,18 0,01 Family with sequence similarity 43, member A 
Fam46a 212943 2,31 0,00 Family with sequence similarity 46, member A 
Fam46c 74645 1,56/1,96 0,01/0,00 Family with sequence similarity 46, member C 
Fam59a 381126 1,24 0,00 Family with sequence similarity 59, member A 
Fam65b 193385 -1,91 0,02 Family with sequence similarity 65, member B 
Fam69a 67266 -1,76 0,05 Family with sequence similarity 69, member A 
Fam81a 76886 1,50 0,00 Family with sequence similarity 81, member A 
Fam82a1 381110 -1,50/-1,48/-1,42 0,01/0,02/0,00 Family with sequence similarity 82, member A1 
Fam84b 399603 2,32 0,00 Family with sequence similarity 84, member B 
Farp2 227377 -1,41/-1,00 0,00/0,00 FERM, RhoGEF and pleckstrin domain protein 2 
Fat1 14107 1,33 0,00 FAT tumor suppressor homolog 1 (Drosophila) 
Fblim1 74202 1,88/2,20 0,00/0,00 Filamin binding LIM protein 1 
Fdft1 14137 1,18/1,27 0,04/0,04 Farnesyl-diphosphate farnesyltransferase 1 
Fgf1 14164 -1,59/-1,34 0,00/0,00 Fibroblast growth factor 1 (acidic) 
Fgf21 56636 1,32 0,04 Fibroblast growth factor 21 
Fgfr2 14183 1,26 0,00 Fibroblast growth factor receptor 2 
Fgl2 14190 2,31/2,69 0,01/0,01 Fibrinogen-like 2 
Fitm1 68680 -1,71 0,00 Fat storage-inducing transmembrane protein 1 
Fkbp11 66120 2,31 0,00 FK506 binding protein 11, 19 kDa 
Fmn1 14260 1,11 0,03 Formin 1 
Fmn2 54418 -2,51/-2,49 0,04/0,02 Formin 2 
Fmnl2 71409 1,29 0,00 Formin-like 2 
Fmo1 14261 -1,20 0,02 Flavin containing monooxygenase 1 
Fn3k 63828 -2,16 0,01 Fructosamine 3 kinase 
Fndc3b 72007 2,08/2,16 0,00/0,00 Fibronectin type III domain containing 3B 
Folr2 14276 -1,18 0,03 Folate receptor 2 (fetal) 
Fos 14281 2,38 0,00 FBJ murine osteosarcoma viral oncogene homolog 
Foxa3 15377 1,07 0,00 Forkhead box A3 
Foxp2 114142 -1,77/-1,62/-1,21 0,00/0,00/0,00 Forkhead box P2 
Frk 14302 1,05/1,09 0,00/0,01 Fyn-related kinase 
Frmd6 319710 1,07 0,01 FERM domain containing 6 
Frmd8 67457 1,10 0,01 FERM domain containing 8 
Fscn1 14086 1,67 0,01 
Fascin homolog 1, actin-bundling protein 
(Strongylocentrotus purpuratus) 
Fst 14313 3,53/4,19 0,00/0,00 Follistatin 
Fubp1 51886 1,02 0,01 Far upstream element (FUSE) binding protein 1 
Fxyd1 56188 -1,14 0,00 FXYD domain containing ion transport regulator 1 
Fzd3 14365 1,13/2,00 0,01/0,00 Frizzled family receptor 3 
Fzd5 14367 1,11 0,01 Frizzled family receptor 5 
G6pc 14377 -2,71 0,01 Glucose-6-phosphatase, catalytic subunit 
G6pdx 14381 1,77 0,00 Glucose-6-phosphate dehydrogenase X-linked 
Gabarapl1 57436 -1,39/-1,27 0,01/0,01 GABA(A) receptor-associated protein like 1 
Galm 319625 -1,08 0,00 Galactose mutarotase (aldose 1-epimerase) 
Galnt12 230145 1,40 0,00 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 12 
(GalNAc-T12) 
Galnt6 207839 1,65/2,55 0,00/0,00 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 6 (GalNAc-T6) 
Galntl2 78754 1,12 0,02 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 2 
Gas1 14451 -3,13/-1,75 0,00/0,00 Growth arrest-specific 1 
Gas2 14453 -2,01 0,00 Growth arrest-specific 2 
Gca 227960 1,13 0,00 Grancalcin, EF-hand calcium binding protein 
Gcdh 270076 -1,18 0,02 Glutaryl-CoA dehydrogenase 
Gch1 14528 -1,20 0,00 GTP cyclohydrolase 1 
Gcnt2 14538 1,00/1,14/1,29 0,02/0,00/0,01 
 Glucosaminyl (N-acetyl) transferase 2, I-
branching enzyme (I blood group) 
Gde1 56209 -1,10 0,02 Glycerophosphodiester phosphodiesterase 1 
Gdf10 14560 -2,39 0,00 Growth differentiation factor 10 
Gdf2 12165 -1,33 0,01 Growth differentiation factor 2 
Gem 14579 -1,41 0,01 GTP binding protein overexpressed in skeletal muscle 
Ggct 110175 1,39 0,01 Gamma-glutamylcyclotransferase 
Ggnbp1 70772 -1,12 0,03 Gametogenetin binding protein 1 
Ggt6 71522 -1,22 0,01 Gamma-glutamyltransferase 6 
Ggta1 14594 1,69 0,00 
Glycoprotein, alpha-galactosyltransferase 1 
pseudogene 
Ghr 14600 -1,99/-1,31/-1,12 0,00/0,00/0,00 Growth hormone receptor 
Glipr1 73690 1,94 0,00 Glioma pathogenesis-related protein 1 
Glis3 226075 1,57 0,00 GLIS family zinc finger 3 
Glo1 109801 -1,62 0,00 Glyoxalase I 
Glrx 93692 -1,17/-1,17 0,00/0,01 Glutaredoxin (thioltransferase) 
Glul 14645 -1,96/-1,34 0,01/0,02 Glutamate-ammonia ligase 
Gmfb 63985 1,10 0,00 Glia maturation factor, beta 
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Gna14 14675 -2,70/-2,32/-2,24 0,00/0,01/0,00 
Guanine nucleotide binding protein (G protein), alpha 
14 
Gnai1 14677 -1,23 0,02 
Guanine nucleotide binding protein (G protein), alpha 
inhibiting activity polypeptide 1 
Gnmt 14711 -1,61 0,01 Glucosaminyl (N-acetyl) transferase 3 
Gnpda1 26384 -1,30 0,00 Glucosamine-6-phosphate deaminase 1 
Golm1 105348 3,51 0,00 Golgi membrane protein 1 
Gpam 14732 1,22 0,03 Glycerol-3-phosphate acyltransferase, mitochondrial 
Gpc1 14733 1,18 0,02 Glypican 1 
Gpc3 14734 4,23 0,00 Glypican 3 
Gpc6 23888 1,64/1,73/2,16 0,01/0,04/0,00 Glypican 6 
Gpr110 77596 1,19 0,03 G protein-coupled receptor 110 
Gpr12 14738 -1,03 0,00 G protein-coupled receptor 12 
Gpr39 71111 1,02 0,01 G protein-coupled receptor 39 
Gpr98 110789 -1,64 0,00 G protein-coupled receptor 98 
Gprc5b 64297 2,54/4,38 0,00/0,00 
G protein-coupled receptor, family C, group 5, member 
B 
Gprc5c 70355 1,10 0,01 
G protein-coupled receptor, family C, group 5, member 
C 
Gpx1 14775 -1,09 0,01 Glutathione peroxidase 1 
Gramd1b 235283 1,26 0,02 GRAM domain containing 1B 
Greb1l 381157 1,46 0,01 Growth regulation by estrogen in breast cancer-like 
Grhl1 195733 1,59 0,00 Grainyhead-like 1 (Drosophila) 
Gria3 53623 1,66/3,31 0,02/0,00 Glutamate receptor, ionotropic, AMPA 3 
Grm8 14823 -1,47 0,00 Glutamate receptor, metabotropic 8 
Gsn 227753 -1,71/-1,67/-1,48 0,04/0,05/0,04 Gelsolin 
Gspt2 14853 2,27/2,47 0,00/0,00 G1 to S phase transition 2 
Gss 14854 1,02 0,00 Glutathione synthetase 
Gsta2 14858 -2,59 0,00 Glutathione S-transferase alpha 2 
Gsta3 14859 -1,58/-1,20 0,00/0,01 Glutathione S-transferase alpha 3 
Gstk1 76263 -1,24 0,01 Glutathione S-transferase kappa 1 
Gucy1a3 60596 -1,17 0,00 Guanylate cyclase 1, soluble, alpha 3 
Gucy1b3 54195 -1,03 0,01 Guanylate cyclase 1, soluble, beta 3 
H19 14955 3,28 0,00 
H19, imprinted maternally expressed transcript (non-
protein coding) 
Haao 107766 -1,01 0,01 3-hydroxyanthranilate 3,4-dioxygenase 
Habp2 226243 -1,26 0,01 Hyaluronan binding protein 2 
Hacl1 56794 -1,99 0,02 2-hydroxyacyl-CoA lyase 1 
Hand2 15111 -1,52 0,01 Heart and neural crest derivatives expressed 2 
Hao2 56185 1,37 0,02 Hydroxyacid oxidase 2 (long chain) 
Haus7 73738 1,09 0,00 HAUS augmin-like complex, subunit 7 
Hcfc1r1 353502 -1,26/-1,23 0,00/0,01 Host cell factor C1 regulator 1 (XPO1 dependent) 
Hebp1 15199 -1,08 0,01 Heme binding protein 1 
Hes1 15205 1,44 0,00 Hairy and enhancer of split 1, (Drosophila) 
Hes6 55927 -1,11 0,01 Hairy and enhancer of split 6 (Drosophila) 
Hexa 15211 1,29 0,00 Hexosaminidase A (alpha polypeptide) 
Hexb 15212 1,06 0,01 Hexosaminidase B (beta polypeptide) 
Hgd 15233 -1,25 0,01 Homogentisate 1,2-dioxygenase 
Hgf 15234 -1,21 0,00 
Hepatocyte growth factor (hepapoietin A; scatter 
factor) 
Hgfac 54426 1,19 0,00 HGF activator 
Hhip 15245 -1,37 0,00 Hedgehog interacting protein 
Hibadh 58875 -1,33/-1,25 0,00/0,00 3-hydroxyisobutyrate dehydrogenase 
Hilpda 69573 1,61 0,00 Hypoxia inducible lipid droplet-associated 
Hmgcr 15357 2,28 0,00 3-hydroxy-3-methylglutaryl-CoA reductase 
Hmgcs1 208715 
1,75/1,79/1,92/2,28/
2,59 0,02/0,02/0,02/0,03/0,02 
3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) 
Hmgcs2 15360 -1,35 0,01 
3-hydroxy-3-methylglutaryl-CoA synthase 2 
(mitochondrial) 
Hn1 15374 1,16 0,00 Hematological and neurological expressed 1 
Homer2 26557 -1,78/-1,52 0,03/0,02 Homer homolog 2 (Drosophila) 
Hpd 15445 -1,86 0,01 4-hydroxyphenylpyruvate dioxygenase 
Hpgd 15446 -1,50/-1,36 0,01/0,01 Hydroxyprostaglandin dehydrogenase 15-(NAD) 
Hps4 192232 -1,29 0,02 Hermansky-Pudlak syndrome 4 
Hsbp1l1 66255 2,18 0,00 Heat shock factor binding protein 1-like 1 
Hsd17b13 243168 1,41 0,00 Hydroxysteroid (17-beta) dehydrogenase 13 
Hsd3b2 15493 -2,28 0,00 
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and 
steroid delta-isomerase 2 
Hsd3b3 15494 -1,40 0,00 
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and 
steroid delta-isomerase 3 
Hsd3b5 15496 -4,07 0,01 
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and 
steroid delta-isomerase 5 
Hsd3b7 101502 -1,18 0,03 
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and 
steroid delta-isomerase 7 
Hsf2bp 74377 1,57 0,03 Heat shock transcription factor 2 binding protein 
Hspa4l 18415 1,14/1,21/1,53 0,02/0,02/0,00 Heat shock 70kDa protein 4-like 
Hspa8 15481 1,06/1,24 0,03/0,01 Heat shock 70kDa protein 8 
Hspb1 15507 -1,09 0,04 Heat shock 27kDa protein 1 
Hspb6 243912 -1,40 0,00 Heat shock protein, alpha-crystallin-related, B6 
Ica1 15893 1,59/1,72 0,01/0,00 Islet cell autoantigen 1, 69kDa 
Id1 15901 2,28 0,01 
Inhibitor of DNA binding 1, dominant negative helix-
loop-helix protein 
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Ido2 209176 -1,11 0,01 Indoleamine 2,3-dioxygenase 2 
Ier3 15937 1,87 0,02 Immediate early response 3 
Ier5 15939 1,00/1,43 0,02/0,00 Immediate early response 5 
Ifi27l2b 217845 3,35 0,00 Alpha-inducible protein 27 like 2B 
Ifi44 99899 1,48 0,00 Interferon-induced protein 44 
Ifitm1 68713 -2,03 0,00 Interferon induced transmembrane protein 1 
Ifngr1 15979 1,71 0,00 Interferon gamma receptor 1 
Ifrd1 15982 1.03 0.04 Interferon-related developmental regulator 1 
Ift122 81896 1.47 0.00 Intraflagellar transport 122 homolog 
Igdcc4 56741 4.41/4.71 0.00/0.00 
Immunoglobulin superfamily, DCC subclass, member 
4 
Igf1 16000 
-1.54/-1.47/-1.27/-
1.24 0.00/0.00/0.01/0.01 
Insulin-like growth factor 1 
Igfals 16005 -3.00 0.00 
Insulin-like growth factor binding protein, acid labile 
subunit 
Igfbp1 16006 3.11 0.00 Insulin-like growth factor-binding protein 1 
Igfbp5 16011 -2.15 0.04 Insulin-like growth factor-binding protein 5 
Ighm 16019 -1.24/-1.09 0.02/0.05 Immunoglobulin heavy constant mu 
Igsf5 72058 1.16 0.00 Immunoglobulin superfamily member 5 
Igsf8 140559 1.17 0.00 Immunoglobulin superfamily member 8 
Ikbip 67454 1.17/1.27 0.00/0.00 IKBKB interacting protein 
Il18 16173 -1.13 0.05 Interleukin 18 (interferon-gamma-inducing factor) 
Il1r1 16177 -1.00 0.02 Interleukin 1 receptor, type I 
Il1rap 16180 -1.36 0.00 Interleukin 1 receptor accessory protein 
Il1rn 16181 1.50/2.97/3.60 0.03/0.00/0.00 Interleukin 1 receptor antagonist 
Il33 77125 1.92 0.00 Interleukin 33 
Il6st 16195 -1.00 0.03 
Interleukin 6 signal transducer (gp130, oncostatin M 
receptor) 
Ildr2 100039795 -2.00/-1.88 0.02/0.02 Immunoglobulin-like domain containing receptor 2 
Inca1 103844 -1.09 0.02 Inhibitor of CDK, cyclin A1 interacting protein 1 
Inf2 70435 1.11 0.01 Inverted formin, FH2 and WH2 domain containing 
Inhbb 16324 3.10 0.01 Inhibin, beta B 
Inpp1 16329 1.52 0.00 Inositol polyphosphate-1-phosphatase 
Ipcef1 320495 4.54 0.00 Interaction protein for cytohesin exchange factors 1 
Iqgap1 29875 1.05 0.02 IQ motif containing GTPase activating protein 1 
Irx3 16373 3.22 0.00 Iroquois homeobox 3 
Islr 26968 -1.17 0.01 
Immunoglobulin superfamily containing leucine-rich 
repeat 
Isyna1 71780 1.24 0.00 Inositol-3-phosphate synthase 1 
Itga6 16403 1.94/2.73 0.00/0.00 Integrin, alpha 6 
Itih5 209378 3.60/3.67/3.89 0.00/0.00/0.00 
Inter-alpha-trypsin inhibitor heavy chain family, 
member 5 
Itm2c 64294 1.43 0.00 Integral membrane protein 2C 
Itpripl2 319622 1.61 0.00 
Inositol 1,4,5-trisphosphate receptor interacting 
protein-like 2 
Ivd 56357 -1.06 0.02 Isovaleryl-CoA dehydrogenase 
Ivns1abp 117198 1.14 0.04 Influenza virus NS1A binding protein 
Jazf1 231986 1.17 0.02 JAZF zinc finger 1 
Jub 16475 2.35 0.00 Ajuba 
Jun 16476 1.12/1.27 0.01/0.00 Jun proto-oncogene 
Junb 16477 1.18 0.01 Jun B proto-oncogene 
Kalrn 545156 -1.16 0.02 Kalirin, RhoGEF kinase 
Kazald1 107250 1.93 0.02 Kazal-type serine peptidase inhibitor domain 1 
Kbtbd13 74492 1.65 0.02 Kelch repeat and BTB (POZ) domain containing 13 
Kbtbd8 243574 1.07 0.00 Kelch repeat and BTB (POZ) domain containing 8 
Kcnj8 16523 1.28 0.02 
Potassium inwardly-rectifying channel, subfamily J, 
member 8 
Kcnk1 16525 -1.39 0.01 Potassium channel, subfamily K, member 1 
Kcnk5 16529 -1.23 0.01 Potassium channel, subfamily K, member 5 
Kcnt2 240776 -2.28 0.00 Potassium channel, subfamily T, member 2 
Kctd12 239217 1.27 0.02 
Potassium channel tetramerisation domain containing 
12 
Kctd12b 207474 1.34 0.01 
Potassium channel tetramerisation domain containing 
12B 
Kctd15 233107 -1.34 0.00 
Potassium channel tetramerisation domain containing 
15 
Kctd3 226823 1.31/1.72 0.00/0.00 
Potassium channel tetramerisation domain containing 
3 
Kdelr3 105785 2.21 0.00 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum 
protein retention receptor 3 
Keg1 64697 -1.96 0.00 Kidney expressed gene 1 
Khdrbs3 13992 -1.49 0.01 
KH domain containing, RNA binding, signal 
transduction associated 3 
Kif13a 16553 1.73 0.04 Kinesin family member 13A 
Kif20a 19348 1.75 0.05 Kinesin family member 20A 
Kif21a 16564 1.05 0.00 Kinesin family member 21A 
Kif5c 16574 3.64/4.89 0.00/0.00 Kinesin family member 5C 
Kifc3 16582 1.30 0.00 Kinesin family member C3 
Klc3 232943 1.28 0.01 Kinesin light chain 3 
Klf1 16596 -1.90 0.00 Krueppel-like factor 1 
Klf4 16600 1.22/1.57 0.00/0.00 Krueppel-like factor 4 
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Klf6 23849 
1.05/1.22/1.35/1.49/
1.66 0.01/0.00/0.00/0.00/0.00 
Krueppel-like factor 6 
Klhdc2 69554 1.20/1.48 0.00/0.00 Kelch domain containing 2 
Klhl13 67455 2.29/2.74 0.00/0.00 Kelch-like 13 
Klhl4 237010 1.11 0.03 Kelch-like 4 
Klk1b4 18048 2.96/3.01 0.00/0.00 Kallikrein 1-related peptidase b4 
Klk1b5 16622 1.18 0.00 Kallikrein 1-related peptidase b5 
Krt18 16668 1.48 0.00 Keratin 18 
Krt23 94179 2.69 0.01 Keratin 23 
Krtap16-4 170654 -1.03 0.00 Keratin associated protein 16-4 
Kynu 70789 -1.46 0.01 Kynureninase 
L2hgdh 217666 -1.03 0.00 L-2-hydroxyglutarate dehydrogenase 
L3mbtl3 237339 1.23 0.00 L(3)mbt-like 3 
Lama1 t16772 -1.01 0.01 Laminin, alpha 1 
Lama3 16774 -2.73 0.00 Laminin, alpha 3 
Lass6 241447 1.74 0.01 Longevity assurance homolog 6 
Lbp 16803 -1.21/-1.08 0.01/0.02 Lipopolysaccharide binding protein 
Lcn13 227627 -3.82 0.01 Lipocalin 13 
Lcn2 16819 2.64 0.03 Lipocalin 2 
Lcp1 18826 -1.50/-1.26 0.02/0.01 Lymphocyte cytosolic protein 1 (L-plastin) 
Ldhd 52815 -2.08/-2.03 0.00/0.00 Lactate dehydrogenase D 
Leap2 259301 -2.00 0.00 Liver expressed antimicrobial peptide 2 
Lect1 16840 -2.15 0.03 Leukocyte cell-derived chemotaxin 1 
Lect2 16841 -1.83 0.00 Leukocyte cell-derived chemotaxin 2 
Lepr 16847 3.01/3.43 0.00/0.00 Leptin receptor 
Leprot 230514 1.15/1.31/1.35 0.01/0.00/0.00 Leptin receptor overlapping transcript 
Lgals1 16852 1.41/1.44 0.00/0.00 Lectin, galactoside-binding, soluble, 1 
Lgmn 19141 1.27 0.00 Legumain 
Lgr5 14160 -1.61 0.00 
Leucine-rich repeat containing G protein-coupled 
receptor 5 
Lhpp 76429 -2.40 0.00 
Phospholysine phosphohistidine inorganic 
pyrophosphate phosphatase 
Lhx2 16870 -1.53 0.00 LIM homeobox 2 
Lif 16878 1.02 0.00 Leukemia inhibitory factor 
Lifr 16880 -1.24 0.01 Leukemia inhibitory factor receptor alpha 
Limd1 29806 1.16/1.35 0.01/0.00 LIM domains containing 1 
Lims2 225341 -1.18 0.03 LIM and senescent cell antigen-like domains 2 
Lin7a 108030 -1.63/-1.59/-1.37 0.03/0.00/0.00 Lin-7 homolog A 
Lipc 15450 -2.48 0.01 Lipase, hepatic 
Lipg 16891 -1.12 0.01 Lipase, endothelial 
Lmna 16905 1.07/1.26 0.00/0.00 Lamin A/C 
Lphn1 330814 -1.03 0.00 Latrophilin 1 
Lpl 16956 1.86/2.29 0.03/0.01 Lipoprotein lipase 
Lrat 79235 -2.13 0.00 Lecithin retinol acyltransferase 
Lrit1 239037 -2.29 0.01 
Leucine-rich repeat, immunoglobulin-like and 
transmembrane domains 1 
Lrit2 239038 -1.90 0.01 
Leucine-rich repeat, immunoglobulin-like and 
transmembrane domains 2 
Lrp11 237253 1.25 0.00 Low density lipoprotein receptor-related protein 11 
Lrp12 239393 1.10 0.01 Low density lipoprotein receptor-related protein 12 
Lrrc24 378937 2.10 0.00 Leucine rich repeat containing 24 
Lrrc8c 100604 1.09 0.00 Leucine rich repeat containing 8 family, member C 
Lrrc8e 72267 1.10/1.21 0.03/0.01 Leucine rich repeat containing 8 family, member E 
Lrtm1 319476 -2.17 0.04 Leucine-rich repeats and transmembrane domains 1 
Lss 16987 1.07/2.36/2.67 0.03/0.01/0.00 
Lanosterol synthase (2,3-oxidosqualene-lanosterol 
cyclase) 
Ltb 16994 2.52 0.01 Lymphotoxin beta (TNF superfamily, member 3) 
Lum 17022 -1.78 0.00 Lumican 
Ly6a 110454 -2.42 0.03 Lymphocyte antigen 6 complex, locus A 
Ly6d 17068 4.37 0.00 Lymphocyte antigen 6 complex, locus D 
Lysmd2 70082 2.26 0.00 Putative peptidoglycan-binding, domain containing 2 
Lyve1 114332 1.40 0.04 Lymphatic vessel endothelial hyaluronan receptor 1 
Macrod1 107227 -2.24 0.00 MACRO domain containing 1 
Macrod2 72899 -1.10 0.01 MACRO domain containing 2 
Mad2l1 56150 1.27 0.00 MAD2 mitotic arrest deficient-like 1 
Maff 17133 1.64 0.00 
V-maf musculoaponeurotic fibrosarcoma oncogene 
homolog F (avian) 
Maged1 94275 1.00/1.20 0.00/0.00 Melanoma antigen family H, 1 
Magi3 99470 1.18 0.00 
Membrane associated guanylate kinase, WW and PDZ 
domain containing 3 
Mamdc2 71738 -2.65 0.00 MAM domain containing 2 
Mansc1 67729 1.74 0.00 MANSC domain containing 1 
Map2k6 26399 -1.07 0.03 Mitogen-activated protein kinase kinase 6 
Map4k4 26921 1.06/1.79 0.00/0.00 
Mitogen-activated protein kinase kinase kinase kinase 
4 
Marveld2 218518 1.07 0.01 MARVEL domain containing 2 
Marveld3 73608 1.56 0.00 MARVEL domain containing 3 
Mast3 546071 -1.21 0.01 Microtubule associated serine/threonine kinase 3 
Mbl1 17194 -1.68 0.00 Mannose-binding lectin (protein A) 1 
Mcart1 230125 -1.14 0.02 Mitochondrial carrier triple repeat 1 
Mcm10 70024 -2.43/-1.40 0.00/0.00 Minichromosome maintenance complex component 10 
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Mcm2 17216 1.76 0.00 Minichromosome maintenance complex component 2 
Me1 17436 -1.48/-1.23 0.03/0.02 Malic enzyme 1, NADP(+)-dependent, cytosolic 
Meg3 17263 -1.07 0.01 Maternally expressed 3 
Mep1b 17288 2.69 0.00 Meprin A subunit beta 
Mfge8 17304 1.30 0.03 Milk fat globule-EGF factor 8 
Mfn2 170731 -1.16 0.00 Mitofusin 2 
Mfsd6 98682 1.18 0.00 Major facilitator superfamily domain containing 6 
Mgat5 107895 1.20/1.49 0.00/0.00 
Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase 
Mgll 23945 -1.12/-1.04 0.05/0.03 Monoacylglycerol lipase 
Minpp1 17330 1.14 0.00 Multiple inositol-polyphosphate phosphatase 1 
Miox 56727 2.75 0.00 Myo-inositol oxygenase 
Mlkl 74568 1.15 0.02 Mixed lineage kinase domain-like 
Mllt3 70122 1.40/1.61/1.96 0.00/0.00/0.00 
Myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 3 
Mmd 67468 -1.20 0.01 Monocyte to macrophage differentiation-associated 
Mmd2 75104 -1.89/-1.48 0.02/0.01 Monocyte to macrophage differentiation-associated 2 
Mmp12 17381 1.76 0.03 Matrix metalloproteinase 12 
Mmp13 17386 1.97 0.01 Matrix metalloproteinase 13 
Mmp14 17387 1.16/1.36 0.00/0.01 Matrix metalloproteinase 14 
Mob3a 208228 1.08 0.00 MOB kinase activator 3A 
Mob3b 214944 1.21 0.01 MOB kinase activator 3B 
Morc4 75746 1.02 0.00 MORC family CW-type zinc finger 4 
Morf4l2 56397 1.01/1.01 0.01/0.01 Mortality factor 4 like 2 
Mpdz 17475 -1.55/-1.04 0.00/0.01 Multiple PDZ domain protein 
Mpeg1 17476 1.46 0.01 Macrophage-expressed gene 1 
Mpp1 17524 1.19 0.01 
Membrane protein, palmitoylated 1 (MAGUK p55 
subfamily member 4) 
Mpp4 227157 -1.22 0.04 
Membrane protein, palmitoylated 4 (MAGUK p55 
subfamily member 4) 
Mpped1 223726 1.47 0.00 Metallophosphoesterase domain containing 1 
Mreg 381269 -1.24 0.05 Melanoregulin 
Ms4a4d 66607 -1.44 0.01 
Membrane-spanning 4-domains, subfamily A, member 
4D 
Msrb3 320183 1.60 0.00 Methionine sulfoxide reductase B3 
Mst1r 19882 1.38 0.02 Macrophage stimulating 1 receptor 
Mthfd2l 665563 1.23 0.00 
Methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2-like 
Mtmr11 194126 3.53 0.00 Myotubularin related protein 11 
Mtmr2 77116 1.06 0.00 Myotubularin related protein 2 
Mtmr4 170749 -1.04 0.01 Myotubularin related protein 4 
Mtpn 14489 1.45 0.00 Myotrophin 
Mtx3 382793 -1.07 0.01 Metaxin 3 
Mup10 100039008 -4.70 0.02 Major urinary protein 10 
Mup3 17842 -2.16/-1.77 0.00/0.01 Major urinary protein 3 
Mup4 17843 -1.49 0.00 Major urinary protein 4 
Mup5 17844 -1.60 0.01 Major urinary protein 5 
Mustn1 66175 -1.18 0.02 Musculoskeletal, embryonic nuclear protein 1 
Mvd 192156 1.46 0.03 Mevalonate (diphospho) decarboxylase 
Myadm 50918 1.87/1.98 0.00/0.00 Myeloid-associated differentiation marker 
Mycn 18109 2.45 0.00 
V-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived 
Myef2 17876 1.05 0.01 Myelin expression factor 2 
Myh9 17886 1.01/1.09/1.24 0.00/0.00/0.00 Myosin, heavy chain 9, non-muscle 
Myo5c 208943 2.13 0.00 Myosin VC 
Myzap 102371 1.27 0.01 Myocardial zonula adherens protein 
N4bp2l1 100637 -1.09 0.01 NEDD4 binding protein 2-like 1 
Nagpa 27426 -1.05 0.00 
N-acetylglucosamine-1-phosphodiester alpha-N-
acetylglucosaminidase 
Naip2 17948 1.46 0.00 NLR family, apoptosis inhibitory protein 2 
Nars2 244141 -1.04 0.00 
Asparaginyl-tRNA synthetase 2, mitochondrial 
(putative) 
Nat1 17960 -1.78 0.00 N-acetyltransferase 1 (arylamine N-acetyltransferase) 
Nat6 56441 -1.00 0.02 N-acetyltransferase 6 (GCN5-related) 
Nat8 68396 -2.97 0.00 N-acetyltransferase 8 (GCN5-related, putative) 
Ncam2 17968 -1.07 0.01 Neural cell adhesion molecule 2 
Ncapg2 76044 1.36 0.01 Non-SMC condensin II complex, subunit G2 
Ndn 17984 
-1.90/-1.70/-1.57/-
1.53 0.00/0.00/0.00/0.00 
Necdin 
Ndrg2 29811 -1.76 0.00 NDRG family member 2 
Neat1 66961 1.67 0.00 Nuclear enriched abundant transcript 1 
Neb 17996 -3.74 0.00 Nebulin 
Nebl 74103 -1.50 0.00 Nebulette 
Nedd9 18003 1.47/1.49 0.04/0.02 
Neural precursor cell expressed, developmentally 
down-regulated 9 
Neto1 246317 1.20 0.00 Neuropilin (NRP) and tolloid (TLL)-like 1 
Nfe2 18022 2.49 0.00 Nuclear factor (erythroid-derived 2), 45kDa 
Nfil3 18030 -1.05 0.03 Nuclear factor, interleukin 3 regulated 
Nfix 18032 -1.45/-1.12/-1.06 0.01/0.02/0.01 Nuclear factor I/X (CCAAT-binding transcription factor) 
Ngfrap1 12070 1.92 0.00 
Nerve growth factor receptor (TNFRSF16) associated 
protein 1 
Nid1 18073 2.42/3.42 0.00/0.00 Nidogen 1 
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Nipal1 70701 2.89/3.00 0.00/0.00 NIPA-like domain containing 1 
Nlrp12 378425 1.84 0.00 NLR family, pyrin domain containing 12 
Nnmt 18113 -3.37 0.01 Nicotinamide N-methyltransferase 
Noa1 56412 -1.12 0.00 Nitric oxide associated 1 
Nop58 55989 1.10 0.02 NOP58 ribonucleoprotein homolog 
Notch4 18132 1.04 0.03 Neurogenic locus notch homolog protein 4 
Notum 77583 -1.01 0.01 Notum pectinacetylesterase homolog 
Nox4 50490 -2.15/-2.06 0.00/0.00 NADPH oxidase 4 
Npc1l1 237636 2.09 0.00 NPC1 (Niemann-Pick disease, type C1, gene)-like 1 
Npdc1 18146 2.34 0.00 Neural proliferation differentiation and control 1 
Npr2 230103 -1.90 0.00 Natriuretic peptide receptor B/guanylate cyclase B 
Nr1i3 12355 -2.46 0.00 Nuclear receptor subfamily 1, group I, member 3 
Nrarp 67122 1.22 0.02 NOTCH-regulated ankyrin repeat protein 
Nrg1 211323 2.20 0.00 Neuregulin 1 
Nrip2 60345 1.18 0.03 Nuclear receptor-interacting protein 2 
Nt5e 23959 1.54 0.04 5'-nucleotidase, ecto (CD73) 
Ntn1 18208 -1.85 0.00 Netrin 1 
Ntn4 57764 1.00/1.43 0.01/0.00 Netrin 4 
Ntrk2 18212 -1.15 0.05 Neurotrophic tyrosine kinase, receptor, type 2 
Nucb2 53322 2.63 0.00 Nucleobindin 2 
Nudt7 67528 -2.27/-1.97/-1.23 0.00/0.00/0.01 
Nudix (nucleoside diphosphate linked moiety X)-type 
motif 7 
Nup93 71805 1.14 0.00 Nucleoporin 93kDa 
Nupl1 71844 1.52 0.00 Nucleoporin like 1 
Nupr1 56312 1.37/1.79 0.02/0.01 Nuclear protein, transcriptional regulator, 1 
Nxn 18230 1.60/1.73 0.00/0.00 Nucleoredoxin 
Oat 18242 -2.95 0.00 Ornithine aminotransferase 
Odz3 23965 -1.67/-1.63 0.01/0.03 Odz, odd Oz/ten-m homolog 3 
Ogfrl1 70155 -1.09 0.02 Opioid growth factor receptor-like 1 
Ogn 18295 -1.92/-1.13 0.04/0.05 Osteoglycin 
Olfm1 56177 -1.19/-1.13 0.03/0.02 Olfactomedin 1 
Olfm3 229759 -2.59/-2.26 0.00/0.00 Olfactomedin 3 
Olig1 50914 -1.81 0.00 Oligodendrocyte transcription factor 1 
Omd 27047 -1.16 0.00 Osteomodulin 
Onecut2 225631 -1.88/-1.84/-1.77 0.04/0.02/0.01 One cut homeobox 2 
Orai2 269717 1.23 0.02 ORAI calcium release-activated calcium modulator 2 
Orm3 18407 -2.16 0.01 Orosomucoid 3 
Osbpl10 74486 1.01 0.00 Oxysterol-binding protein-related protein 10 
Osbpl3 71720 2.01 0.04 Oxysterol-binding protein-related protein 3 
Osgin1 71839 1.47 0.03 Oxidative stress induced growth inhibitor 1 
Osgin2 209212 1.48 0.02 Oxidative stress induced growth inhibitor 2 
Otc 18416 -1.40/-1.22 0.01/0.02 Ornithine carbamoyltransferase 
Otud7b 229603 1.18/1.39 0.00/0.01 OTU domain containing 7B 
P2rx7 18439 2.04/2.88 0.00/0.00 Purinergic receptor P2X, ligand-gated ion channel, 7 
Pafah1b3 18476 1.39 0.00 
Platelet-activating factor acetylhydrolase IB subunit 
gamma 
Pafah2 100163 -1.11 0.00 
Platelet-activating factor acetylhydrolase 2, 
cytoplasmic 
Pak1 18479 1.36/1.53 0.05/0.02 p21 protein (Cdc42/Rac)-activated kinase 1 
Panx1 55991 1.76 0.00 Pannexin 1 
Paqr9 75552 -1.31 0.01 Progestin and adipoQ receptor family member IX 
Pard3b 72823 -1.50 0.00 Par-3 partitioning defective 3 homolog B 
Parva 57342 -1.00 0.00 Parvin, alpha 
Pawr 114774 1.77 0.00 PRKC, apoptosis, WT1, regulator 
Pbk 52033 1.69 0.03 PDZ binding kinase 
Pbld1 68371 -1.19 0.01 
Phenazine biosynthesis-like protein domain containing 
1 
Pbld2 67307 -1.35 0.00 
Phenazine biosynthesis-like protein domain containing 
2 
Pcdh17 219228 2.03/2.39 0.00/0.00 Protocadherin-17 
Pcdhgc4 93707 1.00 0.05 Protocadherin gamma subfamily C, 4 
Pck1 18534 -1.69/-1.44/2.46 0.04/0.03/0.00 Phosphoenolpyruvate carboxykinase 1 (soluble) 
Pck2 74551 1.26/1.82 0.00/0.00 Phosphoenolpyruvate carboxykinase 2 (mitochondrial) 
Pcolce2 76477 -1.85 0.02 Procollagen C-endopeptidase enhancer 2 
Pcsk9 100102 1.63 0.02 Proprotein convertase subtilisin/kexin type 9 
Pde6c 110855 3.56 0.00 
Phosphodiesterase 6C, cGMP-specific, cone, alpha 
prime 
Pde6h 78600 -1.28 0.02 Phosphodiesterase 6H, cGMP-specific, cone, gamma 
Pdgfra 18595 -1.70 0.00 
Platelet-derived growth factor receptor, alpha 
polypeptide 
Pdilt 71830 -3.08/-2.11 0.00/0.00 Protein disulfide isomerase-like, testis expressed 
Pdk1 228026 -1.22 0.03 Pyruvate dehydrogenase kinase, isozyme 1 
Pdlim7 67399 1.19/1.88 0.00/0.00 PDZ and LIM domain 7 (enigma) 
Pdp1 381511 1.27/2.28 0.01/0.00 
Pyruvate dehyrogenase phosphatase catalytic subunit 
1 
Pdpr 319518 -1.26/-1.20/-1.08 0.01/0.04/0.05 
Pyruvate dehydrogenase phosphatase regulatory 
subunit 
Pdzk1ip1 67182 1.53 0.00 PDZK1 interacting protein 1 
Pdzrn3 55983 -1.76 0.05 PDZ domain containing ring finger 3 
Pea15a 18611 1.10 0.00 Phosphoprotein enriched in astrocytes 15A 
Pebp1 23980 -1.09/-1.02 0.00/0.00 Phosphatidylethanolamine binding protein 1 
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Pecr 111175 -1.93 0.00 Peroxisomal trans-2-enoyl-CoA reductase 
Peg3 18616 1.42/2.08 0.02/0.03 Paternally expressed gene 3 
Pemt 18618 -1.49 0.00 phosphatidylethanolamine N-methyltransferase 
Pgd 110208 1.09/1.16 0.00/0.00 Phosphogluconate dehydrogenase 
Pglyrp1 21946 1.18 0.01 Peptidoglycan recognition protein 1 
Pgm1 66681 1.71 0.00 Phosphoglucomutase 1 
Pgm3 109785 1.75 0.00 Phosphoglucomutase 3 
Phf3 213109 1.16 0.01 PHD finger protein 3 
Phgdh 236539 1.32/3.36/3.70 0.02/0.00/0.00 3-Phosphoglycerate dehydrogenase 
Phlda2 22113 1.12 0.01 Pleckstrin homology-like domain, family A, member 2 
Phlda3 27280 1.56 0.00 Pleckstrin homology-like domain, family A, member 3 
Pigq 14755 -1.30 0.00 
Phosphatidylinositol glycan anchor biosynthesis, class 
Q 
Pik3r1 18708 -1.01 0.01 
Phosphoinositide-3-kinase, regulatory subunit 1 
(alpha) 
Pim3 223775 -1.24/-1.23 0.02/0.00 Pim-3 oncogene 
Pitpnm1 18739 1.19 0.02 
Phosphatidylinositol transfer protein, membrane-
associated 1 
Pkhd1 241035 1.10 0.04 Polycystic kidney and hepatic disease 1 
Pkp2 67451 1.02 0.01 Plakophilin 2 
Pla1a 85031 1.05 0.01 Phospholipase A1 member A 
Plat 18791 1.40 0.01 Plasminogen activator, tissue 
Plce1 74055 1.11 0.04 Phospholipase C, epsilon 1 
Plch1 269437 1.65 0.00 Phospholipase C, eta 1 
Pld1 18805 1.28/1.56 0.00/0.00 Phospholipase D1, phosphatidylcholine-specific 
Plek2 27260 2.15 0.00 Pleckstrin 2 
Plekhb1 27276 -2.44/1.22 0.00/0.00 
pleckstrin homology domain containing, family B 
(evectins) member 1 
Plin2 11520 1.07 0.00 Perilipin 2 
Pls1 102502 2.62 0.00 Plastin 1 
Plscr1 22038 2.00/2.10 0.01/0.00 Phospholipid scramblase 1 
Plxnb1 235611 3.04 0.00 Plexin B1 
Pm20d2 242377 -2.10 0.00 Peptidase M20 domain containing 2 
Pnpla3 116939 2.28 0.00 Patatin-like phospholipase domain containing 3 
Pnpla5 75772 3.68 0.00 Patatin-like phospholipase domain containing 5 
Pold4 69745 2.84 0.00 Polymerase (DNA-directed), delta 4 
Pon1 18979 -2.75 0.00 Paraoxonase 1 
Pou3f1 18991 1.35 0.00 POU domain, class 3, transcription factor 1 
Ppap2c 50784 1.93 0.00 Phosphatidic acid phosphatase type 2C 
Ppl 19041 1.77 0.00 Periplakin 
Ppm1h 319468 1.23 0.03 Protein phosphatase, Mg2+/Mn2+ dependent, 1H 
Ppm1k 243382 -1.80/-1.66 0.00/0.01 Protein phosphatase, Mg2+/Mn2+ dependent, 1K 
Ppp1r13b 21981 1.20 0.00 Protein phosphatase 1 regulatory subunit 13B 
Ppp1r14a 68458 -1.27 0.01 Protein phosphatase 1 regulatory subunit 14A 
Ppp1r14b 18938 1.01 0.00 Protein phosphatase 1 regulatory subunit 14B 
Pprc1 226169 1.16 0.00 
Peroxisome proliferator-activated receptor gamma 
coactivator-related protein 1 
Pqlc3 217430 1.77 0.00 PQ loop repeat containing 3 
Prelid2 77619 1.84 0.01 PRELI domain containing 2 
Prkab1 19079 1.00 0.00 
Protein kinase, AMP-activated, beta 1 non-catalytic 
subunit 
Prkca 18750 1.35 0.00 Protein kinase C, alpha 
Prlr 19116 
-2.76/-2.29/-2.28/-
1.43/-1.27/-1.11 
0.00/0.00/0.00/0.04/0.02/0.0
0 
Prolactin receptor 
Prodh 19125 -3.57 0.00 Proline dehydrogenase (oxidase) 1 
Prom1 19126 4.06 0.00 Prominin 1 
Prom2 192212 2.82 0.00 Prominin 2 
Prr5l 72446 1.23 0.01 Proline rich 5 like 
Prrg1 546336 1.41 0.00 Proline rich Gla (G-carboxyglutamic acid) 1 
Prss8 76560 1.58 0.03 Protease, serine, 8 
Prtn3 19152 1.86 0.01 Proteinase 3 
Psat1 107272 3.45/3.61 0.00/0.00 Phosphoserine aminotransferase 1 
Psg18 26438 1.90 0.01 Pregnancy specific glycoprotein 18 
Psph 100678 2.13 0.00 Phosphoserine phosphatase 
Psrc1 56742 1.42/4.40 0.00/0.00 Proline/serine-rich coiled-coil 1 
Ptbp1 19205 -3.05 0.00 Polypyrimidine tract binding protein 1 
Ptger2 19217 -1.18 0.04 Prostaglandin E receptor 2 (subtype EP2), 53kDa 
Ptgfrn 19221 2.19 0.00 Prostaglandin F2 receptor negative regulator 
Ptgr1 67103 2.41 0.00 Prostaglandin reductase 1 
Pth1r 19228 -1.51 0.00 Parathyroid hormone 1 receptor 
Pth2r 213527 1.26 0.01 Parathyroid hormone 2 receptor 
Ptk2b 19229 -1.48 0.01 Protein tyrosine kinase 2 beta 
Ptpla 30963 -1.19/-1.19 0.00/0.01 
Protein tyrosine phosphatase-like (proline instead of 
catalytic arginine), member A 
Ptprd 19266 -1.50/-1.47/-1.35 0.01/0.01/0.00 Protein tyrosine phosphatase, receptor type, D 
Ptpre 19267 2.23/2.77 0.00/0.00 Protein tyrosine phosphatase, receptor type, E 
Ptprk 19272 1.04/1.13 0.00/0.01 Protein tyrosine phosphatase, receptor type, K 
Pycr1 209027 1.16 0.02 Pyrroline-5-carboxylate reductase 1 
Pygb 110078 2.76 0.00 Phosphorylase, glycogen; brain 
Rab11fip5 52055 1.06 0.02 RAB11 family interacting protein 5 (class I) 
Rab23 19335 1.28/1.50 0.00/0.00 Ras-related protein Rab-23 
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Rab34 19376 1.73/1.76 0.00/0.00 Ras-related protein Rab-34 
Rab3d 19340 1.28/1.82 0.00/0.00 Ras-related protein Rab-3D 
Rad51l1 19363 2.16 0.01 RAD51 homolog B 
Rai2 24004 -1.22 0.00 Retinoic acid-induced protein 2 
Ramp1 51801 -1.30 0.00 Receptor activity modifying protein 1 
Ranbp3l 223332 -1.52 0.01 RAN binding protein 3-like 
Rap2a 76108 -1.08 0.00 Ras-related protein Rap-2a 
Rapgef5 217944 1.47/1.69 0.01/0.00 Rap guanine nucleotide exchange factor (GEF) 5 
Rasa2 114713 1.79/1.83 0.00/0.00 RAS p21 protein activator 2 
Rasgrp2 19395 2.69/2.98/3.22 0.00/0.00/0.00 RAS guanyl-releasing protein 2 
Rassf5 54354 -1.34/-1.22 0.02/0.02 Ras association domain-containing protein 5 
Rbfox2 93686 1.24 0.00 RNA binding protein, fox-1 homolog (C. elegans) 2 
Rbl1 19650 1.23 0.02 Retinoblastoma-like 1 
Rbm24 666794 1.09/1.16 0.00/0.00 RNA binding motif protein 24 
Rbms3 207181 -1.19/-1.06 0.01/0.00 
RNA binding motif, single stranded interacting protein 
3. 
Rbp1 19659 3.39 0.00 Retinol binding protein 1 
Rcan3 53902 2.08 0.00 RCAN family member 3 
Rcn2 26611 1.00 0.00 Reticulocalbin 2 
Rdh16 19683 -1.20 0.02 Retinol dehydrogenase 16 
Rdh5 19682 1.33 0.00 Retinol dehydrogenase 5 
Rdh9 103142 1.08 0.02 Retinol dehydrogenase 9 
Reep5 13476 1.19/1.36 0.00/0.00 Receptor accessory protein 5 
Rell1 100532 1.42/1.49 0.00/0.00 RELT-like 1 
Retsat 67442 -1.89/-1.67 0.00/0.00 All-trans-retinol 13,14-reductase 
Rfx4 71137 -2.79 0.00 
Regulatory factor X, 4 (influences HLA class II 
expression) 
Rgn 19733 -2.08 0.00 Regucalcin 
Rgs16 19734 1.42/1.67/1.70 0.00/0.00/0.00 Regulator of G-protein signaling 16 
Rgs20 58175 2.85 0.00 Regulator of G-protein signaling 20 
Rgs4 19736 -1.17 0.05 Regulator of G-protein signaling 4 
Rgs5 19737 
-1.70/-1.66/-1.65/-
1.13 0.00/0.00/0.01/0.03 
Regulator of G-protein signaling 5 
Rhbdf1 13650 1.90 0.00 Rhomboid 5 homolog 1 
Rhoc 11853 2.37/2.45 0.00/0.00 Ras homolog gene family, member C 
Rhod 11854 1.23 0.01 Ras homolog gene family, member D 
Rims2 116838 1.51 0.02 Regulating synaptic membrane exocytosis 2 
Rims4 241770 1.28 0.02 Regulating synaptic membrane exocytosis 4 
Rnase4 58809 -1.76 0.03 Ribonuclease, RNase A family, 4 
Rnf152 320311 -1.07 0.01 Ring finger protein 152 
Rnf39 386454 2.36 0.00 Ring finger protein 39 
Robo1 19876 2.55 0.00 Roundabout homolog 1 
Rogdi 66049 2.02 0.00 Rogdi homolog 
Rora 19883 1.05 0.00 RAR-related orphan receptor A 
Rp2h 19889 1.10/1.36/1.61 0.01/0.00/0.00 Retinitis pigmentosa 2 homolog 
Rpain 69723 -1.13/-1.03 0.00/0.00 RPA interacting protein 
Rpap3 71919 1.09 0.00 RNA polymerase II associated protein 3 
Rpp21 67676 1.02 0.00 Ribonuclease P/MRP 21kDa subunit 
Rrbp1 81910 1.11/1.16/1.22 0.00/0.00/0.01 Ribosome binding protein 1 homolog 180kDa 
Rsph3a 66832 1.45 0.01 Radial spoke 3A homolog 
Rspo3 72780 -1.82 0.01 R-spondin-3 
Rtkn 20166 1.52 0.00 Rhotekin 
Rundc3b 242819 1.82 0.05 RUN domain containing 3B 
Runx2 12393 1.86 0.01 Runt-related transcription factor 2 
S100a1 20193 -1.25/-1.22 0.00/0.00 S100 calcium binding protein A1 
S100a11 20195 2.24 0.00 S100 calcium binding protein A11 
S100g 12309 1.19 0.05 S100 calcium binding protein G 
S1pr3 13610 1.89/2.61 0.00/0.00 Sphingosine-1-phosphate receptor 3 
Saa1 20208 -2.54 0.01 Serum amyloid A1 
Saa4 20211 -1.33/-1.05 0.00/0.01 Serum amyloid A4, constitutive 
Sall1 58198 1.09 0.00 Sal-like 1 
Samd4 74480 1.11/1.17/1.67 0.01/0.00/0.00 Sterile alpha motif domain containing 4 
Sardh 192166 -1.29/-1.11 0.01/0.01 Sarcosine dehydrogenase, mitochondrial 
Satb2 212712 1.14 0.00 Special AT-rich sequence-binding protein 2 
Scamp5 56807 1.14 0.00 Secretory carrier-associated membrane protein 5 
Scara5 71145 -1.41 0.02 Scavenger receptor class A, member 5 (putative) 
Sccpdh 109232 2.23 0.00 Saccharopine dehydrogenase (putative) 
Scd2 20250 3.70/4.02 0.00/0.00 Stearoyl-CoA desaturase (delta-9-desaturase) 
Scel 64929 2.73 0.00 Sciellin 
Scn8a 20273 1.80/2.70/4.57 0.00/0.00/0.00 
Sodium channel, voltage gated, type VIII, alpha 
subunit 
Scnn1a 20276 -1.00 0.00 Sodium channel, nonvoltage-gated 1 alpha 
Sdpr 20324 1.09/1.20/1.65 0.00/0.00/0.00 Serum deprivation response 
Sdr9c7 70061 -1.86/-1.74 0.03/0.02 
Short chain dehydrogenase/reductase family 9C, 
member 7 
Sec14l4 103655 -1.32 0.01 SEC14-like 4 
Sectm1a 209588 1.68 0.01 Secreted and transmembrane 1A 
Sel1l3 231238 1.57 0.00 Sel-1 suppressor of lin-12-like 3 
Sema3d 108151 -2.05 0.00 
Sema domain, immunoglobulin domain (Ig), short 
basic domain, secreted, (semaphorin) 3D 
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Sema3e 20349 -2.34/-1.75/-1.46 0.00/0.00/0.01 
Sema domain, immunoglobulin domain (Ig), short 
basic domain, secreted, (semaphorin) 3E 
Sepn1 74777 1.03 0.01 Selenoprotein N, 1 
Sepw1 20364 -1.09/-1.04 0.01/0.00 Selenoprotein W, 1 
Serpina11 380780 -1.18 0.01 
Serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 11 
Serpina12 68054 1.12/2.18 0.02/0.00 
Serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 12 
Serpina3k 20714 -1.90 0.01 
Serine (or cysteine) peptidase inhibitor, clade A, 
member 3k 
Serpina4-ps1 321018 -3.99/-3.99/-3.83 0.00/0.00/0.00 
Serine (or cysteine) peptidase inhibitor, clade A, 
member 4, pseudogene 1 
Serpinb6b 20708 1.72 0.01 
Serine (or cysteine) peptidase inhibitor, clade B, 
member 6b 
Serpine1 18787 1.77 0.03 
Serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 1 
Serpine2 20720 -2.28 0.01 
Serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), member 2 
Sertad1 55942 1.40 0.00 SERTA domain-containing protein 1 
Sfpq 71514 1.09 0.00 Splicing factor proline/glutamine-rich 
Sfxn5 94282 -1.29 0.00 Sideroflexin 5 
Sgsm1 52850 1.70/2.90 0.00/0.00 Small G protein signaling modulator 1 
Sh3bgrl 56726 1.07/1.11 0.01/0.00 SH3 domain binding glutamic acid-rich protein like 
Sh3bp4 98402 1.27 0.00 SH3-domain binding protein 4 
Sh3pxd2b 268396 1.68 0.00 SH3 and PX domains 2B 
Shc2 216148 1.10 0.01 SHC transforming protein 2 
Shcbp1 20419 1.07 0.02 SHC SH2-domain binding protein 1 
Shroom3 27428 1.29 0.00 Shroom family member 3 
Sidt1 320007 1.23 0.01 SID1 transmembrane family, member 1 
Sik1 17691 1.15 0.02 Salt-inducible kinase 1 
Sirpa 19261 1.46 0.01 Signal-regulatory protein alpha 
Sirt3 64384 -1.26 0.01 Sirtuin 3 
Slc10a1 20493 -1.68/-1.67 0.01/0.00 
Solute carrier family 10 (sodium/bile acid cotransporter 
family), member 1 
Slc12a2 20496 -1.44 0.04 
Solute carrier family 12 (sodium/potassium/chloride 
transporters), member 2 
Slc13a3 114644 -1.22 0.04 
Solute carrier family 13 (sodium-dependent 
dicarboxylate transporter), member 3 
Slc16a10 72472 -1.68/-1.41 0.00/0.01 
Solute carrier family 16, member 10 (aromatic amino 
acid transporter) 
Slc16a6 104681 1.23 0.00 Solute carrier family 16, member 6 
Slc16a9 66859 -1.12 0.04 Solute carrier family 16, member 9 
Slc17a2 218103 -1.23/-1.20 0.00/0.02 
Solute carrier family 17 (sodium phosphate), member 
2 
Slc1a2 20511 -2.21/-2.05/-1.81 0.02/0.01/0.00 
Solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 1 
Slc1a4 55963 1.17/1.61/1.72 0.02/0.01/0.03 
Solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 
Slc20a1 20515 1.33 0.01 
Solute carrier family 20 (phosphate transporter), 
member 1 
Slc22a27 171405 2.16 0.00 
Solute carrier family 22 (organic anion transporter), 
member 27 
Slc22a30 319800 -1.76 0.00 
Solute carrier family 22 (organic anion transporter), 
member 30 
Slc22a4 30805 -1.19 0.02 
Solute carrier family 22 (organic anion transporter), 
member 4 
Slc22a7 108114 -3.34 0.01 
Solute carrier family 22 (organic anion transporter), 
member 7 
Slc24a3 94249 1.91 0.01 
Solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 3 
Slc25a15 18408 -1.13 0.01 
Solute carrier family 25 (mitochondrial carrier; ornithine 
transporter) member 15 
Slc25a30 67554 1.37/1.67/1.70 0.00/0.01/0.00 Solute carrier family 25, member 30 
Slc25a42 73095 -1.50 0.00 Solute carrier family 25, member 42 
Slc26a1 231583 -1.29/-1.14 0.01/0.00 Solute carrier family 26, member 1 
Slc26a4 23985 -1.26 0.00 Solute carrier family 26, member 4 
Slc27a5 26459 -1.09 0.01 
Solute carrier family 27 (fatty acid transporter), 
member 5 
Slc29a1 63959 -1.12 0.01 
Solute carrier family 29 (nucleoside transporters), 
member 1 
Slc35e3 215436 -1.13 0.00 Solute carrier family 35, member E3 
Slc35f2 72022 1.40 0.00 Solute carrier family 35, member F2 
Slc37a3 72144 1.01 0.01 
Solute carrier family 37 (glycerol-3-phosphate 
transporter), member 3 
Slc39a2 214922 -1.11 0.01 Solute carrier family 39 (zinc transporter), member 2 
Slc39a4 72027 2.36 0.00 Solute carrier family 39 (zinc transporter), member 4 
Slc41a2 338365 1.10 0.01 Solute carrier family 41, member 2 
Slc41a3 71699 1.25/2.79 0.00/0.00 Solute carrier family 41, member 3 
Slc44a3 213603 1.11 0.00 Solute carrier family 44, member 3 
Slc48a1 67739 1.26/1.40 0.00/0.00 Solute carrier family 48 (heme transporter), member 1 
Slc6a8 102857 1.09 0.00 
Solute carrier family 6 (neurotransmitter transporter, 
creatine), member 8 
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Slc7a7 20540 1.65 0.00 
Solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 7 
Slc7a9 30962 1.14 0.01 
Solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 9 
Slco1a1 28248 -4.26/-4.23 0.01/0.01 
Solute carrier organic anion transporter family, 
member 1A2 
Slco1b2 28253 -3.24/-3.22/-3.03 0.00/0.00/0.00 
Solute carrier organic anion transporter family, 
member 1B2 
Slco2b1 101488 -3.42/-2.30 0.00/0.00 
Solute carrier organic anion transporter family member 
2B1 
Slpi 20568 4.15 0.00 Secretory leukocyte peptidase inhibitor 
Smoc2 64074 1.95/2.66 0.01/0.00 SPARC-related modular calcium-binding protein 2 
Smox 228608 1.01/2.79 0.00/0.00 Spermine oxidase 
Smpd3 58994 1.78 0.00 
Sphingomyelin phosphodiesterase 3, neutral 
membrane 
Smpdl3b 100340 2.62 0.00 Sphingomyelin phosphodiesterase, acid-like 3B 
Sned1 208777 -1.03 0.02 Sushi, nidogen and EGF-like domains 1 
Snhg11 319317 -2.92 0.00 
Small nucleolar RNA host gene 11 (non-protein 
coding) 
Sntb2 20650 1.23 0.00 Syntrophin, beta 2 
Sntg2 268534 -1.79 0.00 Syntrophin, gamma 2 
Snx6 72183 1.00 0.01 Sorting nexin 6 
Socs5 56468 1.34/1.54 0.00/0.00 Suppressor of cytokine signaling 5 
Sod2 20656 -1.08 0.00 Superoxide dismutase 2, mitochondrial 
Sod3 20657 -1.17 0.01 Superoxide dismutase 3, extracellular 
Sorbs2 234214 1.13 0.02 Sorbin and SH3 domain-containing protein 2 
Sord 20322 -1.59 0.04 Sorbitol dehydrogenase 
Sox4 20677 1.15/1.39/2.74 0.01/0.00/0.00 SRY (sex determining region Y)-box 4 
Spa17 20686 1.17 0.00 Sperm autoantigenic protein 17 
Sparc 20692 2.45/2.46 0.00/0.00 Secreted protein, acidic, cysteine-rich (osteonectin) 
Spc25 66442 1.61 0.01 NDC80 kinetochore complex component, homolog 
Specc1 432572 1.95 0.00 
Sperm antigen with calponin homology and coiled-coil 
domains 1 
Spin2 278240 1.21 0.00 Spindlin family, member 2 
Spink3 20730 4.98 0.00 Serine protease inhibitor Kazal-type 3 
Spna2 20740 1.18/1.27 0.00/0.00 Spectrin alpha 2 
Spred1 114715 1.31/1.44 0.00/0.00 Sprouty-related, EVH1 domain-containing protein 1 
Spred2 114716 1.16 0.00 Sprouty-related, EVH1 domain-containing protein 2 
Sprr1a 20753 1.72 0.00 Small proline-rich protein 1A 
Spry2 24064 2.45 0.00 Sprouty homolog 2 
Spry4 24066 1.25 0.03 Sprouty homolog 4 
Sptlc2 20773 1.31 0.00 Serine palmitoyltransferase, long chain base subunit 2 
Spty2d1 101685 1.14 0.01 Suppressor of Ty, domain containing 1 
Sqle 20775 2.17 0.02 Squalene epoxidase 
Srd5a1 78925 -2.71/-2.28/-2.15 0.00/0.00/0.00 Steroid-5-alpha-reductase, alpha polypeptide 1 
Srd5a2 94224 1.08 0.00 Steroid-5-alpha-reductase, alpha polypeptide 2 
Srr 27364 
-1.21/-1.20/-1.12/-
1.09/-1.06 0.00/0.00/0.00/0.01/0.01 
Serine racemase 
Srxn1 76650 1.01 0.01 Sulfiredoxin 1 
Sstr2 20606 1.37 0.00 Somatostatin receptor 2 
St6gal1 20440 1.09 0.00 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 
Stambpl1 76630 1.54 0.00 STAM binding protein-like 1 
Stard5 170460 -1.19/-1.06 0.03/0.02 StAR-related lipid transfer protein 5 
Steap2 74051 -1.15 0.01 STEAP family member 2, metalloreductase 
Stmn1 16765 1.04/1.60 0.02/0.01 Stathmin 1 
Sulf2 72043 -1.16/-1.13 0.00/0.00 Sulfatase 2 
Sult1b1 56362 -2.02 0.00 Sulfotransferase family 1B, member 1 
Sult2a2 100043194 3.63 0.02 Sulfotransferase family 2A, member 2 
Sult4a1 29859 1.19 0.01 Sulfotransferase family 4A, member 1 
Sult5a1 57429 -2.13 0.00 Sulfotransferase family 5A, member 1 
Suox 211389 -1.91 0.00 Sulfite oxidase 
Susd1 634731 -1.42 0.01 Sushi domain containing 1 
Susd4 96935 -2.68/-2.64 0.00/0.00 Sushi domain containing 4 
Sybu 319613 1.84 0.00 Syntabulin (syntaxin-interacting) 
Sycp3 20962 -1.24 0.02 Synaptonemal complex protein 3 
Synj2 20975 1.13 0.00 Synaptojanin 2 
Synm 233335 1.08 0.00 Synemin, intermediate filament protein 
Tagln2 21346 1.51/1.90 0.00/0.00 Transgelin-2 
Tanc1 66860 1.23 0.00 
tetratricopeptide repeat, ankyrin repeat and coiled-coil 
containing 1 
Tax1bp3 76281 1.03 0.00 Tax1-binding protein 3 
Tbc1d2b 67016 1.08 0.00 TBC1 domain family, member 2B 
Tbx20 57246 -1.37 0.01 T-box 20 
Tbx3 21386 -2.59/-2.14 0.00/0.00 T-box 3 
Tc2n 74413 2.15/2.39/2.80 0.00/0.00/0.00 Tandem C2 domains nuclear protein 
Tceal8 66684 2.75 0.00 Transcription elongation factor A (SII)-like 8 
Tcf21 21412 -1.76 0.00 Transcription factor 21 
Tcf4 21413 1.00 0.01 Transcription factor 4 
Tes 21753 1.25 0.00 Testin 
Tex12 66654 -1.49 0.01 Testis expressed 12 
Tff3 21786 4.50 0.00 Trefoil factor 3 (intestinal) 
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Gene symbol 
EntrezGene 
ID Log-ratio p-value 
Gene name 
Tgfa 21802 1.04 0.01 Transforming growth factor alpha 
Tgfb2 21808 1.64/1.87/1.97 0.00/0.00/0.00 Transforming growth factor, beta 2 
Tgfbr2 21813 2.65 0.00 Transforming growth factor, beta receptor II 
Tgif1 21815 1.34 0.00 TGFB-induced factor homeobox 1 
Thsd4 207596 1.03 0.01 Thrombospondin, type I, domain containing 4 
Tifa 211550 -1.42 0.01 
TRAF-interacting protein with forkhead-associated 
domain 
Timeless 21853 1.01 0.01 Timeless homolog 
Timp2 21858 -1.37/-1.20 0.04/0.03 TIMP metallopeptidase inhibitor 2 
Tinag 26944 3.11 0.00 Tubulointerstitial nephritis antigen 
Tjp2 21873 1.19/1.20 0.02/0.00 Tight junction protein 2 
Tlr1 21897 4.33 0.00 Toll-like receptor 1 
Tlr5 53791 -1.25 0.01 Toll-like receptor 5 
Tm4sf4 229302 1.14 0.00 Transmembrane 4 superfamily member 4 
Tm9sf2 68059 -1.04 0.02 Transmembrane 9 superfamily member 2 
Tmc5 74424 2.25 0.00 Transmembrane channel-like protein 5 
Tmed6 66269 2.12 0.03 
Transmembrane emp24 protein transport domain 
containing 6 
Tmem146 106757 3.00 0.00 Transmembrane protein 146 
Tmem158 72309 1.04 0.03 Transmembrane protein 158 
Tmem191c 224019 1.25 0.01 Transmembrane protein 191C 
Tmem229a 319832 1.96 0.04 Transmembrane protein 229A 
Tmem45b 235135 3.69 0.00 Transmembrane protein 45B 
Tmem62 96957 1.34 0.00 Transmembrane protein 62 
Tmem63a 208795 -1.17 0.00 Transmembrane protein 63A 
Tmem71 213068 2.56 0.00 Transmembrane protein 71 
Tmem86a 67893 2.49 0.00 Transmembrane protein 86A 
Tnfrsf11b 18383 -2.12 0.00 
Tumor necrosis factor receptor superfamily member 
11b 
Tnfrsf12a 27279 2.98/3.17 0.00/0.00 
Tumor necrosis factor receptor superfamily member 
12a 
Tnfrsf18 21936 2.17 0.00 Tumor necrosis factor receptor superfamily member 18 
Tnfrsf21 94185 1.50/1.77 0.00/0.00 Tumor necrosis factor receptor superfamily member 21 
Tnik 665113 2.10 0.00 TRAF2 and NCK-interacting protein kinase 
Tns1 21961 1.00 0.03 Tensin 1 
Tox2 269389 1.38 0.05 TOX high mobility group box family member 2 
Tox3 244579 1.46 0.02 TOX high mobility group box family member 3 
Tpcn1 252972 -1.03 0.01 Two pore segment channel 1 
Tpd52 21985 1.07 0.00 Tumor protein D52 
Tpm1 22003 1.62/1.84 0.00/0.00 Tropomyosin alpha-1 chain 
Tppp 72948 -1.26 0.02 Tubulin polymerization-promoting protein 
Tpra1 24100 1.11 0.00 Transmembrane protein, adipocyte asscociated 1 
Tprkb 69786 -1.25/-1.20 0.00/0.00 TP53RK binding protein 
Trfr2 50765 -1.02 0.00 Transferrin receptor protein 2 
Trib2 217410 1.22 0.01 Tribbles homolog 2 
Trib3 228775 1.93/1.99 0.01/0.01 Tribbles homolog 3 
Trim2 80890 1.31/1.52 0.01/0.03 Tripartite motif-containing protein 2 
Trim68 101700 1.13 0.00 Tripartite motif-containing protein 68 
Trip13 69716 1.30 0.00 Thyroid hormone receptor interactor 13 
Trip4 56404 -1.24 0.00 Thyroid hormone receptor interactor 4 
Trp53inp1 60599 1.16 0.01 p53-dependent damage-inducible nuclear protein 1 
Trpm4 68667 2.10 0.00 
Transient receptor potential cation channel subfamily 
M member 4 
Tsc22d2 72033 1.17 0.00 TSC22 domain family, member 2 
Tsc22d4 78829 1.04 0.02 TSC22 domain family, member 4 
Tspan15 70423 1.23 0.00 Tetraspanin-15 
Tspan2 70747 1.41/2.50 0.01/0.01 Tetraspanin-2 
Tspan8 216350 
2.20/2.20/3.99/4.91/
5.03 0.02/0.00/0.00/0.00/0.00 
Tetraspanin-8 
Tspyl4 72480 -2.60 0.00 TSPY-like 4 
Tstd1 226654 2.64 0.00 
Thiosulfate sulfurtransferase (rhodanese)-like domain 
containing 1 
Ttc39c 72747 -2.03/-1.91/-1.85 0.01/0.02/0.00 Tetratricopeptide repeat domain 39C 
Ttc7b 104718 -1.81 0.00 Tetratricopeptide repeat domain 7B 
Tuba1b 22143 1.41 0.00 Tubulin, alpha 1b 
Tuba8 53857 1.04/1.06 0.02/0.02 Tubulin, alpha 8 
Tubb2a 22151 1.97/2.82 0.00/0.00 Tubulin, beta 4B class IVa 
Tubb2b 73710 1.48 0.04 Tubulin, beta 4B class IIb 
Tubb4b 227613 1.62 0.01 Tubulin, beta 4B class IVb 
Tubb6 67951 2.36 0.00 Tubulin, beta 6 class V 
Tuft1 22156 1.80 0.00 Tuftelin 1 
Tulp2 56734 -1.01 0.00 Tubby like protein 2 
Twf2 23999 1.33/1.38 0.02/0.00 Twinfilin, actin-binding protein, homolog 2 
Uap1l1 227620 2.05 0.00 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 
Ubtd2 327900 1.90 0.00 ubiquitin domain containing 2 
Uggt2 66435 1.10 0.01 UDP-glucose glycoprotein glucosyltransferase 2 
Ugt2a3 72094 -1.34 0.00 UDP glycosyltransferase 2 family, polypeptide A3 
Ugt2b1 71773 -2.21 0.00 UDP glycosyltransferase 2 family, polypeptide B1 
Ugt3a1 105887 -2.13 0.02 UDP glycosyltransferase 3 family, polypeptide A1 
Ugt3a2 223337 -1.65 0.00 UDP glycosyltransferase 3 family, polypeptide A2 
Ulk1 22241 1.03 0.00 Unc-51-like kinase 1 
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Gene symbol 
EntrezGene 
ID Log-ratio p-value 
Gene name 
Unc119 22248 2.28 0.00 Unc-5 homolog 119 
Unc13b 22249 1.04 0.01 Unc-5 homolog 13B 
Unc5b 107449 1.27 0.00 Unc-5 homolog B 
Upp2 76654 -3.48/-3.44/-2.57 0.01/0.01/0.02 Uridine phosphorylase 2 
Uvrag 78610 -1.18 0.01 UV radiation resistance-associated gene 
Vasp 22323 1.55 0.00 Vasodilator-stimulated phosphoprotein 
Vipr1 22354 -1.63 0.00 Vasoactive intestinal polypeptide receptor 1 
Vnn1 22361 4.05/4.16 0.00/0.00 Vanin 1 
Vnn3 26464 2.94 0.00 Vanin 3 
Vrk2 69922 -1.19/-1.13 0.01/0.03 Vaccinia related kinase 2 
Vsig10 231668 1.91 0.00 V-set and immunoglobulin domain containing 10 
Wbp5 22381 1.56 0.00 WW domain binding protein 5 
Wdr1 22388 1.10/1.24/1.26 0.00/0.00/0.00 WD repeat domain 1 
Wdr67 210544 1.78/2.48 0.00/0.00 WD repeat domain 67 
Wdr91 101240 -1.22 0.01 WD repeat domain 91 
Wfdc12 192200 1.68 0.01 WAP four-disulfide core domain protein 12 
Wfdc15b 192201 4.33 0.00 WAP four-disulfide core domain protein  15b 
Wfdc2 67701 -1.19 0.01 WAP four-disulfide core domain protein 2 
Wnk4 69847 1.89 0.00 WNK lysine deficient protein kinase 4 
Wnt2 22413 -1.61 0.00 Wingless-type MMTV integration site family, member 2 
Wnt5b 22419 -1.58/-1.20 0.01/0.03 
Wingless-type MMTV integration site family, member 
5B 
Wsb1 78889 1.27 0.01 WD repeat and SOCS box containing 1 
Wsb2 59043 1.01 0.00 WD repeat and SOCS box containing 2 
Zc3h12d 237256 1.30 0.03 Zinc finger CCCH-type containing 12D 
Zeb2 24136 -1.09 0.04 Zinc finger E-box-binding homeobox 2 
Zfand3 21769 1.02 0.00 Zinc finger, AN1-type domain 3 
Zfp157 72154 -1.02 0.01 Zinc finger protein 137 
Zfp318 57908 -1.18 0.01 Zinc finger protein 318 
Zfp385b 241494 -1.02 0.02 Zinc finger protein 385b 
Zfp386 56220 1.04 0.01 Zinc finger protein 386 
Zfp462 242466 1.97 0.02 Zinc finger protein 462 
Zfp53 24132 1.40 0.05 Zinc finger protein 53 
Zfp54 22712 1.10 0.01 Zinc finger protein 54 
Zfp618 72701 1.16 0.00 Zinc finger protein 618 
Zfp7 223669 1.94 0.00 Zinc finger protein 7 
Zfp704 170753 1.01/1.52 0.00/0.00 Zinc finger protein 704 
Zfp750 319530 1.23 0.01 Zinc finger protein 750 
Zfp871 208292 -1.06 0.02 Zinc finger protein 871 
Zfp9 22750 1.30 0.00 Zinc finger protein 9 
Zfp948 381066 1.08 0.01 Zinc finger protein 948 
Zik1 22775 1.08 0.04 Zinc finger protein interacting with K protein 1 homolog 
Zmat3 22401 1.31 0.00 Zinc finger, matrin-type 3 
 
 
C) miRNAs significantly dysregulated in Ctnnb1-mutated tumors vs. adjacent non-
tumor tissue (log-ratio >1.0, p-value <0.05). 
miRNA name Ensembl Gene ID Log-ratio p-value 
mmu-miR-680 ENSMUSG00000076253 6.11 0.00 
mmu-miR-425 ENSMUSG00000065579 4.01 0.00 
mmu-miR-199a-3p ENSMUSG00000070126 -1.25 0.04 
 
D) miRNAs significantly dysregulated in Ha-ras-mutated tumors vs. adjacent non-
tumor tissue (log-ratio >1.0, p-value <0.05). 
miRNA name Ensembl Gene ID Log-ratio p-value 
mmu-miR-96 ENSMUSG00000065586 7.21 0.00 
mmu-miR-199a-5p ENSMUSG00000070126 -5.45 0.00 
mmu-miR-455 ENSMUSG00000070102 -5.74 0.00 
mmu-miR-146b ENSMUSG00000070127 4.75 0.01 
mmu-miR-199a-3p ENSMUSG00000070126 -1.23 0.05 
mmu-miR-338-3p ENSMUSG00000065600 -1.54 0.05 
mmu-miR-139-5p ENSMUSG00000065446 -1.21 0.05 
mmu-miR-193 ENSMUSG00000065395 -1.41 0.05 
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E) Differentially methylated DNA regions in Ctnnb1-mutated tumors vs. adjacent non-
tumor tissue (log-ratio >1.0, p-value <0.05). 
Probeset ID Gene 
symbol Gene name Strand Chromosome Start End 
Log-
ratio 
p-
value 
ENSMUSG00000066584 Abpb Androgen binding protein beta -1 7 34796951 34798961 -1.02 0.04 
ENSMUSG00000030168 Adipor2 Adiponectin receptor 2 -1 6 119303168 119367501 1.55 0.01 
ENSMUSG00000044033 Ccdc141 Coiled-coil domain containing 141 -1 2 76847960 77008693 1.26 0.05 
ENSMUSG00000059554 Ccdc28a Coiled-coil domain containing 28A -1 10 17933482 17954804 1.34 0.05 
ENSMUSG00000004709 Cd244 Cluster of differentiation 244 1 1 173489324 173515449 -1.59 0.02 
ENSMUSG00000016756 Cmah Cytidine monophosphate-N-
acetylneuraminic acid hydroxylase-like 1 13 24419289 24569154 1.36 0.01 
ENSMUSG00000079415 Cntf Ciliary neurotrophic factor -1 19 12838150 12840122 1.01 0.05 
ENSMUSG00000046516 Cox17 Cytochrome c oxidase assembly homolog 1 16 38347077 38362383 1.09 0.02 
ENSMUSG00000025991 Cps1 Carbamoyl-phosphate synthase 1 1 1 67169600 67277833 1.5 0.03 
ENSMUSG00000029014 Dnajc2 DnaJ (Hsp40) homolog, subfamily C, 
member 2 -1 5 21263085 21291069 1.2 0.05 
ENSMUSG00000003235 Eif2b5 Eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa 1 16 20498890 20510028 1.2 0.03 
ENSMUSG00000019989 Enpp3 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 
family member 3 
-1 10 24493620 24556001 1.25 0.02 
ENSMUSG00000075703 Ept1 Ethanolaminephosphotransferase 1 (CDP-ethanolamine-specific) 1 5 30559121 30598558 1.13 0.05 
ENSMUSG00000061286 Exosc5 Exosome component 5 1 7 26444172 26453050 1.27 0.05 
ENSMUSG00000043230 Fam124b Family with sequence similarity 124B -1 1 80195281 80215048 -1.34 0.05 
ENSMUSG00000069911 Fam196b Family with sequence similarity 196b 1 11 34214822 34322640 -1.13 0.05 
ENSMUSG00000026835 Fcnb Ficolin b -1 2 27931898 27940405 -1.37 0.05 
ENSMUSG00000042993 Ifnk Interferon kappa 1 4 35099305 35101254 1.07 0.03 
ENSMUSG00000020155 Kcnmb1 
Potassium large conductance calcium-
activated channel, subfamily M, beta 
member 1 
1 11 33863013 33873641 -1.17 0.02 
ENSMUSG00000058354 Krt6a Keratin 6A -1 15 101520363 101524738 -1.39 0.04 
ENSMUSG00000019906 Lin7a Lin-7 homolog A 1 10 106708899 106862199 1.22 0.05 
ENSMUSG00000041673 Lrrc18 leucine rich repeat containing 18 1 14 33804568 33828478 -1.41 0.04 
ENSMUSG00000045854 Lyrm2 LYR motif containing 2 1 4 32887228 32888534 1.33 0.03 
ENSMUSG00000040003 Magi2 
Membrane-associated guanylate 
kinase, WW and PDZ domain-
containing 
1 5 18732864 20210616 1.44 0.05 
ENSMUSG00000045973 Mcart1 Mitochondrial carrier triple repeat 1 -1 4 45408795 45421633 1.01/1.01 
0.04/0.
04 
ENSMUSG00000065437 Mir30d microRNA 30d -1 15 68172770 68172851 1.48 0.02 
ENSMUSG00000039956 Mrap Melanocortin 2 receptor accessory protein 1 16 90738569 90750030 1.07 0.05 
ENSMUSG00000023967 Mrps18a Mitochondrial ribosomal protein S18A 1 17 46247935 46265859 1.01 0.05 
ENSMUSG00000061952 Olfr1377 Olfactory receptor 1377 1 11 50798160 50799222 -1.6 0.03 
ENSMUSG00000042849 Olfr1414 Olfactory receptor 1414 -1 1 94407625 94415092 -1.15 0.03 
ENSMUSG00000036381 P2ry14 Purinergic receptor P2Y, G-protein 
coupled, 14 -1 3 58918548 58934546 -1.01 0.05 
ENSMUSG00000005069 Pex5 Peroxisomal targeting signal 1 receptor -1 6 124346834 124365085 1.34 0.05 
ENSMUSG00000020464 Pnpt1 Polyribonucleotide 
nucleotidyltransferase 1 1 11 29030744 29061828 1.46 0.04 
ENSMUSG00000030643 Rab30 RAB30, member RAS oncogene family 1 7 99890113 99985627 1.29 0.04 
ENSMUSG00000032387 Rbpms2 RNA binding protein with multiple 
splicing 2 1 9 65477455 65508335 1.18 0.03 
ENSMUSG00000032050 Rdx Radixin 1 9 51855255 51896842 1.02 0.03 
ENSMUSG00000072945 Ripply1 Ripply1 homolog -1 X 136314088 136316892 1.05 0.04 
ENSMUSG00000021403 Serpinb9b Serine (or cysteine) peptidase inhibitor, 
clade B, member 9b 1 13 33119285 33133753 1.06 0.05 
ENSMUSG00000030382 Slc27a5 Solute carrier family 27 (fatty acid transporter), member 5 -1 7 13573695 13583541 1.21 0.02 
ENSMUSG00000032548 Slco2a1 Solute carrier organic anion transporter family, member 2A1 1 9 102910817 102990179 1.19 0.05 
ENSMUSG00000060429 Sntb1 Beta-1-syntrophin -1 15 55470398 55738504 1.43 0.02 
ENSMUSG00000022658 Tagln3 Transgelin 3 -1 16 45711343 45724721 1.23 0.04 
ENSMUSG00000024287 Thoc1 THO complex 1 1 18 9958178 9995482 1.22 0.03 
ENSMUSG00000046688 Tifa TRAF-interacting protein with forkhead-
associated domain 1 3 127492790 127535053 1.2 0.05 
ENSMUSG00000002032 Tmem25 Transmembrane protein 25 -1 9 44601858 44607390 1.71 0.01 
ENSMUSG00000038984 Tspyl5 TSPY-like 5 -1 15 33613631 33617638 1.02 0.05 
ENSMUSG00000038172 Ttc39b Tetratricopeptide repeat domain 39B -1 4 82866204 82970159 1.22 0.03 
ENSMUSG00000001924 Uba1 Ubiquitin-like modifier activating 
enzyme 1 1 X 20235452 20260305 1.17 0.02 
ENSMUSG00000034429 Zfp707 Zinc finger protein 707 1 15 75799553 75806298 1.25 0.04 
ENSMUSG00000056019 Zfp709 Zinc finger protein 709 1 8 74411163 74414811 1.57 0.03 
ENSMUSG00000071267 Zfp942 Zinc finger protein 942 -1 17 22063927 22099431 1.26 0.02 
ENSMUSG00000018820 Zfyve27 Zinc finger, FYVE domain containing 27 1 19 42238441 42269080 -1.59 0.03 
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F) Differentially methylated DNA regions in Ha-ras-mutated tumors vs. adjacent non-
tumor tissue (log-ratio >1.0, p-value <0.05). 
Probeset ID Gene Symbol 
Gene name 
Strand Chromosome Start End 
Log-
ratio p-value 
ENSMUSG00000028545 Bend5 
BEN domain 
containing 5 1 4 111087611 111132903 -1.67 0.03 
ENSMUSG00000024647 Cbln2 
Cerebellin 2 
precursor 1 18 86880502 86887675 -1.35 0.04 
ENSMUSG00000057110 Cep110 Centriolin 1 2 34965012 35034342 1.79 0.02 
ENSMUSG00000042248 Cyp2c37 
Cytochrome 
P450 2C37 1 19 40066909 40086738 -1.26 0.04 
ENSMUSG00000082932 Cyp2j8 
Cytochrome 
P450 2J8 -1 4 96111287 96174077 -1.31 0.04 
ENSMUSG00000017688 Hnf4g 
Hepatocyte 
nuclear factor 
4 gamma 1 3 3508030 3659775 -1.34 0.04 
ENSMUSG00000019774 Mtrf1l 
Mitochondrial 
translational 
release factor 
1-like 1 10 4522631 4534654 -1.57 0.04 
ENSMUSG00000035177 Nlrp2 
NLR family, 
pyrin domain 
containing 2 -1 7 5250156 5302637 -1.51 0.04 
ENSMUSG00000034738 Nostrin 
Nitric oxide 
synthase 
trafficker 1 2 68973857 69027387 1.45 0.04 
ENSMUSG00000059857 Ntng1 Netrin G1 -1 3 109582958 109938426 -1.66 0.04 
ENSMUSG00000051200 Olfr513 
Olfactory 
receptor 513 1 7 115898372 115899301 -1.32 0.04 
ENSMUSG00000032099 Pate4 
Prostate and 
testis 
expressed 4 -1 9 35414678 35419520 -1.64 0.04 
ENSMUSG00000042700 Sipa1l1 
Signal-
induced 
proliferation-
associated 1 
like 1 1 12 83270407 83552769 -2.00 0.02 
ENSMUSG00000021830 Txndc16 
Thioredoxin 
domain 
containing 16 -1 14 45754123 45840003 -1.39 0.04 
ENSMUSG00000019772 Vip 
Vasoactive 
intestinal 
peptide -1 10 4698927 4707323 -1.45 0.04 
 
 
G)  Differentially expressed protein and phophoprotein in Ha-ras-mutated tumors vs. 
adjacent non-tumor tissue (log-ratio >1.0, p-value <0.05). 
Analyte ID Gene 
symbol Gene name Modification 
EntrezGene 
ID 
Log-
ratio p-value 
BAX BAX BCL2-associated X protein basic 12028 1.25 0.02 
CYP1A2 CYP1A2 Cytochrome P450 1A2 basic 13077 -1.72 0.02 
CYP2C8 CYP2C8 Cytochrome P450 2C8 basic n/a -1.39 0.03 
CYP2E1 CYP2E1 Cytochrome P450 2E1 basic 13106 -2.45/ 
-3.81 0.00/0.01 
GSK3B_P-S9 GSK3B Glycogen synthase kinase 3 beta P-S9 56637 2.01 0.01 
JUN JUN Jun oncoprotein basic 16476 1.54 0.01 
MAP2K1_P-S217/S221 MAP2K1 
Dual specificity mitogen-
activated protein kinase 
kinase 1 
P-S217/S221 26395 1.07 0.04 
MAP2K1_P-S217/S221 MAP2K2 
Dual specificity mitogen-
activated protein kinase 
kinase 2 
P-S217/S221 26396 1.07 0.04 
MAPK3_P-T202/Y204 MAPK Mitogen-activated protein kinase P-T202/Y204 n/a 2.23 0.01 
MAPK8_P-T183/Y185 MAPK10 Mitogen-activated protein kinase 10 P-T183/Y185 26414 1.33 0.02 
MAPK3_P-T202/Y204 MAPK3 Mitogen-activated protein kinase 3 P-T202/Y204 26417 2.23 0.01 
MAPK8_P-T183/Y185 MAPK8 Mitogen-activated protein kinase 8 P-T183/Y185 26419 1.33 0.02 
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Analyte ID Gene 
symbol Gene name Modification 
EntrezGene 
ID 
Log-
ratio p-value 
MAPK8_P-T183/Y185 MAPK9 Mitogen-activated protein kinase 9 P-T183/Y185 26420 1.33 0.02 
MTOR_P-S2448 MTOR Mammalian Target of Rapamycin P-S2448 56717 1.09 0.01 
RPS6KA1_P-S380 RPS6KA1 Ribosomal protein S6 kinase, 90kDa, polypeptide 1 P-S380 20111 2.05 0.02 
RPS6KA1_P-T573 RPS6KA1 Ribosomal protein S6 kinase, 90kDa, polypeptide 1 P-T573 20111 1.17 0.03 
 
